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CHAPTER 1: RATIONALE, RESEARCH QUESTIONS AND OUTLINE OF THE THESIS 
 
1.1 Rationale 
VNS is widely recognized as an adjunctive treatment for refractory epilepsy and medical indications 
for VNS are currently expanding. Nevertheless, understanding the mechanism of action (MAO) of 
VNS remains for a large part unsolved. Moreover, clinical response to VNS is variable and 
unpredictable. In clinical practice, VNS candidates are those patients that run a complete pre-surgical 
evaluation and for which finally no surgery can be offered. There are currently no predictive factors 
in the process of identification of VNS patients. Identifying predictive factors might help to select 
good candidates much earlier in the pre-surgical evaluation. In addition, better comprehension of the 
mechanism of action of VNS, could lead to more appropriate choice of stimulation parameters. 
Worthwhile noticing is the fact that one third of patients treated with VNS do experience a >50% 
seizure reduction and some patients become even seizure free (1, 2) which compares favourably to 
the option of adding a third or fourth anti epileptic drug. Of course, we should consider that VNS 
therapy implicates a large cost (3), all the more reason why the mechanism of action of VNS should 
be investigated more profoundly, as understanding of the therapy will ultimately lead to a better use 
of it. Globally, VNS is considered to be very cost efficient and advancements in VNS technologies are 
still expanding. 
Research on the mechanism of action of VNS consists of two main parts. First, electrical stimulation 
and activation of the vagus nerve is essential, as adequate activation of the vagus nerve itself is 
necessary to induce any upstream effects in the brain (4,5). Surprisingly, electrophysiological data of 
the vagus nerve in humans and animals are scarce and existing data were insufficiently integrated in 
practical use of VNS in epilepsy. A second important branch of research consists in unravelling the 
different effects of VNS in the brain. Anatomically, the vagus nerve has wide and broad connections 
with several structures that play an important role in epilepsy, such as for example amygdala, 
hippocampus and thalamus. Effects of VNS in the brain can be examined in experimental animal 
models, through intra and extracellular recordings of different projection sites (6,7), by non invasive 
imaging techniques (8-10) or with post-mortem immune histochemical stainings. 
The main goal of this thesis is to identify and characterize a parameter that reflects activation of the 
vagus nerve, which eventually could be used as a biological marker for stimulation. This might be of a 
clinical importance, as parameters of stimulation could therefore be derived from objective patient 
specific information. 
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For this purpose, research on Compound Action Potentials (CAPs) of the vagus nerve in animals and 
humans was performed. For animal use a custom made spiral cuff electrode was designed to 
stimulate and record stimulation induced vagal activity. In humans, a new vagus nerve stimulator, 
the ADNS-300 provided by Neurotech, was implanted in three patients and postoperative recordings 
of vagal nerve compound action potentials in humans were described for the first time. 
1.2 RESEARCH QUESTIONS 
The following questions were raised: 
 
Animals: 
1. Is the implantation of a combined stimulation and recording spiral cuff electrode around the 
left cervical vagus nerve in rats feasible?  
2. Can we identify a parameter that reflects adequate stimulation of the vagus nerve using our 
new electrode and applying parameters that are commonly used in clinical practice? 
3. If yes, what is the nature of this physiological parameter: does recorded activity correspond 
to a compound action potential of the vagus nerve? 
4. Is it possible to record earlier described VNS activation parameters in a chronic way? 
5. Do the characteristics of this VNS-induced stimulation parameter remain stable over time? 
6. How does the impedance of stimulation electrodes contact evolve over time? 
7. Is it possible to record in all implanted rats a VNS activation parameter immediately after 
surgery? 
8. Is it possible to record a VNS-induced evoked potential in one of the vagal projection sites in 
the rat brain using stainless steel depth electrodes? 
9. What could hypothetically improve recording of VNS induced evoked potentials in the rat 
brain? 
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Humans: 
1. What are the technical advancements and improvements of the Cyberonics VNS model 103 
and 104 (Demipulse) for treatment of refractory epilepsy? 
2. What are the main differences between ADNS-300 and Demipulse VNS systems for refractory 
epilepsy? 
3. What was the patient outcome of the first pilot trial with the ADNS VNS device? 
4. Could vagal nerve CAPs be recorded and what were the characteristics of the recorded 
signals? 
5. During which time period could vagal nerve CAPs be recorded? 
6. Can dose-response curves of vagal CAP be recorded? Is it possible to distinguish different 
fiber bundles of the vagal nerve CAP by applying higher charge values? 
7. What are technical and practical aspects of the ADNS that need to be improved? 
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1.3. Outline of the thesis 
Chapter1: Describes the rationale and research questions 
Chapter 2: Provides a general introduction on epilepsy and gives an overview of existing anti 
epileptic drug treatments and highlights the pre-surgical evaluation for medically refractory epilepsy. 
In addition, a short overview of different neurostimulation techniques for refractory epilepsy are 
listed and briefly explained. Finally, a subchapter is dedicated to VNS, in which history, clinical 
efficacy, acute and long term side effects and possible research fields are summarized Chapter 3:  
Describes the theoretical background and is divided in two sections.  
The first section gives a comprehensive overview of the electrophysiology of extracellular stimulation 
of nerves. In this context, extracellular recordings and the recording of the Compound Action 
Potential are defined. In addition, the effects of extracellular stimulation on neural tissue are briefly 
explained. The first section ends with an illustration of the different kinds of stimulation pulses that 
can be used for extracellular stimulation. 
The second section of this chapter gives an overview of the different parameters in the literature for 
electrical activation of the vagus nerve. Markers of stimulation range from non invasive human scalp 
recordings of vagal evoked potentials to more invasive depth electrode recordings of vagal evoked 
potentials in experimental animal studies. In addition, the effects of VNS on other commonly used 
evoked potentials in clinical practice are reviewed. Finally, effects of VNS in the brain visualized 
through different neuro-imaging techniques are summarized and the possible relationships to seizure 
outcome are highlighted. 
Chapter 4: Manuscript: “Evolution in VNS therapy for refractory epilepsy, experience with Demipulse 
devices at Ghent University Hospital” 
Chapter 5: Manuscript: “A novel implantable vagus nerve stimulation system (ADNS-300) for 
combined stimulation and recording of the vagus nerve: pilot trial at Ghent University Hospital” 
Chapter 6: Manuscript: “Chronic electrophysiological properties of human vagus nerve recorded with 
the ADNS-300” 
Chapter 7: Manuscript: “Implantation of self sizing cuff electrode around the vagus nerve in 
experimental rats for repeated assessment of larynx muscle compound action potentials in rodents” 
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Chapter 8: Experimental vignettes 
8.1 Identification and characterization of a vagal evoked potential? 
8.2 Implantation of a VNS model 102 in a horse for recurrent laryngeal nerve stimulation 
Chapter 9:  Conclusion, discussion and future perspectives 
Chapter 10:  Summary/Samenvatting/Résumé 
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CHAPTER 2: INTRODUCTION 
2.1 Epilepsy: epidemiology, definition, classification 
Epilepsy is a chronic neurological disorder that is characterized by recurrent epileptic seizures. It has  
a prevalence of 0.5 to 1% of the population and appears as frequently in men as in women. The 
highest rate is observed in the first week of life; thereafter incidence is lowest during adulthood and 
increases again in the elderly due to a higher prevalence of cerebro-vascular disorders (1,2). 
The traditional definition of ‘epilepsy’ as more than one unprovoked seizure episode seems to be 
changing as the International League against Epilepsy (ILAE) has proposed to adapt the definition to 
‘at least one seizure and evidence of an enduring predisposition for further seizures’ (3). In this way 
multiple epileptic seizures due to multiple different causes in the same patient would not be 
considered as epilepsy. However, a single seizure due to an enduring epileptogenic abnormality 
would indicate epilepsy. As inevitably always is the case with definitions, there is a certain grey area 
in which every neurologist decides individually upon further treatment and follow-up (4). 
Neurologists must determine the cause of the seizure or define the type of epilepsy and if possible 
establish a syndromic diagnosis by means of clinical examination, EEG, video-EEG monitoring and 
neuro-imaging. Such distinctions are important for an optimal management of the patient. 
Epileptic seizures are classified in two categories based on ictal semiology and 
electroencephalographic (EEG) characteristics (5). Table 1 gives an overview of classification of 
seizures. 
1. Focal epileptic seizures are conceptualized as originating within a network limited to part of one 
hemisphere. They maybe discretely localized or more distributed, but for every seizure type, ictal 
onset is consistent for recurrent seizures. In addition, it is possible that several different networks are 
involved, leading to several seizures types in one patient. Depending on regions involved, clinical 
symptoms include motor, somato-sensory, visual, gustatory, auditory and or autonomic phenomena 
(6). 
2. Generalized epileptic seizures originate at one point within, and rapidly engage bilaterally 
distributed networks. Although individual seizure onsets can be lateralized, the location and 
lateralization are not consistent from one seizure to another. In this sense, generalized seizures can 
be asymmetric. Pattern and rate of propagation of seizure activity determine the sequence of signs 
and symptoms that develop throughout the course of the seizure.  
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Table 1: Classification of seizure types 
I. Focal seizures  
1. Without impairment of consciousness or awareness 
 With observable motor or autonomic components (This roughly corresponds to 
earlier concept of ‘simple’ partial seizure) 
 Involving subjective sensory or psychic phenomena only. (This corresponds to 
the concept of an aura) 
2. With impairment of consciousness or awareness (This roughly corresponds to the 
complex partial seizure). Can be accompanied by motor, sensory and autonomic 
events) 
3. Evolving to a bilateral, convulsive seizure (involving tonic, clonic or tonic-clonic 
components). This expression replaces the term secondarily generalized seizure. 
II. Generalized seizures  
1. Tonic clonic 
2. Absence (Typical, Atypical, Absence with special features (Myoclonic 
absence, Eyelid Myoclonia)) 
3. Myoclonic (Myoclonic, Myoclonic atonic, Myoclonic tonic) 
4. Clonic 
5. Tonic 
6. Atonic 
III. Unknown 
After defining the type of seizure, recognition of aetiology and syndrome diagnosis is the second step 
in the general work-up. 
Previous classifications used to subdivide epilepsies into epilepsies  without an identifiable lesion or 
aetiology and presumed hereditary predisposition (‘idiopathic’), epilepsies with known aetiology 
(‘symptomatic’) and finally epilepsies in which aetiology is suspected but not proved (‘cryptogenic’). 
These terms are nowadays replaced by ‘genetic’, ‘structural/metabolic’ and of ‘unknown cause’ (5). 
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Further subdivisions are based on the basis of the age onset of specific electro-clinical syndromes. In 
addition to the electro-clinical syndromes with strong developmental and genetic components, 
distinctive constellations are made on the basis of specific lesions or other causes. They are 
diagnostically meaningful forms of epilepsy and have particular implications for clinical treatment, 
particularly for epilepsy surgery. These include for example mesial temporal lobe epilepsy with 
hippocampal sclerosis or hypothalamic hamartoma with gelastic seizures. In these disorders age at 
presentation is not a defining feature. The next group includes epilepsies that are secondary to 
specific structural or metabolic lesions or conditions, such as for example malformations of cortical 
development, tumours, infections or trauma. Finally, these epilepsies that in the past were called 
cryptogenic are now being referred to as being of ‘unknown’ cause (5). 
2.2 Anti-epileptic drug (AED) treatment 
Anti-epileptic drugs are the mainstay of the treatment of epilepsy, and although their number has 
expanded exponentially, current principles governing drug therapy haven’t changed spectacularly 
over time. 
Firstly, treatment is indicated after two seizures, given the interval between them is not more than 1 
or 2 years. Other element to be considered is the individual wish of the patient (7). 
Secondly, because about 50% of individuals with a first unprovoked seizure who are not treated will 
never have a second seizure, and because AED treatment carries a substantial risk of adverse effects, 
it is reasonable to defer treatment until after seizure recurrence in most cases. However, early 
treatment might be justified in patients with a high recurrence risk, such as for example in patients 
with a first unprovoked seizure after a stroke or a seizure caused by other identifiable lesions 
(7,8,9,13). After having decided whether or not to treat the patient, the next question is off course 
which anti- epileptic drug should be administered in first line? 
For focal seizures—by far the most prevalent seizure type in adults—the American Academy of 
Neurology guidelines (10) lists many old and new AEDs without expressing any preferences among 
them; the UK National Institute for Health and Clinical Excellence (11) recommends preferential use 
of older agents unless there are specific reasons for doing otherwise; the Scottish Intercollegiate 
Guideline  Network  (SIGN) identifies specifically carbamazepine, valproate, lamotrigine, and 
oxcarbazepine as first-line agents (12); and the ILAE rates phenytoin and carbamazepine as the AEDs 
with the highest quality of evidence for efficacy and effectiveness (13). In Belgium, the first choice 
treatment as initial monotherapy in focal seizures is carbamazepine, followed by levetiracetam and 
lamotrigine (14). 
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There are several properties in addition to efficacy that might affect the choice of AEDs. These 
include adverse effects such as rare idiosyncratic reactions, teratogenic effects and chronic side-
effects. Enzyme-inducing effects and potential for drug interactions are also important, as are the 
availability of parenteral formulations and the possibility of rapidly reaching an efficacious target 
dose in some cases. Selection of an AED needs an individual approach, in which elements such as 
childbearing potential, old age and co-morbidities play an important role. The dosage of the AEDs 
should be the lowest possible to achieve sustained seizure freedom and minimal side-effects. If a 
change in AED treatment is indicated, the conventional recommendation is to switch gradually to 
monotherapy with another drug (15). Other authors, however, feel that a combination therapy could 
be tried earlier, particularly in severe epilepsies when the first AED seems to have been partially 
effective and well tolerated, and the probability of seizure freedom with monotherapy is regarded as 
low (9). 
Patients who do not achieve sustained seizure freedom after adequate trials of at least two 
appropriate AEDs, given alone or in combination, meet ILAE criteria for pharmaco-resistance (17). 
The rationale for this definition is that the probability of seizure freedom with another AED decreases 
in proportion to the number of drugs tried unsuccessfully in the past, and is probably no greater than 
20% after failure of two such drugs (13). Aspects to be considered when trying an additional AED 
include its spectrum of efficacy, its adverse effects profile, its expected effect based on the patient’s 
characteristics, and the possibility of pharmacokinetic and pharmacodynamic drug interactions, 
which can require dosage adjustments (7,8,13). 
Finally, when seizure freedom cannot be achieved, the ultimate goal is the best possible quality of 
life, to be obtained through a compromise between reduction in seizure frequency or severity and 
the burden of side-effects.  
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2.3 Pre-surgical evaluation and treatment options for refractory epilepsy 
Nearly all patients with recurrent seizures treated with anti-epileptic drugs respond well. 
Nevertheless, one third of the patients are not fully controlled or experience intolerable side effects 
(8). Epilepsy is regarded as refractory when seizures are difficult to control despite adequate mono- 
or poly-therapy with anti-epileptic drugs that do not cause significant adverse events (8,17). 
Consequently, these patients suffer from long term morbidity, disability and underemployment. For 
these patients, referral to a Reference Centre for Refractory Epilepsy may offer new opportunities. 
The first step in identifying patients for possible surgical therapy is to confirm the diagnosis of 
epilepsy and to attempt to localize the onset of seizures. Importantly, non-epileptic attacks, 
particularly psychiatric disorders are diagnosed in 10-20% of patients admitted to monitoring units. 
Moreover, cardiovascular and sleep disturbances may also be misdiagnosed as epilepsy as well (18). 
Table 2 : Efficacy spectrum of the main  AEDs in different seizure types in adults (13,16) 
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The second step is to determine whether a patient can benefit from epilepsy surgery or other 
alternative treatment, a multidisciplinary team of epileptologists, neuroradiologists, neurosurgeons 
and neuropsychologists is required. The pre-surgical evaluation has as a main goal to identify the 
epileptogenic onset zone and to determine whether this zone can be surgically removed without 
injury to brain regions that mediate key neurological functions. For this purpose, a series of 
complementary technical investigations are necessary. The pre-surgical work up consists of a (1) 
precise and concise personal and familial history of epilepsy history, (2) a long term video-EEG 
monitoring to record habitual seizures, (3) optimal 3 Tesla MRI of the brain, (4) a positron emission 
tomography (PET), (5) a neuropsychological assessment to clarify cognitive deficits. Once the patient 
has been discussed in a multidisciplinary staff, additional examinations such as a single-photon 
emission computed tomography (SPECT),  magneto-encephalography (MEG), a Wada test or fMRI 
can be performed to further characterize the epileptogenic zone or to determine laterality of 
memory function and language dominance and other eloquent area’s (19-21). 
Epilepsy surgery is an efficacious alternative therapy for selected patients with intractable epilepsy 
(22-27). Patients with medial temporal lobe epilepsy (and lesional epilepsy), may be suitable 
candidates for epilepsy surgery (28, 29). The hallmark pathology of medial temporal lobe epilepsy is 
medial temporal sclerosis (30, 31). Histological examination of surgically excised hippocampus in 
these patients shows focal cell loss and gliosis. These patients have a good postoperative outcome. 
Approximately 60-80% of patients with unilateral mesial temporal sclerosis, but also patients with a 
low-grade glial neoplasm or cavernous hemangioma, commonly become seizure-free after surgical 
treatment. In contrast, post-operative outcome is distinctly less favourable in individuals with focal 
cortical dysplasia and non-lesional epilepsy (32, 33). Potential reasons for reduced efficacy of surgery 
include the extra-temporal onset of seizures and the non-favourable localization of epileptic brain 
tissue   (34, 35). 
The management of the patient with medically refractory epilepsy who is not a candidate for a 
‘curative’ surgical procedure can be very challenging. Treatment options for these individuals include 
continued AED treatment; ‘palliative’ surgical procedures, such as callosotomy or a subtotal resection 
of the epileptogenic zone, AED investigational studies, vagus nerve stimulation (VNS), deep brain 
stimulation and ketogenic diet. 
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2.4 Neurostimulation 
2.4.1 Extra-cranial neurostimulation 
2.4.1.1 VNS 
VNS consists of stimulation of the tenth cranial nerve or vagus nerve and was developed in the 
eighties (VNS TherapyTM device, Cyberonics, USA). Through an implanted programmable pulse 
generator and a bipolar helical electrode, electrical pulses are administered to the left vagus nerve in 
the neck. VNS is a widely recognized adjunctive treatment for patients with refractory epilepsy who 
cannot benefit from epilepsy surgery. Improvement resulting from treatment is not immediate but 
tends to increase over time (36, 39). 
2.4.1.2 Repetitive Transcranial magnetic Stimulation (rTMS) 
Transcranial magnetic stimulation (TMS) is a non-invasive, generally well-tolerated method for 
cortical stimulation that is based on principles of electromagnetic induction, where small intra-cranial 
electric currents are generated by a strong fluctuating extra-cranial magnetic field (40). The 
presumed mechanisms underlying these lasting changes in cortical excitability are similar to those of 
long-term depression (LTD) and long-term potentiation (LTP) of synaptic strength, which are seen 
with low- and high-frequency electrical brain stimulation respectively (41). Anti-seizure properties of 
rTMS were studied previously, but results of randomized, double-blind and sham controlled studies 
show diverting results (43, 44). For this reason rTMS has not yet been widely adopted as a treatment 
of refractory epilepsy. 
2.4.1.3. Transcranial Dirrect Current Stimulation (tDCS) 
tDCS involves the application of electrical currents to the scalp via anodal or cathodal electrodes and 
influence cortical excitability. In a double-blinded, sham-controlled, randomized trial tDCS 
significantly reduced epileptiform discharges.  
Moreover, in the month after tDCS, the number of epileptic seizures decreased trend-wise while it 
was stable in the group treated with sham tDCS (42). Future clinical research will point out whether 
this treatment can be used as a new neurostimulation treatment for epilepsy. 
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2.4.2. Intra-cranial neurostimulation : Deep Brain Stimulation  
2.4.2.1. Hippocampal stimulation in patients with hippocampal sclerosis 
High frequency stimulation of the hippocampus as epileptic focus, showed to have seizure reducing 
effects in two studies (45,46). One randomized double-blind examination studied efficacy of bilateral 
hippocampal stimulation in 9 patients with temporal lobe epilepsy due to uni- or bilateral 
hippocampal sclerosis. From those patients 5/9 became seizure-free en 4/9 experienced a reduction 
of > 50 % (45). These positive results were reproduced by our group, in which an open prospective 
study with bilateral temporal lobe epilepsy showed 1/10 seizure-free patient, 6/10 experienced a 
seizure reduction of > 50%, while in 3/10 seizures diminished with less than 50% (46, 47). Currently, 
our centre is performing a double-blind randomized study of selective amygdalo hippocampectomy 
versus medial temporal lobe deep brain stimulation (CoRaStiR). 
2.4.2.2. Responsive Neurostimulation System (ongoing clinical trial) 
NeuroPace Inc., is sponsoring an investigational device study of the Responsive Neurostimulation 
System (RNS) for treating refractory epilepsy. The pivotal trial is a randomized, double-blind, sham-
stimulation controlled investigation conducted in the United States. The RNS System is designed to 
detect abnormal electrical activity in the brain and to deliver small amounts of electrical stimulation 
to suppress seizures before any seizure symptoms occur. The RNS is placed within the skull and 
underneath the scalp and is connected to one or two wires containing electrodes that are placed 
within the brain or that rest on the brain surface over the area of seizure focus. This type of 
treatment is still under research and it is not yet known whether it will work for the treatment of 
epilepsy (48, 49) 
2.4.2.3. Stimulation of the anterior nucleus of the thalamus  
In epileptic patients, the effect of anterior nucleus high frequency stimulation has been reported in 
different recent open label trials (50-52), although reduction in seizure frequency varied from 14-76 % 
according to the study performed (50, 53, 54). In addition, one report showed that the insertion of 
the electrode itself reduced seizures (52) and one observed benefits that did not differ between 
stimulation-on and stimulation-off periods (50). The randomized, double-blind SANTE study 
(Stimulation of the Anterior Nucleus of the Thalamus for epilepsy) was published, in which bilateral 
anterior nucleus stimulation of the thalamus induced seizure reduction during 2 year follow-up. After 
2 years of stimulation, seizures were reduced by a median 56%, a 50%-responder rate improvement 
occurred in 54% of patients, seizures were less severe and quality-of-life was improved. Additional 
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clinical experience may help establishing the best candidates and to further refine the risk-benefit 
ratio of this treatment (55). 
2.5. VNS: overview of clinical efficacy 
2.5.1. History 
The historical basis of stimulating peripheral nerves for treatment of seizures dates back to the 
sixteenth and seventeenth century. Greek author Pelops described that ligature of the limb in which 
the seizure started, could terminate the progress of the seizure from that specific limb. Later on, in 
the nineteen century, Odier and Brown-Séquard showed that ligatures are as efficacious in 
preventing seizures caused by a organic brain disease (56). At the end of the century Gowers 
attributed this effect to a raised resistance in the sensory and motor nerve cells in the brain that 
correspond with the limb involved, which in turn would prevent spread of the discharge (57). Finally, 
in 1991, Zabara and Terry launched the first implantable neurocybernetic prosthesis system (58). 
2.5.2. Clinical efficacy: short overview 
Clinical efficacy trials started out with the randomized controlled trials phase-1 EO1 and EO2 in which 
a small amount of patients (N=14) were implanted with a VNS device. After 3 to 22 months of follow-
up, a 50% seizure reduction was observed (59-61). Beneficial effect in the patient population was 
sustained after a longer follow-up of 14-35 months (62). Thereafter, two prospective double-blind 
randomized studies, EO3 and EO5 were started. 
In these studies, larger patient groups were divided in a “high” (mean stimulation intensity 1.3 mA, 
30 Hz, 500 µsec, 30 sec on, 5 min off) and “low” stimulation group (single increase to point of patient 
perception, with a mean stimulation intensity of 1.2mA, 1 Hz, 130 µsec, 30 sec on, 3 hours off). In 
both studies the “high” stimulation group produced better seizure reducing effects that ranged 
between 24 to 28% compared to maximal 15% in the low stimulation group (63-65). 
These study results lead to a Food and Drug Administration (FDA) approval and were subsequently 
followed by open label extension trials, in which was shown that the effect of VNS clearly increased 
over time to values between 35 en 44% seizure reduction, but ultimately reaches a plateau phase 
after 2 years of stimulation (62,63,66-69). In the following years, a growing amount of clinical data 
confirmed efficacy of VNS. For example, a joint study of two epilepsy centres in Belgium and in the 
USA recruited 118 patients with a minimum follow up of 6 months and found a reduction of 55% in 
mean monthly seizure frequency (70).  
 28 
 
In addition, in a retrospective Belgian multicenter study in which 138 patients with a minimal follow-
up of one year were included, an overall seizure reduction of 51% was observed (71). 
VNS also appeared to have beneficial effects in certain epilepsy syndromes, such as for example 
Lennox-Gastaut (72-74). In addition, generalized epilepsy syndromes responded equally well to VNS 
than focal epilepsy syndromes (75). 
A few case reports that describe a beneficial effect of VNS in both convulsive and non-convulsive 
status epilepticus (76, 77). 
2.5.3. Side effects and tolerability 
2.5.3.1. Acute side effects 
Postoperative infections occur in 3-6% of patients. Fluid accumulation at the generator site with or 
without infections occurs in 1-2% of patients. These side effects are treated with oral antibiotics, but 
in rare cases the generator or electrode must be removed (65, 78). 
Ventricular asystole during testing of the device (1 mA, 20Hz, 500µsec, 17 sec) on implantation has 
been reported, in patients who did not have any history of cardiac dysfunction, nor showed any 
cardiac problems after surgery (79- 81). All those patients had been able to use VNS postoperatively. 
Adverse cardiac complications at start or during ramping up of stimulation intensity have not been 
observed (82), although one case report described a late brady- arrhythmia after 2 years of 
stimulation (83). 
Until recently it was thought that the stimulation electrode should be implanted on the left vagus 
nerve, as it contains less sino-atrial fibres compared to the right side and consequently would 
provoke less cardiac side effects. In contrast, several other studies report implantation of the right 
vagus nerve in humans, mainly due to complications related to left vagus nerve surgery. Infection of 
the implant or wound opening with explantation as a consequence, intra-operative bleeding in the 
approach of the left vagal nerve, but also mechanical dysfunction due to fibrosis and high impedance 
of the electrode, have been reported as reasons to implant the right vagus nerve (84, 85, 86). Right 
vagus nerve stimulation induced at 0.75 mA in one case bradycardia and ventricular extra systoles 
(85) and respiratory symptoms and secondary tachycardia were presented in a second case (84).  
Recent technology advancements, more specifically the introduction of the CardioFit, have proposed 
stimulation of the right vagus nerve as a therapy for chronic heart failure. The initial results indicate 
that stimulation of the right vagus nerve in patients with heart failure, improves left ventricular 
function and long term survival (87). 
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2.5.3.2. Adverse events related to long-term use & tolerability 
The most common side effects are stimulus-related coughing, throat pain, hoarseness and hiccup, all 
of which tend to improve over time (88). Less often dyspnoea during exercise and vomiting were 
reported (63). No changes in autonomic functions were reported (i.e. blood pressure, heart rate, lung 
function or blood chemistry) (89). VNS had no effects on AED serum levels (62). 
Psychiatric side effects have been described. In patients with pre existing psychiatric disorders 
decreased sedation and increased alertness may manifest itself as psychosis (90, 91). 
The mortality and rates of sudden death in epilepsy (SUDEP) of patients receiving VNS therapy are 
comparable with those of other groups of patients with medically refractory seizures (92). 
Performing a body MRI could heat the electrode leads and thereby damage local tissue. When used 
according to the manufacturer’s guidelines, a brain MRI conducted with a send-and-receive head coil 
is safe (93). 
Relative contra-indications include progressive neurologic or systemic diseases, cardiac arrhythmia, 
asthma, chronic obstructive pulmonary disease, active peptic ulcer and insulin dependent diabetes 
mellitus (94). 
2.6. VNS Research  
Currently, the precise mechanism of action of VNS as a treatment for refractory epilepsy remains to 
be elucidated (89). VNS seems to exert an acute seizure aborting effect together with a sustained 
long-term seizure preventing effect (65, 95). Stimulation parameters were derived from animal 
experimental studies in which anti-seizure effects of VNS were proven (96-102). Later on, these pre-
clinical VNS parameters were applied in early clinical randomized controlled trials (56, 68, 103, 104). 
However, in none of these studies, stimulation parameters were derived from individual 
electrophysiological properties of the human vagus nerve. Beside unravelling and understanding the 
effects of VNS in the brain, research on activation of the vagus nerve itself remains a key point, as 
adequate activation of the vagus nerve is ultimately necessary to achieve any positive effects. For 
this purpose, different techniques representing stimulation of the vagus nerve in the literature were 
reported. This was done by means of characterization of vagal evoked scalp potentials in humans 
(105), but also by analyzing the effect of VNS on clinically-commonly evoked potentials (106,107), by 
studying the effects of VNS in the brain with functional imaging studies (108) and finally by examining 
the neurochemical effects of VNS in CSF (109) or its relation to serum cytokine production (110). Only 
a small number of studies have investigated local activation of the vagus nerve by means of 
compound action potentials (CAP’s) of the vagus nerve (111,112). There were some attempts to 
correlate different biological activation parameters to seizure outcome in VNS practice, but data 
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were insufficient to drawn any strong conclusions. Consequently VNS is still being used in a rather 
arbitrary way, without any support of physiological activation information of the vagus nerve itself. 
Introduction of CAP’s into the clinical practice, could teach clinicians how to choose stimulation 
parameters more adequately, which in turn could have important clinical repercussions. CAP’s may in 
the future be relevant for the choice of cost-effective stimulation parameters and help identifying 
VNS-responders and non-responders. 
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CHAPTER 3: THEORETICAL NEUROPHYSIOLOGICAL BACKGROUND 
3.1 The vagus nerve 
3.1.1 Anatomy 
The vagus nerve carries somatic and visceral afferents and efferents. Afferents compose about 80% 
of the cervical portion of the vagus and are mainly narrow- calibre unmyelinated C fibres, which 
predominate over faster conducting myelinated A and B fibres. Viscero-motor efferents originate 
from the nucleus dorsalis, while efferents that innervate the striated muscles of the pharynx and 
larynx have their origin in the nucleus ambiguous. Afferent fibres have their origin in the nodose 
ganglion and conduct viscero-sensory information from organs to the brain via the nucleus tractus 
solitarius (NTS) in the brainstem. Each vagus nerve bifurcates on entering the medulla to synapse in 
the NTS bilaterally. In addition to viscera-sensible information, afferents are also represented by 
taste fibres from the dorsal part of the tongue and sensory information of the external auditory canal 
including the inner side of the tragus, although the latter fibres make synapse in nucleus spinalis 
trigeminus and not in the NTS. The NTS projects to inferior and medial cerebellar regions and to 
multiple pontine and mesencephalic nuclei (parabrachial nucleus, locus coeruleus (LC), raphe magne 
nucleus). From the NTS, there are direct and indirect projections to various structures in the brain, 
such as amygdale and thalamus which play a key role in the process of epileptogenesis. In addition, 
vagus nerve also has wide spread indirect cortical connections, such as the anterior insula, infralimbic 
cortex and prefrontal cortex (1, 2). 
3.1.2 Physiology 
The diffuse pathways of the vagus nerve mediate important visceral reflexes such as coughing, 
vomiting, swallowing, control of blood pressure and heart rate (2). Heart rate is mostly influenced by 
the right vagus nerve, which has dense projections to the atria of the heart (1). 
3.2 General principles of stimulation 
3.2.1 Physiology of excitation 
Neural membranes at rest exhibit a transmembrane potential (TMP) of -60 to -100mV, which is the 
result of alignment of negative charges along the inner surface and of positive charges along the 
outer surface of the membrane. This dipole layer is maintained by diffusion and active ionic transport 
mechanisms across the lipid bilayer.  
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Passive changes in TMP occur when a constant current is applied to a membrane and resting level 
reaches a new steady state level. This process happens in an exponential way governed by the 
membrane time constant. Time constant equals the duration to achieve 63% of the steady state 
membrane potential and correlates with the product of membrane resistance and capacitance.  
When the passive changes decrease TMP to a threshold of -40 to -60mV (Fig. 1a), ion channels briefly 
open and allow inward current of sodium ions, reversing the TMP to +20mV. An outflow of 
potassium ions occurs next, together with an inhibition of sodium inflow, which restores the TMP to 
a resting level. The resulting sequence of rapid TMP fluctuation as described above is called an action 
potential (Fig. 1b, c, d) (3). 
 
 
The relation between stimulus parameters and tissue excitability are illustrated in Fig. 1. With very 
brief pulse durations despite use of high intensity no excitation will take place. Likewise, excitation 
will not occur below a certain minimum level called the rheobase, which is the minimum intensity 
needed to obtain an excitation with a stimulus of infinite duration. The chronaxie of the strength 
duration curve is the pulse duration required to elicit a response with an intensity that equals twice 
the rheobase. 
 
Fig. 1 (a,b,c,d) Changes in transmembrane potential by different constant current pulses. Fig. inspired from Jayakar 
P, Adv Neurol 1993;63:17-27. 
 43 
 
This point is considered to be most efficient stimulation and requires the least energy (Fig. 1 b). A 
shorter pulse width than the chronaxie, involves that cells will respond with less stimulus charge for a 
given current level (Fig. 1 c) Chronaxie and Rheobase principles were published for the first time by 
Louis Lapicque’s in his famous paper on ‘Définition experimentale de l’excitabilité’ that was 
published 100 years ago (4). Later on, strength duration curves were further described by the Hill’s 
Equitation (5). 
 
  
 
In which Th(D) = magnitude of the stimulus, Rh= Rheobase current, D= pulse duration, Chr=chronaxie, 
ln(2)= natural logarithm of 2 
In addition, the equitation was further simplified by Weiis which allows estimations of chronaxie on 
the basis of two threshold and pulse duration values. 
 
 
Magnitude of Rheobase is dependent on the separation between the electrode and target exicitable 
tissues, while chronaxie is primarly dependent on the tissues, with typical values of less than 1 msec 
for neural tissues and greater than 10 msec for muscle. Both parameters are influenced by changes 
in membrane potential, impedance and myelinisation (6). 
3.2.2 Extracellular Field recordings 
3.2.2.1 Action potential along a nerve 
Electric signals that are measured in the extracellular space and are generated by the electric fields 
produced by the activity of a single neuron or groups of neurons are called ‘Extracellular Field 
recordings’. Typically these are recorded between two points in the extracellular space rather than 
across the membrane of neurons. Examples of Extracellular field potentials include recordings of a 
passing action potential of a nerve, or more complex electroencephalographic recordings of a small 
part of the brain from the scalp. 
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If an action potential is elicited at A, the membrane will momentarily reverse polarity and local 
currents will flow into the nerve cells as is indicated by a ‘’sink’’ (Fig.2).  
While the site where currents exist the cells is called “source” If we were recording extra-cellularly at 
point A (with respect to a distant ground), we would record a negative potential during the action 
potential, while in B we would record a positivity (Fig. 2) In the example demonstrated in Fig. 3, 
action potential is not stationary, but propagates over the nerve from the left to the right. Therefore 
local current sinks and sources changes over time. As the action potential passes over the different 
recordings sites,  the shape of the extracellular field potential will evolve. 
 
 
To summarize, when an action potential occurs at place A, but the recording site is located further on 
the nerve on place B, the extracellular field potential will first be positive, then show a large negative 
peak as the result of inward current of Na that has now reached point B. Once the action potential 
reached point C, extracellular field potential becomes positive again  (Fig. 3)(7). 
3.2.2.2. Active neuron is an electric dipole 
In Fig. 4 for example an action potential is initiated in the soma and is called active sink, while 
changements in the dendrites are called a passive source. The neuron can be considered as an 
electric dipole, because during the action potential the dendrites are positive with respect to the 
soma. At the same time, excitatory inputs can reach dendrites creating new active sinks. 
Fig. 2 Extracellular field recordings sink and source Fig.3 Propagation of an action potential 
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 All these extracellular signals are not stationary in 
time and space, the resultant extracellular field 
recording of a group of neurons results from these 
local excitatory and inhibitory synapses. 
 
Fig. 4 Neurons are active dipoles. Extracellular recordings results 
from of a complex integration in time and space of different sinks 
and sources. 
 
3.2.2.3. Volume conductor theory 
In addition to integration of sinks and sources, the measured extracellular field also depends on the 
solid angle made with the dipole. The solid angle depends on the physical size of the dipole and the 
distance between the observation point and the dipole. In Fig. 5.an example is shown, where a small 
part of the EEG represented as dipole illustrating some type of nervous tissue in which there is a 
separation of charge. The observation point at the left would measure a negative potential with 
respect to a distant ground while the one on the right side would measure a positive potential. For 
EEG, predictions are thus very difficult to make, as observation points are on the surface of the scalp, 
while dipoles from neurons come from the underlying cortex that show multiple folding and curving 
(7). 
    Fig. 5 Electrical field in a volume conductor 
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3.2.2.4 Classification of fields 
Optimal recording of extracellular fields that result from the integration of sinks and sources in time 
and space depends also the internal arrangements of these specific neurons. There are three main 
types of geometrical arrangements of neurons: open field, closed field and open-closed field (Fig. 6). 
The open field is encountered when neurons organize in a laminar array in which dendrites are facing 
in one direction and the somata in the other. This types of field is typically found in the cerebellum, 
neocortex and hippocampus (Fig. 7).These are highly laminated structures that allow adding up of 
dipoles which renders recordings of extra -cellular fields more effective. In contrast, when a spherical 
array of neurons in which or somata or dendrites are directed toward periphery, synchronous 
activation produces dipoles with spherical symmetry. Measurements outside the field record a zero 
potential as dipoles cancel each other within the sphere (7). 
 
   
Fig. 6 Open and closed fields 
   
 
Fig. 7: In vivo stimulation of right perforant path of rat hippocampus and recording of a population spike of dendate gyrus. 
This example illustrates the importance of open linearly arranged neurons to be able to record extracellular field potentials 
3.2.2.5 Compound action potential (CAP) 
In mammals, large peripheral nerves, such for example the vagus nerve, are a result of bundles of 
thousands on individual axons enclosed in a loose connective tissue sheet, the epineurium. Within 
the epineurium, axons are further sub grouped into smaller fascicles that are embedded in perineum. 
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Finally, individual axons are covered by individual endonurium. The axons within a compound nerve 
include afferent (sensory) and efferent (motor and autonomic) nerves. Individual axons vary in 
diameter, myelinisation, excitability, threshold and conduction speed. 
The compound action potential is the algebraic sum of many ‘all or none’’ action potentials arising 
more or less simultaneously in a large number of individual axons in a large compound nerve.  
The CAP does not occur naturally, but results from an experimentally or clinically induced stimulus 
with extracellular stimulating electrodes and can be recorded with extracellular electrodes, that 
measure the summed electrical response of all the excited axons in the nerve. The properties of the 
CAP are threshold, amplitude, conduction velocity are determined by the type and number of 
individual axons recruited. The number and type of axons excited depends on the intensity of the 
applied stimulus. The CAP differs from ‘’all-or-none’’ action potential response of a single neuron in 
several ways.  
The CAP demonstrated by extracellular recording from many axons, is a graded response whose 
magnitude increases with intensity of stimulation. This is due to different thresholds of excitation of 
the different axons. In terms of excitability Aα>Aβ>Aɣ>Aδ>B>C, see table 1. At low stimulus 
intensities only the largest axons are activated, but as the stimulus gradually increases, more and 
more smaller axons are recruited (8,9). 
 
Table 1: Mammalian Axon Properties at 37°C 
Fibre types Diameter (µm) Conduction 
velocity 
(msec) 
Action potential 
duration (msec) 
Absolute refractory 
period (msec) 
Functions 
Aα 12-22 70-100 0.4-0.5 0.2-1 Efferent alpha 
Afferent muscle spindles, 
tendon organs 
Aβ 5-13 30-70 0.4-0.5 0.2-1 Afferent, cutaneous, touch, 
pressure 
Aɣ 3-8 15-40 0.4-0.7 0.2-1 Gamma motor neurons 
Aδ 1-5 12-30 0.2-1 1.2 Afferent, fast pain, 
temperature 
B 1-3 3-15 1.2 2 Efferent autonomic (only 
pre-ganglionic) 
C 0.2-1.2 0.2-2 2  Afferent, ‘’slow’’ Pain, 
efferent autonomic 
postganglionic 
 48 
 
3.2.3 Effects of stimulation on neural tissue 
As mentioned above CAP is induced by an experimentally induced extracellular stimulus. This 
subchapter will describe which kind of electrical stimuli can be applied and what the effects are of 
electrical stimulation on neural tissue. 
3.2.3.1 Electrochemical processes 
Electrical stimulation with metal electrodes requires a flow of ionic charge in biological tissues. When 
a metal electrode is placed into a physiological medium such as extracellular fluid, an interface is 
formed between the two phases. In the metal electrode phase and in attached electrical circuits, 
charge is carried out by electrons. 
 In the physiological medium, charge is carried out by ions, including sodium, potassium and chloride 
in the extracellular space. When a voltage source is applied across two electrodes, so that one 
electrode is driven to relatively negative potential and the other to a relatively positive potential, the 
interface that is driven negative (cathode), will have an excess of negative charge. This will attract 
positive cations in solution towards the electrode and repel anions. In the interfacial region, there 
will reach net electro neutrality, because the negative charge excess on the electrode will equal the 
positive charge solution near the interface. At the second electrode, the opposite occurs, i.e. 
repulsion of anions by the negative electrode is countered by attraction of anions at the positive 
electrode (anode). If the total amount of charge delivered is sufficiently small, no transfer of 
electrons across the interface will take place and the interface can be modelled by a simple capacitor. 
If polarity of stimulus is reversed, directions of currents reverse and subsequently charge 
redistributions reverse and the charge that was injected from the electrode into the electrolyte and 
stored by the capacitor may be recovered (10). This capacitive mechanism is safe, as no chemical 
changes are induced in the neural tissue. However, the amount of charge that can be injected this 
way is limited and is not able to produce an action potential. Further charge injection will lead to 
reduction and oxidation reactions in the solution, which can lead to storage of these electrochemical 
products near the surface.  In general, reduction requires addition of an electron and occurs at the 
cathode, while oxidation demands a removal of an electron, which finds place at the anode. Unlike, 
capacitive mechanisms, Faradaic charge injection forms toxic products in solution that cannot be 
recovered upon reversing the direction of the current. Next question is how we can induce action 
potentials by stimulating nerves extracellularly without immediately inducing toxic effects? 
Faradaic reactions are divided into reversible and irreversible reactions (11). The degree of 
reversibility depends on relative rates of kinetics (electron transfer at the electrode) and mass 
 49 
 
transport. A Faradaic reaction with very fast kinetics relative to the rate of mass transport, will allow 
electrochemical products not to move far away from the electrode surface and when direction of 
currents is reversed, some product that has recently been formed can be reversed back to its initial 
form. In contrast, when slow kinetics are involved, chemical reactions are able to diffuse away from 
the electrode interface (see Fig.8) and reversion of current will not reverse the chemical reactions, as 
products have diffused away from the electrode contacts.  
In this case, chemical reactants or formation of gas bubbles lead to irreversible Faradaic reactions, 
which leads to corrosion of the electrodes and production of toxic molecules (11). 
One of the parameters that determine the limit of injected charge and reversible Faradaic reaction 
are parameters of stimulation waveform. Other factors that play a role are the kind of material used, 
shape and size of the electrodes and electrical composition of the electrolyte in which the stimulus is 
given (10). 
 
Fig.8. Electrochemical processes induced by electrical stimulation
 
(12) 
3.2.4 Stimulus waveforms and stimulation parameters 
Pulse train stimulus is described by the pulse waveform, amplitude, duration, polarity and frequency 
Fig. 9 summarizes key features of various stimulation waveform types. The cathodic monophasic 
waveform illustrated in Fig. 9a, consists of pulses of current passed in one direction and is the most 
efficacious for stimulation. However, monophasic pulses are not used in long term where tissue 
damage must be avoided. Greater negative over potentials are reached during monophasic pulsing 
then with biphasic pulsing. Furthermore, electrode potential remains longer negative and the 
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charged electrode capacitance slowly discharges through Faradaic reactions, allowing deleterious 
reduction reactions. 
Biphasic waveforms are illustrated in Fig. 9b. The first stimulating phase elicits the desired 
physiological effect such as initiation of an action potential and the second (reversal) phase is used to 
reverse direction of electrochemical processes. Reversal of both phases is possible too (see later 
ADNS-300 pulse) The charge balanced biphasic waveform is widely used to prevent tissue damage, 
although we must bear in mind that biphasic pulses do not completely protect tissue from injury. The 
charge imbalanced waveform (Fig. 9c) may be used to reduce the most positive potentials during the 
anodic phase of a balanced waveform and prevent electrode corrosion. In addition to electrode 
corrosion, a second concern with biphasic pulses is that the reversal phase may reverse some of the 
desired physiological effect of the stimulation phase. This effect causes an increased threshold for 
biphasic pulses compared to monophasic pulses. An interphase delay between stimulating and 
reversing phases may lower the threshold of biphasic pulses (Fig.9d) A delay of 100µsec is typically 
sufficient to prevent the suppressing effect of the reversal phase and be short enough to prevent 
accumulation of toxic Faradaic reactions.  
Finally, the ADNS-300 for therapeutic vagus nerve stimulation used a particular stimulation 
waveform (Fig.9e). An initial sub treshold long recovery phase was followed by a sharp cathodic pulse. 
This initial low amplitude recovery phase permitted necessary local recovery from electrochemical 
process without activating the heart. As the recovery phase was chosen to be low in amplitude, 
duration had to be longer to achieve a charge balanced pulse. Initiation of this long low amplitude 
phase before cathodic stimulation also prevents artifact related problems when recording CAPs. 
Fig.9 (a,b,c,d,e) Different stimulation pulses 
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3.2.5 Electrode implant biocompatibility and general methodology 
Cuff electrodes are composed of an insulating tubular sheath that completely encircles the nerve and 
contains two or more electrode contacts exposed at the inner surface that are connected to 
insulated lead wires. Cuff electrodes have the particular advantage of confining the stimulating 
current to the inner space of the electrode, thus avoiding stimulation of other neighbouring tissues 
(13) and diminishing power consumption of the stimulator system. Moreover, cuff electrodes allow 
correct positioning of electrode leads to minimize mechanical distortion of electrode leads and 
probability of lead failure (14). Implanted electrodes must fulfil to a certain amount of 
biocompatibility issues, which are represented by three main pillars (i) degree of inflammation 
responses (ii) mechanical and (iii) electrical aspects of nerve damage. 
Implant biocompatibility should ideally provoke a restricted immune reaction, although no reaction 
at all is not feasible. After implantation an acute inflammatory response with development of 
oedema and invasion of inflammatory cells will take place, which is followed by a chronic 
inflammation (15) and finally fibrosis granulation tissue will encapsulate the implant and isolate it 
from local tissue environment (16).  
With regard to mechanical properties, cuff electrodes should be flexible and self sizing in order to 
avoid stretching and compression of the nerve (17). On electrical level, biocompatibility implies 
prevention of tissue damage provoked by creation of toxic electro-chemical reaction products at the 
electrode surface by Faradaic processes. In addition, high duration, high frequency biphasic 
stimulation can lead to altered extra axonal environment and ionic homeostasis which might 
precipitate injury (17). 
General methodology: electrodes for experimental rats 
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Fig. 10 Fabrication of spiral cuff electrodes 
The self-sizing spiral cuff electrode is composed of two 80µm thick silicon rubber sheets (Statice 
Santé, France) glued together with an adhesive which polymerizes at room temperature (Part A and 
B MED 4-4210, Nusil). The internal sheet is stretched (stretch factor of 0.5) for curling of the spiral 
cuff. The cuff has an internal diameter of 1 mm and a total length of 9 mm. The sheets have three 
pieces of platinum (Alfa Aesar, 99.9% metal basis, 0.25 mm thick) inserted between them, which 
form stimulation and recording contacts. Anode and cathode (3x1 mm) are 1 mm separated from 
each other, while the recording contact (1x1mm) is situated 2 mm distal to the cathode. In order to 
create internal contacts, windows of 500µm size are cut out in the internal sheet at the level of the 
platinum contacts.  Teflon coated stainless steel wires (FWM 1x7x0.02/316LVM/EFTE, Fort Wayne 
metals) of 20 cm were welded to each end of platinum contact (Fig. 10, 11). 
 
 
 
 
 
 
Fig.11: Custom made self sizing cuff electrode for combined stimulation and recording of the vagus nerve in rats. 
 
3.3 Overview of biological markers reflecting electrical activation of the vagus nerve 
3.3.1 Introduction 
Epilepsy is one of the most common neurological disorders, yet one third of patients do not respond 
favourably to classical anti-epileptic drugs and a considerable amount of patients report major side 
effects. Epilepsy surgery or neurostimulation are treatment alternatives for some types of epilepsy. 
Although vagus nerve stimulation (VNS) has been introduced many years ago and more than 50,000 
patients were implanted with a vagus nerve stimulator, there are no predictive factors for response. 
Duration of epilepsy (18-21), age at time of implantation (22), type of epilepsy or epilepsy syndrome 
(23-29), age at time of epilepsy onset, do not seem to be independent predictors of outcome( 21). In 
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addition to analysis of large patients groups, identification of neurochemical and electrophysiological 
effects of VNS might lead to more efficient recognition of predictive factors for clinical response. This 
subchapter will review different parameters that reflect electrical stimulation and activation of the 
vagus nerve and highlight those that were correlated with seizure outcome after VNS. 
3.3.2. Vagus nerve stimulation induced evoked potentials 
3.3.2.1 Human experiments 
Evoked potential (EP) recording is a special type of electro-encephalography (EEG) where an 
electrical potential is recorded from the nervous system following presentation of a stimulus. In 
clinical practice, auditory, visual and somatosensory evoked potentials are commonly used to 
evaluate integrity of neural functioning. In addition to appreciating functioning of CNS pathways, EP’s 
can also provide us with a proof of adequate stimulation.  
Therefore, VNS-induced EPs could be used as an indicator for effective stimulation and successful 
transmission to the brain. Only a few studies have measured VNS-induced EPs probably because 
somatotopic cortical representation of vagal information is not fully understood (30). 
Tougas et al. compared cerebral EPs in response to direct vagal and esophageal stimulation in 
humans in order to examine the potential usefulness of studying esophageal EPs as a measure of 
vagal afferent neural function (31). Stimulation of the vagus nerve was provided by a Cyberonics 
model 100 generator who delivered 200 µsec square wave pulses of 1 mA at a rate of 2 Hz. Evoked 
potentials over midline at Cz (international 21 electrode system) were obtained 6 weeks after 
implantation. Vagal and esophageal EPs were similar and consisted of three negative peaks (N1, N2, 
N3) with two intercalated peaks (P1 and P2). Mean latency to the first peak (N1) was 71 +/- 12 msec 
while the latest component (N3) appeared 328 +/- 46 msec after stimulation of the left vagus nerve. 
Authors found a significant delay in latencies of the evoked responses obtained in epileptic patients 
treated with VNS compared to healthy patients. The measured conduction velocity of the afferent 
response was 7.5 m/sec in epileptic subjects and 10 m/sec in healthy controls, suggesting that 
afferent conduction is the result of A-fibres rather than slower C afferent fibres activation. As control 
subjects did not have epilepsy nor VNS, it remains difficult to interpret these results, but authors 
hypothesized their findings could be due to treatment with anti-epileptic drug or to long standing 
poorly controlled epilepsy, although afferent neural damage after surgery may be another possible 
cause for the reported delayed responses. Unfortunately, authors did not check whether a 
correlation between VNS induced seizure reduction and vagal evoked EP’s existed. 
 
 54 
 
The previous study was put into question when Hammond et al. performed a study in which in 
similar way left vagus nerve was stimulated with a Cyberonics model 100 generator (250 µsec, 1 mA, 
5 Hz), but a single negative potential of high amplitude with a peak at about 12 msec and a 
widespread field was recorded (32). 
The generators were shown to be left anterior cervical skeletal muscles by abolishing the vagus 
evoked potential with a neuromuscular agent, and then showing the return of the vagus evoked 
potential after the effects of the blocker were reversed. This response was initiated at low 
stimulation intensity of 1 mA, while Tougas stimulated up to 14 mA and did not report any interfering 
muscle activity (31).  
Interestingly, Hammond proposed activation of the recurrent laryngeal nerve and contraction of 
laryngeal muscles as possible explanation for the myogenic EP. Indeed, all patients reported effects 
on their voice, indicating activation of the recurrent laryngeal nerve. 
Penry JK also reported a cortical vagal EP with a latency of 8.2 msec, though no further analysis was 
done to check whether the EP was myogenic in origin or not (33). 
 
Besides left cervical vagus nerve stimulation with an implanted device, transcutaneous stimulation of 
the vagus nerve (t-VNS) was proposed by Ventureyra (34). Indeed, the vagal nerve has a cutaneous 
representation in the external auditory canal including the inner side of the tragus. Cutaneous stimuli 
of this region are transported via the auricular nerve to the jugular ganglion and from there with the 
vagus nerve into the medulla oblongata and the nucleus tractus solitarius (NTS). Falgatter et al 
described a vagal somatosensory evoked potential (VSEP) in 5 patients, which consisted of two 
positive peaks and one negative peak (P1N1P2) and was most prominent at C4-P4 (35). Mean latency 
for P1 was 2.4 msec, while N1 and P2 appeared at 3.58 and 4.88 msec respectively. VSEP was only 
observed when stimulating within the innervation area of the auricular branch of the vagus nerve, 
while no EP was elicited at other sites. Authors proposed VSEP to be a far field potential of 
postsynaptic brain activity from the vagus nerve nuclei, although it was not excluded that the VSEP 
was a result of the activation of vagus nerve in combination with other brainstem nerves, such as 
facial and trigeminal nerve. In addition, latencies were significantly longer in elderly healthy patients 
as compared to younger participants (36). In context of search of non invasive diagnostic tools, Polak 
et al. found significantly longer VSEP latencies in ten patients with Alzheimer disease and mild 
cognitive impairment (37, 38). This study was based on the knowledge that several vagal nuclei in the 
brainstem show pathological changes and autonomic functions are often impaired in the course of 
Alzheimer disease. In a similar way as it was applied for disease of Alzheimer, research on whether 
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VSEP could function as a predictive tool to identify VNS responders has still to be performed, as no 
literature addresses this question. 
Considering t-VNS, we must bear in mind that transcutaneous approach of  stimulating is far away of 
being a valid alternative for left cervical stimulation, although one study already has shown that t-
VNS shares similar features in bold-fMRI  brain activation patterns with invasive vagus nerve 
stimulation (39). 
3.3.2.2 Animal studies 
In rats, vagal evoked potentials have been recorded from different brain regions.  
The NTS is a main gate of vagal afferents to the rest of the brain and evoked potentials in this 
structure were described by Nosaka for the first time in 1978 (40).  
Results were reproduced by Ito and showed a negative deflection with 4 msec of latency and a 
second negative peak at 25 msec. Both Authors described the first peak as a myelinated (A) response 
and the second one as an unmyelinated (C) response. Interestingly, latency of C response decreased 
as stimulus intensity increased (41). 
Insular cortex is widely accepted to incorporate visceral sensory information transmitted from the 
vagus nerve. Ito has identified two distinct insular cortical responses, an early and late positive 
negative (PN) potential in the granular layer and an equivalent early and late negative positive (NP) 
potential in the agranular layer of the insular cortex, which indicates a local generator of the evoked 
potential (42). 
The early PN and NP potential resulted from activation of myelinated fibres of the vagus nerve and 
had a latency in the range of 20 to 40 msec, while the late response only appeared when c afferents 
were stimulated and occurred between 40 to 90 msec. In addition to activation in the insular cortex, 
Ito also examined whether visceral information projects to an area around S1 (primary 
somatosensory cortex), as natural esophageal stimulation induces activity changes in this region in 
different non-invasive imaging studies (fMRI, MEG and PET) (43-45). Moreover, older studies such as 
the study by O’Brien, have demonstrated evoked bilateral cortical responses in monkeys after 
stimulation of the cervical nerve in the region ventral to the precentral cortex with a latency of < 50 
msec (46). Although regarded as ‘motor cortex’, the area ventral to the motor cortex is known to be 
occupied by the S1. Based on these elements, Ito further analyzed this subject in rats and described 
an S1 field potential, which was comparable in waveform, latency and amplitude to previous granular 
insular potential (positive negative, peak latency 62 +/- 14 ms) and located at the most rostral part of 
parietal granular cortex. Authors concluded that the rat S1 contains a region representing general 
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visceral information, topographically located as if the visceral organs protruded from the mouth in 
the Homunculus of Penfield (30). Furthermore, it was shown through pharmacological studies that 
the three vagal afferent projection sites, namely the S1, granular and agranular insular cortex, 
functioned independently from each other (30, 41, 42).  
One important limitation in these vagal field potential studies is the fact that stimulation of the 
cervical vagal nerve must have activated laryngeal afferents, which are pure somatic in nature and 
consequently the cortical evoked potential recorded probably represents activation of both 
oropharyngeal as well as afferents from visceral tissues (31). 
 
In addition to insular and lateral sensorimotor cortices, vagal activation was also found in the 
thalamus. Based upon anatomical information, Ito et al. found an evoked potential in the expected 
gustatory/visceral thalamic relay nucleus in monkeys (47). In addition, he reported an earlier and 
larger response in the adjacent parafascicular nucleus (Pf) of the thalamus (onset 18msec, peak 35 
msec), which is regarded as an integral component of the striatal network controlling movement. 
Stimulation in the region of the Pf or its main projection target, the basal ganglia, was shown to have 
anti-epileptic effects (48, 49). In addition, functional imaging studies indicate that VNS produces 
strong activation of the basal ganglia (50).  
Finally, vagal evoked responses were reported in the cerebellum of rabbits, more specifically in the 
medial region in lobule VIIa, which was shown to play a role in cardiovascular control (51). Electrical 
stimulation of this region produced an inhibition of the renal sympathic nerve activity and a fall in 
blood pressure in anesthetized rabbits (52). 
In summary, vagal evoked potentials were observed in the NTS, thalamus, lateral portion of 
sensorimotor cortex, insula and cerebellum in different species (rats, rabbits and monkeys). In 
humans, no similar experiments were described, as introduction of depth electrodes remains 
invasive and clinical value of vagal evoked potentials remains to be proven. For this purpose, more 
extensive animal research in which different vagal evoked potentials are correlated with seizure 
outcome after treatment with VNS is needed. 
3.3.3. Effect of VNS on clinically commonly used evoked potentials 
In addition to vagal evoked scalp potentials, Hammond also studied whether VNS induces changes in 
other EP’s, such as auditory brainstem evoked potentials, auditory 40 Hz potentials or cognitive 
evoked potentials, though no effects were found (32). 
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In contrast, Naritoku et al reported significant prolongation of the cervicomedullary to 
thalamocortical potential (N13-N20) on somatosensory evoked potential in three patients
 (53). Two of 
the three patients experienced an improved seizure control.  
As patient population was small no conclusions were made whether N13-N20 interval could be used as 
a predictive factor for beneficial response. Furthermore, anti epileptic drug regiments were not 
specified for the included patients although increases of interpeak latencies of SSEP were described 
during treatment with for example carabamazepine and phenytoin (54).  
 
Therefore influence of anti-epileptic drug treatment on increased latencies of SSEP is not fully 
excluded. Contrary to the study of Hammond, Bradzil et al. described in nine patients treated with 
VNS higher N2/P3 amplitudes of visual EPs (which are cognitive evoked potentials) prior to 
implantation of the VNS system compared to 3-6 months after device activation (55). As alertness 
possibly played a role in P3 parameters, alert state was monitored in patients by means of EEG and 
motor responses. Both remained comparable preceding and following VNS. In addition, a direct 
association between visual N2/P3 peak-to-peak amplitude increase and clinical effects of VNS 
treatment was found, although this was based on a small amount of patients. 
3.3.4. Functional imaging studies 
Different neuro-imaging techniques, like single photon computed tomography (SPECT), positron 
emission computed tomography (PET) and functional magnetic resonance imaging (fMRI), have been 
used to assess changes in brain activations patterns after VNS. There is growing literature about VNS 
combined with functional neuro-imaging, but divergent methodologies make it difficult to compare 
results. For a systematic review we refer to article of Chae et al. (56). 
This subchapter of the thesis will highlight some particular findings especially those that were 
correlated with seizure reduction after VNS. 
Henry et al. performed several acute and chronic PET studies. First, authors studied the acute effects 
in 10 patients who had a H2O (15) IV injection before receiving VNS and again in less than 20h after 
VNS initiation (57). By use of the magnet function which triggers a 30 sec train of VNS, injection of 
H2O (15) O was delivered at the beginning of stimulation when the magnet was placed over the VNS 
generator. 
VNS was given at high and low levels in two groups of 5 patients. Bilateral thalamic increases in 
cerebral blood flow (CBF) occurred in both high- and low-stimulation groups during VNS. In addition, 
significant blood flow increases were observed in both groups in the hypothalami and in the left and 
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right anterior insular cortices, while significant decreases in amygdalar, hippocampal and posterior 
cingulated gyral blood flow were found.  
The authors suggested that the VNS induced decreases might have been a reflection of anti-
convulsant effects of the device, with lower sustaining repetitive ictal firing in these regions, although 
no intracellular recordings were performed to confirm this hypothesis.  
In addition, the high stimulation group had significant blood flow increases in the left and right 
orbitofrontal gyri, right entorhinal cortex and the right temporal pole, which did not occur in the low 
stimulation group, indicating a dose dependent VNS effect. Most importantly, Henry et al. were able 
to demonstrate that acute bilateral thalamic cerebral increases in CBF were correlated with 
decreased seizure frequency, although no definite dose-response correlation was described. Chronic 
VNS after three months of treatment showed similar PET changes, although initial described 
decreases in bilateral hippocampus, amygdala and cingulate gyrus and increases in the bilateral 
insula were not detected in the chronic study. During the chronic study, no CBF changes were 
observed in any region that did not have CBF changes during immediate-effect studies (58,59). 
Interestingly, acute thalamic activations persisted during chronic VNS. In general, authors concluded 
that subcortical regions which showed CBF changes in the short term study persisted in showing the 
same activation in the long-term VNS study, while cortical changes did not persist. Differences might 
have been a reflection of the brain’s adaptation to chronic VNS, as identical PET protocols were 
applied and no changes in VNS parameters or anti epileptic drug treatment were made. Ko et al. 
performed H2O (15) PET scans in patients who were treated with VNS during 5 to 16 months and 
compared scans before and after switching on and off the stimulator (2 mA, 30 Hz) (60) The 
difference between PET with VNS and without revealed that left VNS activated right thalamus, right 
posterior temporal cortex, left putamen and left inferior cerebellum. 
 
In contrast with the PET studies of Henry, our group showed decreased thalamic activity in a SPECT 
study with 99mTC-ethyl cysteinate dimer (ECD:Neurolite) (61, 62). 
A baseline scan was taken 10 min after injection of the bolus of Neurolite while VNS was off and a 
second scan later the same day with VNS switched on from 0.25 mA to 0.5 mA, depending on 
individual tolerance. The second dose was injected at the end of a 30 sec train of VNS. Decreased 
thalamic CBF in acute VNS suggested reduction of seizure onset or propagation through inhibition of 
the thalamic relay centre.  
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The difference between the study of Vonck et al. and Henry may be partially explained by the fact 
that Henry took PET images during the VNS on cycle, while the SPECT study images were taken just 
after VNS was stopped. Moreover, PET and SPECT studies are quite different imaging techniques, 
which also may account for some of the observed differences.  
Nevertheless, it can be speculated that during VNS thalamus has an increased blood flow and that 
immediately after there is a decreased CBF compared to baseline, which could be considered as a 
kind of rebound phenomena. With respect to seizure reduction, Vonck et al found a correlation 
between increased uptake in the left medial inferior temporal lobe and higher seizure reduction. 
Moreover, decreased left thalamic uptake was positively correlated with clinical efficacy. 
Interestingly, thalamic decrease in CBF persisted in chronic SPECT and moreover, no other alterations 
were observed (63). In addition to PET and SPECT, BOLD fMRI studies were performed in patients 
with refractory epilepsy and VNS. This technique doesn’t use any radioactive tracer, but is based on 
detecting changes in cerebral blood oxygenation. Importantly, in a study of Liu, two patients with 
thalamic activation were shown to have a more than 50% seizure reduction, while the other three 
participating patients were non responders and showed no thalamic activation (64). Additionally, the 
patient with greater seizure control had a more robust thalamic activation pattern. Although 
sampling size was small, important role of the thalamus is highlighted once again. 
3.3.5. Cerebrospinal fluid (CSF) 
Ben-Menachem analysed CSF in patients with refractory epilepsy treated with VNS, before initiation 
and after three months of therapy and correlated these findings with seizure reduction up to 9 
months of VNS (65). A trend for decrease of excitatory amino acid asparagine was correlated with 
decreased seizure frequency at maximal follow-up, while GABA, an inhibitory amino acid, was 
elevated in both responders and non- responders. Surprisingly, GABA seemed to be elevated even 
more in non-responders. Similarly, elevated ethanolamine (EA) and phospho-ethanolamine (PEA) at 
three and 9 months respectively also correlated with increased seizure reduction. These substrates 
are brain phospholipids and mark turnover of neural membranes and were shown to be increased in 
extracellular spaces in experimentally induced seizures in animals (66). Possibly, responders were 
patients with initially highest seizure frequency, which could be an explanation for higher levels of EA 
and PEA, but no baseline levels before implantation were available.  
On the other hand, VNS might have induced more neuroplastic changes in the brain of responders, in 
this case EA and PEA possibly could function as a potential VNS predictor, although this a very 
speculative idea. 
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 3.3.6. Transcranial Direct Current Stimulation (tDCS) 
tDCS is non-invasive stimulation technique which was shown to suppress epileptic activity and 
epileptic seizures in animal experiments (67,68) In patients, tDCS was demonstrated to decrease 
frequency of epileptic discharges on EEG and to produce a trend to seizure reduction 1 month after 
application of stimulation (69,70). Currently, a study is being carried out at University of Luebeck 
(Germany), to examine whether tDCS can be used as a predictive tool in VNS responder identification. 
A prior positive effect after a single tDCS on short time seizure reduction and epileptiform discharges 
on EEG will be correlated be VNS outcome in patients with refractory epilepsy 
3.3. 7. Effects of VNS on IL-8 
The role of VNS in controlling and modulating inflammatory responses was investigated by our group 
by measuring cytokines produced by peripheral blood mononuclear cells before and after VNS (71). 
IL-8 was significantly decreased after 6 months of VNS. No correlation could be made between 
decrease of IL-8 and seizure outcome, but patient population was small (n=10). Il-8 is a chemokine 
produced by macrophages and other immune cells and it has a major role in the inflammatory 
response. Future studies on larger amounts of patients might clarify whether responders and non 
responders have a different cytokine profile after VNS. 
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Chapter 4 
Regarding optimization of VNS technology, this study describes in a retrospective way 
implementation of the latest Cyberonics VNS device, i.e. the Demipulse generator. Results showed 
that similar positive effects on seizure reduction were obtained compared to older generators. More 
importantly, main technical advancements were decreased size and improved software for the 
follow-up of impedance measurements and battery life. 
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Abstract  
Rationale: Vagus nerve stimulation (VNS) is a frequently used treatment for patients with refractory 
epilepsy who are unsuitable candidates for epilepsy surgery. There has been a steady evolution in 
VNS technology, as generators´ volumes have become smaller and battery life expectancy longer. 
This pilot study is an open label retrospective study that describes our experience with the latest 
commercially available generator ie. the VNS TherapyTM Demipulse Model 103. Treatment efficacy 
and side-effects, as well as technical and practical enhancements useful for the patient and for the 
medical staff are discussed in this study.  
Methods: Twenty patients (11F/9M) with a mean age of 40 years (range 8-61), who were considered 
unsuitable candidates for resective surgery, were implanted with a VNS TherapyTM Demipulse Model 
103. Mean monthly seizure frequency reduction and side effects were evaluated 1 year after 
implantation.  
Results: Mean monthly seizure frequency decreased significantly from 54 seizures/month (SEM 30; 
range 1-555) before treatment to 33 (SEM 24, range 0-445) following 12 months of treatment. 
(p<0.05). Seven patients (39%) were considered responders with a reduction in seizure frequency of 
more than 50%. One of those seven patients became seizure free. Side effects were stimulation-
related tingling sensation in the throat and/or hoarseness, a painful sensation in the left neck or ear 
region and a lead breakage In addition; one case of “sudden unexpected death in epilepsy” (SUDEP) 
was reported. 
Conclusion: Patients treated with VNS TherapyTM Demipulse generators proved to have a significant 
decrease in seizure frequency. In this patient group, VNS was well tolerated. The main technical 
advances are the decrease in size and improved options for battery life follow-up. 
Keywords: vagus nerve stimulation, generator, Demipulse, refractory epilepsy 
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4.1. Introduction 
Vagus nerve stimulation (VNS) is indicated in patients with medically or surgically refractory epilepsy. 
More than 50.000 patients worldwide have been implanted with VNS therapy TM devices since 1989. 
Initially, efficacy of VNS for refractory epilepsy was studied in the randomised double-blind placebo-
controlled E03 and E05 studies, which included 114 and 198 patients with a follow-up of three 
months (1, 2). In these studies, seizure frequency reduction was compared between a high, so-called 
effective stimulation group and a low, so-called placebo stimulation group. The E03 study found a 
decrease in seizures of 24 % in the high stimulation group versus 6 % in the low stimulation group, 
while the E05 study found a 28 % decrease in seizure frequency in the high stimulation group versus 
15 % in the low stimulation group (1, 2). Prospective and retrospective long-term open-label studies 
confirmed VNS efficacy and safety in adults and children with refractory epilepsy (3-11). In parallel 
with the increasing amount of clinical data, there has been a steady evolution in VNS technology, as 
the size of the generator has become smaller (Fig.1) and battery life expectancy has increased at 
each new generator release.  
 
 
 
 
 
 
 
Fig. 1- Volume reduction of VNS generators over time 
 
This pilot study is an open-label retrospective study that describes our experience with the latest 
commercially available generator ie. the VNS TherapyTM Demipulse Model 103. Treatment efficacy 
and side-effects, as well as technical and practical enhancements useful for neurologists, 
neurosurgeons and for the patient, are discussed in this study. This study is the first to date to report 
clinical experience with Demipulse generators. 
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4.2. Patients and Methods 
4.2.1 Patient population and pre-surgical evaluation 
Between 1/6/2007 and 1/12/2009, 40 patients were implanted with a VNS device (Cyberonics®, 
Houston, USA) at the Ghent University Hospital. All patients were diagnosed with refractory epilepsy 
and underwent long-term video-EEG monitoring for seizure detection, 3 Tesla brain MRI and PET 
scan as part of the pre-surgical evaluation. All patients were considered unsuitable candidates for 
resective surgery, either because the epileptic focus remained unidentified, or because it was located 
in functional cortex. Subsequently they were offered treatment with VNS. For the purpose of this 
study, medical records of patients implanted with a VNS therapy TM Demipulse Model 103 were 
evaluated. Patients with a post-implantation follow-up of at least 1 year were included in this study. 
Additionally, a documentation of seizure frequency before implantation and at maximal follow-up 
was required.  
4.2.2 Implantation procedure 
The system was implanted under general anaesthesia via two short incisions.  The first incision was 
placed in a skin fold at the left base of the neck, about 3 cm above the clavicle and across the medial 
border of the sternocleidomastoid muscle. The left vagus nerve was searched for between the 
common carotid artery and the internal jugular vein, and exposed over a distance of 3 cm. Using 
optical magnification, the helical tether and the two helical electrodes were wrapped around the 
nerve.  The lead was carried to the surface in smooth loops and anchored twice, both to the deep 
and to the superficial cervical fascia.  Through a second, also transverse, incision below the left 
clavicle on the mamillary line, a small epifascial pouch was shaped in which the pulse generator 
(Cyberonics Demipulse, model 103 or 104) was placed.  The lead was subcutaneously tunneled from 
the first to the second incision and plugged into the pulse generator. The system was telemetrically 
verified before the pulse generator was anchored to the pectoral fascia and the wounds were closed. 
4.2.3 Ramping-up procedure and stimulation parameters 
Stimulation was initiated 2 to 4 weeks after surgery at the epilepsy clinic. Stimulation intensity was 
gradually increased over the next months with steps of 0.25 mA until seizure control was reached or 
side effects appeared. The other stimulation parameters were programmed as follows: pulse width 
250-500 µsec; frequency 20-30 Hz; on/off cycle 30 sec on/10 min off or 30 sec on /5min off. As part 
of normal clinical practice in patients treated with VNS at the Ghent University Hospital, anti-
epileptic drug (AED) treatment was preferably left unchanged during the first 12 months of follow-up. 
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4.2.4 Outcome measures 
The clinical data collected for this study included: gender and age at time of implantation; type of 
epilepsy; mean monthly seizure frequency before implantation and at maximal follow-up; number of 
anti-epileptic drugs taken before implantation and at maximal follow-up; stimulation intensity at 
maximum follow-up. In addition, properties of the surgical implantation procedure as well as user 
friendly characteristics for neurologist and patients were assessed.  
Monthly seizure frequency pre-VNS was based on seizure frequency reported one month before date 
of surgery. Mean monthly seizure frequency post-VNS resulted from an average of two to three 
consecutive months at maximum follow-up.  
Type of epilepsy was based on clinical semiology of the seizures and ictal and interictal 
electroencephalographic recordings.  
Primary outcome measures included reduction in mean monthly seizure frequency and the 
percentage of patients with a seizure frequency reduction of 50% or more (responder rate). 
Secondary outcome measures were the changes in number of concomitant AEDs taken at maximum 
follow-up compared to before stimulation and stimulation output at maximum follow-up. 
Outcome measures were first calculated for the entire study group. Subsequently, the study 
population was divided into two groups: responders (seizure frequency reduction of 50% or more) 
and non-responders (seizure frequency reduction between of less than 50%). Outcome parameters 
were assessed for the two groups separately. 
4.2.5 Ethical approval  
This retrospective study was approved by the Ethical Committee of Ghent University Hospital (EC 
2005/238 and EC 2009/604). Informed consent was obtained from all patients.  
4.2.6 Statistical analysis 
Group mean differences in percentage of reductions in seizure frequency and differences in mean 
monthly seizure frequencies were tested non-parametrically. Statistical significance was set on p< 
0.05. All calculations were performed using SPSS 15.0. 
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4.3. Results 
4.3.1 Patient population 
Twenty patients (11 females, 9 males) with a mean age of 40 years (range 8-61) were included in the 
study. Sixteen patients had localised epilepsy with complex partial seizures with or without 
secondary generalisation. Four patients had generalised epilepsy with tonic clonic seizures, absences 
or myoclonic seizures. Two patients had a follow-up of 6 and 8 months due to early discontinuation 
of VNS therapy (1 sudden unexplained death in epilepsy (SUDEP) and 1 lead breakage respectively). 
They were excluded from further statistical analysis.  
4.3.2 Seizure frequency reduction and responder rate (Table 1) 
Mean monthly seizure frequency before implantation was 54 seizures/month (SEM 30, range 1-555), 
mean monthly seizure frequency at maximum follow-up was 33 seizures/month (SEM 24, range 0- 
445) (Wilcoxon Signed Ranks test, <0.05) Seven patients (39%) were considered responders with a 
reduction in seizure frequency of more than 50%. One of those seven patients became seizure free. 
Eleven patients (61%) were non responders (reduction in seizure frequency of less than 50%). In the 
non responder group, three patients (16%)  
responded with a seizure frequency reduction between 30 and 50%, two patients (11%) responded 
with a seizure frequency reduction of less than 30%, five patients (28%) experienced no change in 
seizure frequency and one patient reported a small increase in seizure frequency.  
 
 
 
 
 
 
 
 
 
 
 
 
Table1: Overview of 
primary and 
secondary outcome 
parameters in patient 
population. 
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Responders started to respond to their VNS treatment at month 7 after date of implantation, while 
no effect was seen over time in the non responder group (see Fig 2) (Wilcoxon Signed Ranks test, 
p<0.05). 
 
 
. 
 
4.3.3 Comparison between responders, partial responders and non-responders 
There were no significant differences regarding seizure frequency before VNS, mean age at time of 
implantation and number of AEDs before implantation, between the responder and non-responder 
group (Table 1).  
The mean stimulation output current at maximal follow-up was 1.79 mA (range 0.75 -2.5 mA) (Fig.3). 
Responders had a lower mean stimulation output at maximal follow-up (1.64 mA, range 0.75 - 
2.25mA) in comparison to non-responders (1.88 mA, range 1.5 - 2.5 mA), although these differences 
were not statistically significant. Mean number of AEDs before and after implantation in the 
responder and non-responder was 3 (range of 2-5 for the responders and 2-4 for the non-
responders). These results, although based on small amount of patients, are in accordance with data 
in the literature in which these variables did not appear to be independent predictors of outcome  
(7, 14-19). 
Fig. 2 Evolution of mean monthly seizure frequency in responders and partial responders compared to non 
responders over time. Responders started to respond to their VNS treatment at month 7 after date of 
implantation 
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Fig. 3 Percentage of patients programmed at different stimulation outputs at maximal follow-up. 
4.3.4 Reported side effects 
All patients reported a stimulation-related tingling sensation in the throat and/or hoarseness, 
especially during the ramping-up period. Two patients reported a painful sensation in the left neck or 
ear during stimulation at 2 and 2.25 mA, respectively. Other stimulation parameters for both patients 
were: 20 Hz, 500 µsec, 30 sec on/5 min off. One of those patients also complained of a light 
dyspnoea when lying on her left side. The dyspnoea was not continuously present over time, even 
though stimulation parameters were not adjusted.  
One mentally retarded patient, which was considered as a partial responder at 6 months of follow-up, 
had a habit to frequently rotate his generator subcutaneously, which resulted in a corkscrew shaped 
lead and finally to a lead breakage. Consequently, at 8 months of follow up, interrogation of his VNS 
device showed a very low lead impedance (< 200 ohm), which indicated a short-circuit of his VNS 
system. Subsequently, the output current was programmed at 0 mA. As seizure frequency did not 
increase in the following months, it was decided not to replace the VNS device. 
4.4. SUDEP 
One patient died suddenly at the age of 62 after 6 months of follow-up. She was found at home in 
asystole with bilateral light-rigid pupils. The patient was transported to an intensive care unit after 
receiving emergency care at home, but she died shortly after. No specific cause of death was 
identified on autopsy. This case was considered as a ‘sudden unexpected death in epilepsy (SUDEP). 
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4.5 Discussion  
In this retrospective study we evaluated the efficacy, safety and practical enhancements of the latest 
commercially available VNS device, the VNS Therapy Demipulse 103 Model (Cyberonics®, Houston, 
USA), in the treatment of patients with refractory epilepsy.  
Demipulse generators seem to have similar efficacy as previous generators in the treatment of 
refractory epilepsy. We evaluated VNS therapy with Demipulse generators after 12 months of 
stimulation. Our study yielded a responder rate of 39%. This result is comparable to the results 
obtained with previous models of VNS generators, such as the study by Morris et al, who described 
responder rates of 23% at 3 months and 37% at 1 year (12). Other retrospective and prospective 
studies reported similar or slightly higher responder rates after at least one year of stimulation, such 
as 26% (10), 48% (7), 50% (11) or 54%. (3). In our study, mean stimulation output in the responder 
group was 1.79 mA range (0.75 -2.5), which is similar to results reported by DeGiorgio (13). 
Besides equivalent efficacy, Demipulse generators appeared to have similar tolerability as previous 
generators, as no new side effects were described in our study. (1-3, 12, 13).  We report 1 case of 
SUDEP and one case in which VNS therapy was stopped due to a lead breakage. The relationship 
between VNS and SUDEP has been subject of research, although no correlations between VNS 
treatment and SUDEP were found (8, 20-22). Lead breakages were also reported in previous studies, 
especially in children en mentally retarded patients (23, 24). 
Due to reduced generator volume, Demipulse generators are more easily implanted, which reduces 
considerably possible surgery related complications. Earlier versions of the VNS pulse generator 
required larger incisions and larger pouches for implantation; they also brought about more distinct 
skin eminences in the pectoral region and some tension on the wound edges. In order to avoid 
unaesthetic scars the insertion of the pulse generator was often performed via an incision on the 
anterior axillary line (and in some cases underneath the pectoralis muscle), which implicated a longer 
and broader range of dissection and, hence, more frequent problems of pouch hematoma and pain 
after surgery. The pulse generators n° 103 and 104, in virtue of their small size and weight, do not 
require such coping strategies. The short skin incision can be placed directly over the site of insertion 
in the pectoral region, and can be aesthetically closed with a running intradermal suture or with glue. 
Problems of pouch hematoma or pain have become virtually eliminated. Moreover, in our study no 
single infection of generator or lead implantation site was reported, although this is the most 
common observed surgical complication in published trials with older devices with an incidence 
varying around 3% (23, 25). Even though cosmetic advantages are not a priority in health care in 
general, it is worthwhile noting that epilepsy patients often deal with a lot of prejudice, which 
indirectly affects their social and economic integration in our society.  
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Discrete scars enhance their well being and ameliorate their daily social life. For this reason cosmetic 
advantage of Demipulse must be emphasized. 
Besides the surgical and esthetical advantages of smaller generator volume, Demipulse generators 
also enhance treatment and clinical follow-up of patients. First of all, the generator life projection 
system displays the end of life (EOL) in exact amount of years and months in function of programmed 
parameters and warns the clinician 6 months ahead to foresee generator replacement. This is of 
particular value, as postponing generator replacement may result into permanent loss of seizure 
control (26). Battery life depends on many factors including the generator model, stimulation 
parameters, lead impedance and magnet use. The first model developed for human use, Model 100 
(2002), had an expected battery life of 4-8 years. For the second generation of generators i.e. Model 
101 (2003) battery life increased to 8-12 years. Model 102 and models 103/104 (2007, Demipulse) 
have similar life expectancies as model 101. Ideally, future technology development will allow 
transcutaneous battery recharge and render generator replacements unnecessary. This will further 
ameliorate quality of life of patients and reduce health care costs. 
Another important feature useful for clinicians is the fact that Demipulse generators are capable of 
measuring lead impedances in Ohms, while older models only delivered DC-DC converter codes. This 
gives the clinician more accurate information about the good functioning of the VNS device. Lead 
impedance should vary between 200 Ohm (low impedance) and 7kOhm (high impedance). If high 
impedance is discovered upon interrogation of the device, a discontinuity of the lead or fibrosis 
between the nerve and the lead may be the reason. To check whether a lead breakage is present, a 
radiography or CT scan of the neck can be performed. In other cases a surgical revision of the device 
may be needed. Demipulse generators are able to measure lead impedance every 24 hours. If the 
impedance has reached “high” or “low” values between interrogations at office visits, a warning 
message will be displayed when interrogating the device. For the moment, the device does not 
inform the clinician about the exact date/hour on which lead impedance changed. This element 
could be useful to correlate with certain potentially harmful events, such as an important head or 
neck trauma which could explain breakage of the lead. In our study, one mentally retarded patient, 
showed a very low impedance (<200 ohm), which indicated a short circuit of his VNS device. 
Despite the fact that VNS therapy as a treatment for epilepsy has proven to reduce significantly 
health care utilisation and its related costs (27, 28), Demipulse generators are not reimbursed in all 
countries. In addition to equal efficacy and tolerability in comparison with older devices,  
Demipulse generators have better surgical characteristics and improve clinical follow-up of patients 
treated with VNS. Future studies with larger amount of patients are needed to confirm improved 
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capacities of Demipulse VNS devices, which hopefully will lead to reimbursements of the new model 
103 in all concerned countries. 
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Chapter 5 
Improvement of VNS technology is a growing field of interest. This chapter describes a pilot trial with 
a new VNS device, the ADNS-300. Main keyfeatures include a transcutaneous rechargeable generator 
and a combined stimulation and recording electrode. We report for the first time human vagus nerve 
CAP’s in vivo with an implantable device. This study demonstrates the use of the ADNS-300 system 
for combined therapeutic stimulation and recording of CAPs in response to VNS. 
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Abstract 
Purpose: Vagus nerve stimulation (VNS) is an established treatment for refractory epilepsy. The 
ADNS-300 is a new system for VNS that includes a rechargeable stimulus generator and an electrode 
for combined stimulation and recording. In this feasibility study, three patients were implanted with 
ADNS-300 for therapeutic VNS. In addition, Compound Action Potentials (CAPs) were recorded to 
evaluate activation of the vagus nerve in response to VNS. 
Methods: Three patients were implanted with a cuff-electrode around the left vagus nerve that was 
connected to a rechargeable pulse generator under the left clavicula. Two weeks after surgery, 
therapeutic VNS (0.25 mA to 1.25 mA, 500µsec, 30 sec On, 10 min Off and 30 Hz) was initiated and 
stimulus-induced CAPs were recorded. 
Results:  
The ADNS-300 system was successfully implanted in all three patients and patients were 
appropriately stimulated during six months of follow-up. 
A reduction in seizure frequency was demonstrated in two patients (43% and 40% in patient 1 and 3 
respectively), while in patient 2 seizure frequency remained unchanged. CAPs could be recorded in 
patient 1 and 2, proving stimulation-induced activation of the vagus nerve. 
Conclusion: 
This feasibility study demonstrates that the ADNS-300 system can be used for combined therapeutic 
stimulation (in 3/3 patients) and recording of CAPs in response to VNS (in 2/3 patients) up to three 
weeks after surgery. Implantation in a larger number of patients will lead to a better understanding 
of the electrophysiology of the vagus nerve, which in turn could result in more adequate and 
individualized VNS parameter choice.  
Keywords: vagus nerve stimulation, Compound action potential, epilepsy 
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5.1 Introduction: 
Vagus nerve stimulation (VNS) is an established treatment for refractory epilepsy. More than 50,000 
patients worldwide have been implanted with VNS therapy TM (Cyberonics®) devices since 1989. 
Despite the fact that VNS is a recognised adjunctive treatment for epilepsy, the mechanism by which 
therapeutic VNS reduces seizure activity is not yet fully understood. Moreover, reduction in seizure 
frequency in patients treated with VNS varies considerably (1-9). Unfortunately, no predictive factors 
to identify responders have been found to date (5,6,10-18). Unravelling the mechanism of action of 
VNS could lead to improved treatment and follow-up of patients treated with VNS. In this context, a 
new VNS device, the Advanced Nerve Stimulator version 300 (ADNS-300, Neurotech SA, Louvain-La-
Neuve, Belgium), allows recording of compound action potentials (CAPs) of the vagus nerve in 
addition to stimulation of the vagus nerve. 
Recordings may result into better understanding of the electrophysiological properties of the vagus 
nerve. Optimal VNS parameters were derived from animal experimental studies in which anti-seizure 
effects of VNS were proven (19-25). Later on, these pre-clinical VNS parameters were applied in early 
clinical randomized controlled trials (1-4,8). However, in none of these studies, stimulation 
parameters were derived from individual electrophysiological properties of the human vagus nerve. 
The incorporated recording option of the ADNS-300 may remedy this shortcoming and may offer the 
opportunity to select stimulation parameters on an individual basis. Apart from this new feature, the 
ADNS-300 has a transcutaneous battery recharging system, that may reduce the need for generator 
replacements. The ADNS-300 is further designed to be implanted in approximately the same way as 
the Cyberonics device 
This feasibility study aimed at evaluating the use of the ADNS-300 system for therapeutic VNS and 
reporting, for the first time, in vivo recording of CAPs of the vagus nerve with an implantable device. 
5.2 Patients, materials and methods 
5.2.1 Patients 
Three patients with refractory epilepsy underwent a full pre-surgical evaluation that included a 
video-EEG monitoring, 3 Tesla MRI and FDG-PET of the brain. A multidisciplinary epilepsy surgery 
team considered these patients unsuitable candidates for resective surgery, either because no clear 
epileptic focus was found or because the epileptogenic focus was located in eloquent brain tissue. 
 Patients were then considered candidates for VNS treatment. Seizure frequency was evaluated 
prospectively three months before implantation and monthly after implantation up to a 6 months 
follow-up period. 
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5.2.2 ADNS 3.0 device (Fig 1) 
5.2.2.1 Generator, electrode and lead  
The ADNS-300 generator has a volume of 7 cc is surgically implanted in a subcutaneous pouch under 
the left clavicle and is connected with a subcutaneous lead to the stimulation/recording electrode 
around the left vagus nerve. The generator is a bipolar current source with a compliance of +/- 8VDC.  
 
 
The electrode is a self-sizing spiral cuff consisting of two separate rings of 3 platinum contacts with a 
total surface of 0.6 mm² which are used as stimulation cathode and anode. A longitudinally arranged 
tripolar set of 0.2 mm² contacts provides the compound nerve action potentials recording derivation. 
The stimulation anode and cathode are spaced 4 mm from each other, while the first recording 
contact is situated 5 mm rostral from the stimulation cathode (Fig 2). The three recording contacts 
are separated by 5 mm intervals. The middle one is considered as the active recording contact 
referred to the outer two which are connected to each other. The total length of the cuff electrode is 
22 mm. The stimulation anode is oriented caudally, while the cathode and recording contacts are 
directed rostrally, allowing recording of orthodromic signals. The inner cuff diameter is 1,9 mm and is 
designed to fit the nerve snugly.  
 
The lead is 43 cm long and is made of four helically wounded Teflon insulated multi-strand wires 
embedded in silicone rubber.  From a surgical point of view the implantation of the ADNS-300 pulse 
generator does not differ from the implantation of the Cyberonics device. The electrode of the ADNS-
300 system, however, resembles a miniature parchment roll whereas the Cyberonics electrode 
Fig. 2: Schematic representation of the ADNS-300 electrode 
Fig. 1 T he ADNS-300 vagus nerve stimulator. 
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consists of three separate springlike spirals. The latter are at implantation consecutively stretched via 
bits of strings at their ends in order to allow the vagus nerve to enter the spirals´ cores, where after 
the spirals regain their original shapes and thus contain the nerve.  Some additional manipulation 
may, however, be necessary to wrap the spirals properly around the nerve.  The ADNS-300 electrode 
is being unwrapped to a sheet that is placed underneath the vagus nerve. At releasing the sheet 
margins, the electrode folds back to its original roll-like shape to contain the nerve. In either system 
the lead is secured to the deep and the superficial tissue layers to protect the electrode and the 
nerve against traction. 
5.2.2.2 Patient’s and physician’s external controller  
The patient’s external controller is a handheld battery-operated device that enables the patient to 
visualize the status of the implanted generator’s battery, to carry out a pause or an additional acute 
stimulation at the onset of a seizure.  
In both cases parameters of temporary interruption or additional stimulation are programmed 
beforehand by the neurologist. The external pebble does not allow the patient to adapt the 
stimulation parameters own handed. 
The physician’s external controller allows interrogating the implanted device, checking battery 
voltage as well as lead impedance, programming of new parameter settings and recording CAPs. 
These functions use a Medical Implant Communication Service (MICS) communication between the 
implant and the main computer system. 
5.2.3 Ramping-up procedure and stimulation parameters 
The stimulation paradigm was comparable to the one used in previous studies done by our group 
(26-30). Stimulation was initiated two weeks after surgery at the epilepsy clinic using the following 
parameters: pulse width 500µsec; frequency 30 Hz; duty cycle 30 sec on/10 min off. The stimulation 
intensity was gradually increased with steps of 0.20 mA or 0.25 mA at intervals of at least two weeks 
until either seizure control was reached or side effects appeared. Anti-epileptic drug treatment was 
kept unchanged during the entire follow-up. This regimen was applied in all three patients. Other 
possible parameter settings, such as pulse frequency, pulse duration and signal time on or off were 
identical to previous reported studies using the Cyberonics VNS device (26-30). Only the parameters 
described above were adjusted here. 
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5.2.4 Clinical outcome measures 
The clinical data collected for this study included the following: gender, age, type of seizures and 
epilepsy, mean monthly seizure frequency before implantation and at the end of the follow-up 
period. The stimulation intensity reached at the end of the follow-up was also recorded. Pre-VNS 
monthly seizure frequencies were prospectively assessed during three consecutive months before 
the date of surgery. Mean post-VNS monthly seizure frequency was based on the reported seizure 
frequency at the sixth month after implantation. At each time point, patients carefully noted the 
number of seizures in a commonly used seizure diary. 
5.2.5 CAPs 
The vagus nerve was stimulated at a frequency of 1 or 2 Hz with a biphasic charge-balanced pulse of 
500 µA and 250 µsec pulse width. The initial anodic ‘recovery’ or charge balancing phase had a lower 
(1/5 ratio) amplitude and longer (5/1) duration than the second cathodic stimulation phase. 
Amplitude and duration values refer to the current intensity and duration of this second phase. This 
‘recovery-before-stimulating-phase’ scheme avoids the charge recovery to interfere with the CAP 
recording. To further reduce stimulation related artifacts, the amplifier was shorted from the start of 
the stimulation until 200 µs thereafter. 
 Signals were recorded starting 200 µs after the end of the second phase of the stimulation pulse. To 
obtain clean traces, 4 to 32 identical sweeps were recorded and averaged. In addition, battery level 
and impedance of the stimulation contacts were measured on consecutive visits. The contact 
impedance of the stimulation electrodes is expressed in kOhms and defined as the voltage to current 
ratio measured at the end of the second phase of a stimulation pulse with 500 µA amplitude and 150 
µs duration. 
5.2.6 Data analysis 
Data analysis of the CAPs was carried out offline using Mathcad 13. Because of the proximity 
between the stimulating and recording electrodes, a large stimulus artifact hides the neural 
responses. Hence, artifact reducing algorithms were applied using Mathcad 13. First, the raw traces 
were compensated for the 66 msec time constant of the single pole high-pass filter of the implanted 
amplifier. The result is characterized by a DC offset and a trend that is estimated by linear regression 
on the last 2.5 msec of 12.8 msec traces which subsequently was subtracted from the signals. Finally, 
if an exponential could be fitted simultaneously on the first maximum value and on the trace area, it 
was subtracted from the trace as well. This subtraction is justified on the basis of the known 
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exponential post-stimulus potentials resulting from local ionic shifts induced by the applied current 
pulses (31). 
Latency was measured from the beginning of the stimulus artifact to various peaks of the compound 
action potential waveforms. 
5.2.7 Ethical approval 
The ADNS-300 system is complying with applicable European and Belgian regulatory requirements 
and in particular the European Council Directive 90/385/EEC relevant to Active Implantable Medical 
Devices. 
This study was approved by the Ethics Committee of Ghent University hospital (EC 2008/274). 
Informed consent was given by all patients. 
5.3 Results 
5.3.1 Feasibility 
All three patients were successfully implanted with the ADNS-300 system. No postoperative 
complications occurred. Impedance values over consecutive visits remained below 8 kOhm (Fig. 3). 
Transcutaneous recharging of the generator was performed once to twice a week for about two 
hours, which was sufficient to allow appropriate therapeutic stimulation. Patients did not feel any 
discomfort while charging the battery.  
 
 
 
 
 
 
 
 
 
 
Fig.3: Stimulation electrode impedance (kOhms) history for all three patients. 
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Electrode contact impedance values are largely non-linear, i.e. dependent on the applied current or 
voltage. For this reason, it remains difficult to compare electrode impedances between two different 
VNS systems, as the method to estimate the impedance differ.  
On the other hand, the total stimulation contact surface area is smaller for the Neurotech electrode 
compared to the Cyberonics device, also explaining some of the difference. More importantly, Fig 3 
shows that impedance values remain quite stable over time. 
5.3.2 Patient outcome (Table 1). 
The first patient was a 59-year-old female with focal symptomatic epilepsy and seizure onset from 
the right parietal or frontal region. Seizures were characterized by an aura of a tingling sensation in 
the left hand, followed by an impairment of consciousness with important hyperventilation and 
motor automatisms of both shoulders and arms, most pronounced on the right side. The patient 
showed a seizure frequency reduction of 43% (28 seizures/month before VNS compared to 16 
seizures/month after 6 months of VNS) At that time point, VNS had been ramped up to 1.25 mA.  
The second patient was a 47-year-old male who developed post-lesional epilepsy 6 months after 
experiencing a stroke of the left medial cerebral artery. This resulted in a mixed aphasia and a 
residual minor hemiparesis of the right arm and leg.  
The patient suffered from simple partial motor seizures with clonic movements of the right arm and 
leg, complex partial seizures with mainly staring and occasionally secondary generalization. 
After six months follow-up, there was no reduction in the seizure frequency. VNS was ramped up 
until 0.75 mA and stopped thereafter due to the appearance of painful sensation in the left neck area. 
The third patient was a 35-year-old female who experienced salmonella encephalitis at the age of 9 
months. She developed a right hemispastic syndrome and postlesional epilepsy. Her seizures were 
characterized by an aura of a bad taste in the mouth, followed by a complex partial phase with 
behavioral arrest, orobuccal and manual automatisms which were occasionally accompanied by 
clonic movements of the right arm. This patient was rather cautious for her VNS treatment and had a 
very anxious character. As the ADNS-300 allowed up titrating in smaller steps of 0.2 mA, we have 
chosen to apply this option in her case. Seizure frequency decreased by 40% after 6 months of VNS 
(seizure frequency decreased from 15 to 9 seizures/ month). Output intensity at 6 months of follow-
up was 1.2 mA.  
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In all cases, the ‘temporary interruption’ or ‘additional stimulation at seizure onset’ functions were 
not used by our patients, as they felt no need for it, either because hoarseness did not affect their 
daily life, or because seizures started too quickly, leaving them no time to switch on the external 
controller. There was no difference in tolerability whether the stimulus intensity was increased by 0.2 
or 0.25 mA steps. 
 
5.3.3 Reported side effects (Table 2). 
All patients reported stimulation-related hoarseness, especially during the ramping-up period. In 
patient 3, this side effect completely disappeared after a few months of stimulation. In the other two 
patients, hoarseness persisted but did not lead to any inconvenience in daily life (Table 2). Patient 1 
and 2 reported at 1 mA of output intensity and frequency of 30 Hz, a stimulus-related painful 
sensation in left side of the neck which radiated towards the left ear. Consequently, stimulation 
intensity had to be reduced to 0.75 mA in patient 2, while in patient 1 this side effect attenuated 
over time. Moreover, patient 2 experienced a beneficial effect of VNS and consequently intensity was 
further increased to 1.25 mA. 
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5.3.4 CAPs of the vagus nerve 
CAPs were recorded at week 2 or 3 in patient 1 and 2 respectively. No reproducible CAP recording 
was possible in patient 3. X-ray could not show loss of continuity in this patient. In this patient, we 
checked whether stimulation pulses were delivered appropriately with an amplifier and oscilloscope 
setup. In fig. 4a and 4b two examples of vagal CAPs are presented from patient 1 and 2 respectively. 
In both cases the vagus nerve was stimulated with a pulse of 500 µA intensity, 250 µsec pulse 
duration. The first peak of the CAP appeared at 0.4 msec after the end of the stimulus and consisted 
of a sharp negative deflection (N1), that was followed by a positive (P1) (0.65 msec) and second 
negative deflection (N2) (1.35-1.45 msec). Despite optimized filtering, N1 was masked by a large initial 
artifact in patient 2. In contrast, the later waves P1 and N2 were more consistently recognised. 
Therefore, in patient 2, we chose to concentrate on the P1-N2 difference for amplitude 
measurements. In addition to P1-N2, more common and logical N1-P1 was calculated in patient 1. The 
maximal amplitude of N1-P1 in patient 1 was 58.26 µV, while P1-N2 was 19.44 µV. In patient 2, P1-N2 
amplitude was 61.4 µV. The threshold for these responses was situated between 100 and 150 µA in 
both patients. When pulse duration was shortened to 100 µsec, the threshold stimulus intensity 
increased to a value between 200 and 250 µA in patient 1 and 250 and 500 µA in patient 2. 
 
 
 
 
5.4 Discussion 
Previous human studies on VNS mainly focused on clinical response in terms of seizure reduction (2-
8,10-18,32-33) and a wide range of studies attempted to unravel the mechanism of action of VNS by 
Fig 4 (a,b): CAPs obtained from the vagus nerve after applying a 500 µA stimulus of 250 µsec duration at week 2 to 3 after 
date of implantation. a: in patient 1 a N1P1N2 CAP was measured. b: in patient 2 N1 was masked by a large initial 
stimulation artefact and only P1-N2 was identifiable. 
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means of electrophysiological recordings, mainly EEG (34-40),evoked potentials (41-45) and 
functional radiological imaging (26,28,46-50). As the effect of VNS on the brain is ultimately 
dependent on the activation of the vagus nerve itself (20-21), a study of the electrophysiological 
nerve response is essential for a better understanding of VNS. To date, no biological markers of 
effective vagal stimulation are available. CAPs of the vagus nerve may serve as a new tool to indicate 
effective stimulation and choose more adequate stimulation parameters. The ADNS-300 offers such 
an opportunity to combine VNS with CAP recording. 
Three patients with refractory epilepsy were successfully implanted with the new stimulator. Two of 
the three patients responded to the treatment and reported a 43% and 40% reduction of seizure 
frequency (patient 1 and 3). 
Patient 2 experienced no improvement after 6 months of treatment but side effects limited further 
increase of the stimulation intensity baseline seizure frequency was already relatively low.  
Moreover, evaluation of the VNS treatment was performed at month 6, while the literature 
recommends treating patients up to 12 or 18 months before drawing any conclusions about seizure 
outcome (4,7-9). In terms of side effects, patients reported stimulation-related hoarseness, which 
was transient in patient 3, but persisted in patient 1 and 2. In addition, patient 1 and 2 experienced 
pain in the left neck region at 1 mA and 0,75 mA respectively. Both side effects have already been 
described in earlier studies with Cyberonics® vagus nerve stimulator (1,2,4,7,32), although in the 
present cases these complaints as well as the therapeutic effect appeared at relatively low intensities 
compared to previous studies. This could be partially explained by the fact that the implanted 
electrode of the ADNS-300 has a cuff structure in which the shielding effect of the insulating silicone 
rubber sheet minimizes leakage of current to the surrounding tissues and provides more efficient 
stimulation of the vagus nerve. 
Regarding user friendliness, the ADNS 300 generator can be recharged transcutaneously, resulting in 
a postponed surgical replacement of the generator and a prolonged battery lifespan of 
approximately 12 years. Interrogation of the device informs the physician about impedance values of 
the stimulation contacts and delivers a history chart of these measurements. In the event of a lead 
breakage, for example, the impedance history could be compared with the history reporting a 
trauma or other incidents that might explain the failure. In addition to the impedance history, the 
ADNS 300 also provides the physician with a battery recharge history. This information allows the 
physician to evaluate the patient’s recharging habits.  
A second part of this study was performed to evaluate whether CAPs of the vagus nerve could be 
measured with the ADNS-300.  
 96 
 
In preclinical data, only one author has implemented a cuff electrode for combined stimulation and 
recording of the vagus nerve in a epilepsy model. Woodburry and Woodburry performed several 
experiments in the PTZ and MES model in 1990 and 1991 (20-21). They claimed to have recorded 
CAPs of the vagus nerve and derived useful stimulation parameters from these recordings. 
In their study, the vagus nerve with was stimulated with a pulse of 200 µsec and 30 µA, which 
allowed to record a first component of the CAP which appeared at 1 msec. This volley of the CAP was 
considered to represent an activation of A type and B type fibres.  
The distance between the stimulation and recording contacts was about 1 mm, so that the 
conduction velocity would have been about 1m/s, which is far too low to represent activation of 
myelinated fibres.  
Moreover, the authors tried to record those signals chronically, but A and B fibres tended to lose 
their excitability after a few days. Therefore, to our knowledge, no animal study has prospectively 
analyzed the vagus nerve electrophysiology over time after surgery or correlated such recordings 
with seizure outcome. So far, only two studies have reported intra-operative CAPs recorded from the 
human vagus nerve (51,52), and no postoperative CAP data are available. 
Evans described three different fibre populations (A, Aδ and C), on the basis of the latency of each 
waveform from the stimulus artifact onset (51). CAPs were recorded using a recording hook 
electrode placed 2 cm distal to the stimulation contacts. Mean conduction velocities of 18.8, 9.5 and 
2.1 m/sec corresponding respectively to the different fibre types of the vagus nerve were described. 
The initial component, consistent with the activation of myelinated fibres, occurred after 1 msec, 
which might seem early compared to our findings at a fourfold shorter distance. The ADNS-300 uses 
one set of recording contacts and the stimulus to the nearest contact distance is very short, namely 5 
mm. Hence a stimulus artifact must be dealt with, which could obscure early CAP components. In 
addition, it is also possible that in our 2 to 3 week postoperative recordings gliosis develops and the 
production of inflammatory cytokines slows down the nerve response at least temporarily (53). 
Amplitude range of recorded CAPs falls within values given by the group of Evans. The threshold to 
elicit a CAP in our study was low (between 100 and 150 µA for a stimulus of 250 µsec), which 
indicates that the obtained responses most likely correspond to the activation of large myelinated 
fibres. 
Koo et al. also reported intra-operative myelinated fibre CAPs with completely different electrodes 
(52). These authors described a threshold intensity of 1 mA at a pulse width of 100 µsec to activate 
the CAP, while in our study intensities between half and a fourth of that level were sufficient to 
initiate a response.  
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Interestingly, important latency and threshold changes with age from childhood to adulthood were 
described. This indicates that an individual adjustment of the stimulus strength based on the 
observed nerve activation is absolutely necessary. 
CAPs of the vagus nerve might help clinicians to select stimulation parameters more adequately. One 
of the important issues is whether higher stimulation currents can provide greater efficacy (32). 
Currently, there is no dose-response curve for VNS available. In clinical practice, due to the lack of 
electrophysiological information of the vagus nerve itself, VNS is gradually up titrated according to 
the reported seizure reduction or side effects.  
This method requires months of adjustments and might lead to unnecessary strong stimuli. 
Moreover, long durations and high current intensities may carry a greater risk for nerve injury, use 
more power and activate nearby somatosensory nerves resulting in unnecessary pain or discomfort.  
CAP measurements may one day replace this empiric and arbitrary upward titration with an objective 
calculation of the optimal parameters. In this context, stimulus response curves may help clinicians 
to determine the individual maximal intensity required to fully activate myelinated fibres of the 
vagus nerve, which in turn could be used as a patient specific VNS maximal output value. 
Further clinical trials with the ADNS-300 are needed to fully characterize the vagus nerve CAP in 
humans. Implantation in a larger number of patients will lead to a better understanding of the 
electrophysiology of the vagus nerve, which hopefully will lead to more adequate and individual 
optimized choice of the VNS parameters. Hypothetically, non-responders could be those patients in 
whom the vagus nerve does not recover from surgery sufficiently and consequently less or no 
beneficial anti seizure effects may be achieved with VNS. In addition, the vagus nerve contains a 
number of functionally different fibres that contribute with different latencies and amplitudes to the 
CAP. It is unlikely that they all serve the anti-epileptic effect. By recording CAPs postoperatively over 
time and performing longitudinal prospective correlations between CAP recordings and seizure 
outcomes, more insight would be available in the subpopulations are to be targeted and with what 
stimulus parameters they are best activated. 
5.5 Acknowledgements 
Riëm El Tahry is supported by a grant from the Ghent University Research Fund (BOF). Prof. Dr. P. 
Boon is supported by grants from FWO; grants from BOF and by the Clinical Epilepsy Grant from 
Ghent University Hospital. Prof. Dr. K Vonck is supported by a grant of the BOF. This study was 
partially funded by Neurotech Belgium. 
 
 98 
 
5.6 Disclosure of conflicts of interest 
Pascal Doguet and Jean Delbeke are respectively employee and advisor at Neurotech. None of the 
other authors has any conflict of interest to disclose. All authors confirm they have read the Journal’s 
position on issues involved in ethical publication and affirm this report is consistent with those 
guidelines. 
 99 
 
Reference List 
 
1. Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, Willis J, et al. Vagus nerve 
stimulation for treatment of partial seizures: 2. safety, side effects, and tolerability. first 
international vagus nerve stimulation study group. Epilepsia 1994;35(3):627-636.  
2. BenMenachem E, Manonespaillat R, Ristanovic R, Wilder BJ, Stefan H, Mirza W, et al. Vagus 
Nerve-Stimulation for Treatment of Partial Seizures .1. A Controlled-Study of Effect on Seizures. 
Epilepsia 1994;35(3):616-26. 
3. Handforth A, DeSalles AAF, Asatourian AA, Krahl SE, Us Vns SG. Seizure response to long-interval 
vagus nerve stimulation (VNS) is predictive of response to conventional VNS, suggesting a long-
duration anti-epileptic mechanism. Neurology 1998;50(4):S05006. 
4. Morris GL, III, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with 
refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 
1990;53(8):1731-1735.  
5. Ben Renfroe J, Wheless JW. Earlier use of adjunctive vagus nerve stimulation therapy for 
refractory epilepsy. Neurology 2002;59(6):S26-S30. 
6. Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged anti-epileptic drugs. 
Seizure 2004;13(6):392-398.  
7. Uthman BM, Reichl AM, Dean JC, Eisenschenk S, Gilmore R, Reid S, et al. Effectiveness of vagus 
nerve stimulation in epilepsy patients: a 12-year observation. Neurology 2004;63(6):1124-1126.  
8. Holder LK, Wernicke JF, Tarver WB. Long-Term Follow-Up of 37 Patients with Refractory Partial 
Seizures Treated with Vagus Nerve-Stimulation. Journal of Epilepsy 1993;6(4): 206-14. 
9. Hui AC, Lam JM, Wong KS, Kay R, Poon WS. Vagus nerve stimulation for refractory epilepsy: long 
term efficacy and side-effects. Chin Med J (Engl ) 2004 Jan;117(1):58-6 
10. Helmers S. Comparison of early and later initiation of vagus nerve stimulation for refractory 
epilepsy. Neurology 2001;56(8):A267-A268. 
11. Janszky J, Hoppe M, Behne F, Tuxhorn I, Pannek HW, Ebner A. Vagus nerve stimulation: 
predictors of seizure freedom. Journal of Neurology, Neurosurgery and Psychiatry 2005;76(3): 
384-389.  
12. Sirven JI, Sperling M, Naritoku D, Schachter S, Labar D, Holmes M, et al. Vagus nerve stimulation 
therapy for epilepsy in older adults. Neurology 2000 14;54(5):1179-82. 
 100 
 
13. Frost M, Gates J, Helmers SL, Wheless JW, Levisohn P, Tardo C, et al. Vagus nerve stimulation in 
children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 
2001;42(9):1148-1152.  
14. Karceski S. Vagus nerve stimulation and Lennox-Gastaut syndrome: a review of the literature and 
data from the VNS patient registry. CNS.Spectr. 2001;6(9):766-770.  
15. Majoie HJM, Berfelo MW, Aldenkamp AP, Evers SMAA, Kessels AGH, Renier WO. Vagus nerve 
stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome - 
Clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol 
2001;18(5):419-28. 
16. Valencia I, Holder DL, Helmers SL, Madsen JR, Riviello JJ, Jr. Vagus nerve stimulation in pediatric 
epilepsy: a review. Pediatr.Neurol 2001;25(5):368-376.  
17. Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised epilepsy. Seizure. 
2004;13(3):176-178.  
18. Holmes MD, Silbergeld DL, Drouhard D, Wilensky AJ, Ojemann LM. Effect of vagus nerve 
stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure. 
2004;13(5):340-345.  
19. McLachlan RS. Electrical-Stimulation of the Vagus Nerve for the Treatment of Epilepsy - Support 
from Experimental-Models. Annals of Neurology 1992;32(2):245. 
20. Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in 
rats. Epilepsia 1990;31 Suppl 2:S7-19.  
21. Woodbury JW, Woodbury DM. Vagal stimulation reduces the severity of maximal electroshock 
seizures in intact rats: use of a cuff electrode for stimulating and recording. Pacing Clin 
Electrophysiol 1991;14(1):94-107.  
22. Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 
1992;33(6):1005-1012.  
23. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by 
anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995;22(1):53-62.  
24. Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant 
effect. Epilepsia 1996;37(11):1111-1116.  
 101 
 
25. De Herdt, V, De WJ, Raedt R, Wyckhuys T, El TR, Vonck K, et al. Modulation of seizure threshold 
by vagus nerve stimulation in an animal model for motor seizures. Acta Neurologica 
scandinavica.2010 Apr; 121(4):271-276. 
 
26. Vonck K, De Herdt, V, Bosman T, Dedeurwaerdere S, Van LK, Boon P. Thalamic and limbic 
involvement in the mechanism of action of vagus nerve stimulation, a SPECT study. Seizure 2008 
Dec;17(8):699-706. 
27. De Herdt V, Boon P, Ceulemans B, Hauman H, Lagae L, Legros B, et al. Vagus nerve stimulation for 
refractory epilepsy: a Belgian multicenter study. Eur J Paediatr.Neurol 2007;11(5):261-269.  
28. Vonck K, Boon P, Van Laere K, D'Have M, Vandekerckhove T, O'Connor S, et al. Acute single 
photon emission computed tomographic study of vagus nerve stimulation in refractory epilepsy. 
Epilepsia 2000;41(5):601-609.  
29. Boon P, Vonck K, Van Walleghem P, D'Have M, Caemaert J, De Reuck J. Vagus nerve stimulation 
for epilepsy, clinical efficacy of programmed and magnet stimulation. Acta Neurochir.Suppl 
2002;79:93-98.  
30. Vonck K, Thadani V, Gilbert K, Dedeurwaerdere S, De Groote L, De Herdt V, et al. Vagus nerve 
stimulation for refractory epilepsy: a transatlantic experience. Journal of Clinical Neurophysiology 
2004;21(4):283-289.  
31. Marin J, De Lannoy G, Delbeke J (2009) When can we recover charges with a biphasic charge 
balanced stimulation pulse? Proceedings of the IFESS conference: 55-57.  
32. DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A, et al. Vagus nerve 
stimulation: analysis of device parameters in 154 patients during the long-term XE5 study. 
Epilepsia 2001;42(8):1017-1020.  
33. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, et al. Prospective 
long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 
2000;41(9):1195-1200.  
34. Jaseja H (2009) EEG-desynchronization as the major mechanism of anti-epileptic action of vagal 
nerve stimulation in patients with intractable seizures: Clinical neurophysiological evidence. Med 
Hypotheses 74[5], 855-856. 
35. Salinsky MC, Burchiel KJ. Vagus nerve stimulation has no effect on awake EEG rhythms in humans. 
Epilepsia 1993;34(2):299-304.  
36. Wang H, Chen X, Lin Z, Shao Z, Sun B, Shen H, et al. Long-term effect of vagus nerve stimulation 
on interictal epileptiform discharges in refractory epilepsy. J Neurol Sci 2009;284(1-2):96-102. 
 102 
 
37. Santiago-Rodriguez E, Alonso-Vanegas M, Cardenas-Morales L, Harmony T, Bernardino M, 
Fernandez-Bouzas A. Effects of two different cycles of vagus nerve stimulation on interictal 
epileptiform discharges. Seizure 2006;15(8):615-20. 
38. Rizzo P, Beelke M, De CF, Canovaro P, Nobili L, Robert A, et al. Modifications of sleep EEG induced 
by chronic vagus nerve stimulation in patients affected by refractory epilepsy. Clin Neurophysiol 
2004;115(3):658-64. 
39. Kuba R, Guzaninova M, Brazdil M, Novak Z, Chrastina J, Rektor I. Effect of vagal nerve stimulation 
on interictal epileptiform discharges: a scalp EEG study. Epilepsia 2002;43(10):1181-8. 
40. Koo B. EEG changes with vagus nerve stimulation. J Clin Neurophysiol 2001;18(5):434-41. 
41. Upton AR, Tougas G, Talalla A, White A, Hudoba P, Fitzpatrick D, et al. Neurophysiological effects 
of left vagal stimulation in man. Pacing Clin Electrophysiol 1991;14(1):70-6. 
42. Tougas G, Hudoba P, Fitzpatrick D, Hunt RH, Upton AR (1993) Cerebral-evoked potential 
responses following direct vagal and esophageal electrical stimulation in humans. Am J Physiol 
264[3], 486-491. 
43. Hammond EJ, Uthman BM, Reid SA, Wilder BJ. Electrophysiologic studies of cervical vagus nerve 
stimulation in humans: ii. evoked potentials. Epilepsia 1992;33(6):1021-1028.  
44. Naritoku DK, Morales A, Pencek TL, Winkler D. Chronic Vagus Nerve-Stimulation Increases the 
Latency of the Thalamocortical Somatosensory Evoked-Potential. Pace-Pacing and Clinical 
Electrophysiology 1992;15(10):1572-8. 
45. Brazdil M, Chadim P, Daniel P, Kuba R, Rektor I, Novak Z, et al. Effect of vagal nerve stimulation 
on auditory and visual event-related potentials. Eur J Neurol 2001;8(5):    457-461.  
46. Chae JH, Nahas Z, Lomarev M, Denslow S, Lorberbaum JP, Bohning DE, et al. A review of 
functional neuroimaging studies of vagus nerve stimulation (VNS). J Psychiatr Res 2003;37(6): 
443-455.  
47. Henry TR, Votaw JR, Pennell PB, Epstein CM, Bakay RA, Faber TL, et al. Therapeutic response 
correlates with thalamic blood flow increases induced acutely by vagus nerve stimulation in 
partial epilepsy. Neurology 1998;50(4):S05008. 
48. Henry TR, Votaw JR, Pennell PB, Epstein CM, Bakay RA, Faber TL, et al. Acute blood flow changes 
and efficacy of vagus nerve stimulation in partial epilepsy. Neurology 1999;52(6):1166-1173.  
 103 
 
49. Henry TR, Bakay RA, Pennell PB, Epstein CM, Votaw JR. Brain blood-flow alterations induced by 
therapeutic vagus nerve stimulation in partial epilepsy: II. prolonged effects at high and low 
levels of stimulation. Epilepsia 2004;45(9):1064-1070.  
50. Van Laere K, Vonck K, Boon P, Brans B, Vandekerckhove T, Dierckx R. Vagus nerve stimulation in 
refractory epilepsy: SPECT activation study. J Nucl.Med 2000;41(7):     1145-1154.  
51. Evans MS, Verma-Ahuja S, Naritoku DK, Espinosa JA. Intraoperative human vagus nerve 
compound action potentials. Acta Neurologica Scandinavica 2004;110(4):232-238.  
52. Koo B, Ham SD, Sood S, Tarver B. Human vagus nerve electrophysiology: a guide to vagus nerve 
stimulation parameters. Journal of Clinical Neurophysiology 2001;18(5):429-433.  
53. Thil MA, Tran Duy D, Colin IM, Delbeke J. Time course of tissue remodelling and 
electrophysiology in the rat sciatic nerve after spiral cuff electrode implantation.               J 
Neuroimmunol. 2006;185:103-114.  
 
 
 
 
 105 
 
Chapter 6 
This study describes further exeperience in one patient implanted with the ADNS-300 during one 
year of follow-up. CAP’s were succesfully recoreded at different time points after surgery. In addition, 
different pulse widths were used, doses repons curves were recorded and finally a estimation of 
chronaxie and rheobase of myelinated fibers were calculated. These results give a first hint how 
individual electrophysiological information of the vagus nerve can be implemeted in clinical practice. 
This of particular value, as recordings of individual CAP’s of the vagus nerve may one day replace the 
rather emperic way of uptitration of stimulation output. In addition, future exepriments may indicate 
wheter non-responders are patients with insuffient or delayed activation of the vagus nerve due to 
for example increased local inflammatory reactions. 
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Abstract 
 
Rationale: VNS (vagus nerve stimulation) is a recognized adjunctive therapy for refractory epilepsy. 
Since its introduction in 1989, little efforts have been made to optimize the stimulation parameters. 
Individual recording of vagus nerve compound action potentials may represent one strategy to guide 
stimulation parameter adjustments. 
Methods: In a patient with refractory epilepsy, the Advanced Nerve Stimulator version 300 (ADNS-
3.00) was used for therapeutic stimulation of the vagus nerve. In addition, compound action 
potentials (CAPs) were recorded over a time span of 1 year. Recruitment curves of the CAPs were 
recorded at week 3, month 11 and 12. From these curves, maximal CAP amplitude (PN max ), intensity 
needed to reach 50% of the maximal amplitude response (I50%) and the slope factor (k) were 
determined. In addition, chronaxie and rheobase were calculated.  
Results:  Recruitment curves of the CAPs were successfully recorded at consecutive visits. Latency of 
P1 kept stable between 0.8 0 msec +/-0.01 and 0.88 msec +/-0.01, while N2 occurred between 1.15 
msec +/-0.03 and 1.21 +/-0.02 msec. PNmax varied between 16 and 21.3 µV. Characteristics of the 
recorded dose response curves were similar at different visits. In addition, two different groups of 
fibres of myelinated fibers were recruited. Finally, the rheobase and chronaxie at week 3 values were 
found to be 125 µA and 121 µs respectively.  
Conclusion: This study demonstrates for the first time that chronic vagal CAP recording in patients is 
feasible and may guide individual stimulation parameter settings.  
Keywords: vagus nerve stimulation, epilepsy, compound action potentials, recruitment curve, 
chronaxie, rheobase 
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6.1 Introduction 
VNS is a recognised adjunctive treatment for refractory epilepsy. The stimulation parameters applied 
in clinical practice were derived from a limited number of animal experiments (1-3). Since its 
introduction in 1989, little efforts have been made to optimize the stimulation parameters to 
improve efficacy. One strategy to guide stimulation parameter adjustments may be to explore 
individual vagus nerve responses to electrical stimulation. The Advanced Nerve Stimulator, version 
3.00 delivers electrical pulses to the vagus nerve and is designed to record vagal nerve compound 
action potentials (CAPs). The CAP is the algebraic sum of many ‘all or none’’ action potentials arising 
more or less simultaneously in a large number of individual axons in a compound nerve, such as the 
vagus nerve. The CAP of the vagus nerve does not occur naturally, but results from an experimentally 
or clinical induced stimulus with extracellular stimulating electrodes and can be recorded with 
extracellular electrodes, which measure the summed electrical response of all the excited axons in 
the vagus nerve. This offers the opportunity to determine the electrical charge required to activate 
vagal nerve fibres in a given patient. Previously, our group has reported postoperative N1P1N2 and 
P1N2 recorded CAPs from the vagus nerve in two implanted patients (4). Here, a 12 month follow-up 
study is presented during which we obtained successive recruitment curves of the vagus nerve in one 
patient. The patient received vagus nerve stimulation according to the standard paradigm used in our 
centre (5-7). 
We report for the first time chronically obtained recruitment curves from a human vagus nerve and 
propose a novel approach to VNS therapy.  
6.2 Methods 
In one patient VNS therapy was delivered during the first year according to classical stimulation 
parameters (gradually increasing intensity of 0.25 mA every 2-3 weeks, 500 µs pulse duration, 30 Hz 
frequency, 30 sec On, 10 min Off). At different visits after implantation, namely week 3, month 11 
and month 12, the vagus nerve was stimulated with a biphasic charge-balanced pulse and CAPs of 
the vagus nerve were recorded. The CAP is characterized by its latency (msec), which was calculated 
as the delay between the end of the cathodic phase of stimulation artifact and the occurrence of its 
first positive (P1) and consecutive negative peak (N2). In addition, the maximal amplitude of the CAP 
(µV) was calculated as the difference in voltage between P1 and N2 (= P1-N2).  
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Recruitment curves were obtained by increasing stimulus current intensity of the cathodic phase of 
the stimulus in steps of 50,100,250or 500µA starting at a minimum intensity of 50 µA until a 
maximum of 1mA. For this purpose, at week 3 pulse widths of 50 and 250 µsec were used, while at 
the following visits due to time constraints, only 50 µsec was used. In order to obtain clean traces, 2 
to 32 identical sweeps were recorded and averaged. Subsequently, data were fitted to a Boltzman 
function: 
k
II
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IPN



50
max
1
)(  
In which PN is the amplitude of the compound action potential  and calculated as P1-N2.  PNmax is the 
maximal value of PN and I50% is the stimulation current whereby PN = PNmax/2. I is the stimulus 
intensity applied to the vagus nerve. The slope factor k describes the recruitment homogeneity of the 
vagus nerve fibres. The correlation coefficient R between the fitted model and the recruitment curve 
was > 0.95. Besides the latency of P1 and N2, PNmax, I50% , the slope factor k and the impedance of 
stimulation electrodes were measured at the consecutive visits. Finally, rheobase and chronaxie were 
calculated. The rheobase (Rh) is the minimum intensity needed to obtain an excitation with a 
stimulus of infinite duration. The chronaxie (Ch) is the pulse duration required to elicit a response 
with an intensity that equals twice the rheobase. The chronaxie is considered to represent the most 
efficient stimulation, which requires the least of energy to activate the vagus nerve adequately. 
These parameters were estimated on the basis of the thresholds Th (D) of two stimulation pulses 
with two different durations (D) recorded at week 3. For this purpose, the strength-duration model 
of Weiss was used (8).  
 
Further technical details about the stimulation as well as signal recording and filtering have been 
described earlier (4).  
6.3 Ethical approval 
This study complies with applicable European and Belgian regulatory requirements and in particular 
the European Council Directive 90/385/EEC relevant to Active Implantable Medical Devices. 
This study was approved by the Ethics Committee of Ghent University hospital (EC 2008/274). Patient 
gave informed consent. 
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6.4 Results 
6.4.1 Patient outcome 
The patient is a 47-year-old male who developed post-lesional epilepsy 6 months after a stroke of the 
left medial cerebral artery. This resulted in a mixed aphasia and a residual minor hemi paresis of the 
right arm and leg. Before implantation, the patient suffered from 1 complex partial seizure with 
secondary generalized seizure a month. Several anti-epileptic drugs (AEDs) failed to obtain seizure 
freedom. Moreover the patient was very sensitive to various AED side effects which often limited the 
up-titration of his anti- epileptic drugs. Following VNS treatment, the patient became seizure free 
starting month 7. At that time, the stimulation parameters were 0.75 mA intensity, 500 µs duration, 
30 Hz frequency with a 30 sec On, 10 min Off duty cycle. Treatment of the patient was modified 6 
months after initiating the VNS because of complaints of extreme drowsiness and tiredness. 
Consequently, the Phenytoïne dosage was reduced from 300 mg to 200 mg/day and Pregabaline 300 
mg/day was added to the patient’s regimen. Therefore, it remains uncertain whether seizure 
freedom (from month 7 to 12) resulted from the addition of Pregabaline or VNS or the combination 
of both.  
6.4.2 CAPs of the vagus nerve in vivo (Fig1.) 
6.4.2.1 Latency of P1 and N2  of the CAP 
Latency of the P1-N2 CAPs was reliably recorded over time. P1 kept stable between 0.8 0 msec +/-0.01 
and 0.88 msec +/-0.01, while N2 occurred between 1.15 msec +/-0.03 and 1.21 +/-0.02 msec. 
 
 
 
 
 
 
Fig 1: The vagus nerve was stimulated with pulses of 500µA intensity and 
250 µs duration. A P1N2 compound action potential was simultaneously 
recorded with the ADNS-300 electrode 
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6.4.2.2 Amplitude of the CAP  
Maximal amplitude PNmax of the CAPS were deduced from recruitment curve to 50 µsec pulses at 
each visit. At week 3, month 11 and 12, PNmax   remained stable between 16 and 21.3 µV (Fig 2a,b,c).  
At week 3 the vagus nerve was additionally stimulated with a higher pulse width of 250 µsec. As 
shown in Fig 3, amplitude of the CAP increased up to 82.7 µV. From both curves, a first threshold is 
observed at a stimulation strength 500 µA x 50 µs (Fig 2a), corresponding to the activation of a first 
group of fibres, most likely the largest fibres in the nerve.   Increasing the stimulation charge density, 
suggests the recruitment of an additional and different population of fibres, presumably of smaller 
diameter. These fibres had a threshold of approximately 150 µA x 250 µs (Fig 3). The low charge of 
the applied stimuli indicates that myelinated fibres are concerned. 
 
6.4.2.3 Recruitment curves: I50% and slope factor k 
I50%   deduced from the fitted curves varied between 492 µA at week 3, 572 µA at month 11 and 594 
µA at month 12. The slope factor k was 6.9 µA at week 3; 12,2 µA at month 11 and 3.7 µA at month 
12. (Fig 2 a,b,c). When the vagus nerve is stimulated with larger charge density, recruitment curve 
showed a I50%   of 259 µA and a slope factor k of 53.2µA, corresponding to the activation of a second 
additional group of vagus nerve fibers (Fig 3). The equivalent amount of charge was 64.75mCoulomb, 
which is more than two fold of the applied charge for the 50 µs pulses above.  
Fig 2 (a,b,c): The vagus nerve was stimulated with a biphasic 
balanced charged pulse of increasing intensity and pulse 
width  of 50 µsec. Dose response curves were fitted to a 
Boltzman function 
(P1-N2) = (P1-N2)max / 1+ e 
(I 50%-x)/k)
, from which (P1-N2)max , I50% 
and slope factor k were determined over time span of 1 
year. A: week 3, B: month 11, C: month 12 
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6.4.2.4 Impedance  
The impedance of stimulation contacts remained stable between 5.3 and 7.2 kOhm, which is in the 
range of impedance for which the constant current stimulator can function adequately. 
Consequently, it can be assumed that the stimulation electrode transferred electricity to the nerve in 
a satisfactory way. 
6.4.2.5 Chronaxie and rheobase 
Based on our experimental results of week 3, in which a threshold of 500 µA was necessary to 
activate the nerve using a pulse width of 50 µs and similarly 150 µA for a pulse width of 250 µs, using 
strength-duration model of Weiss we calculated a rheobase of 125 µA and a chronaxie of 121 µs. 
6.5 Discussion 
Although VNS is widely used as a treatment for refractory epilepsy, the actual choice of optimal 
stimulation parameters is arbitrary. Since its introduction in 1989, little efforts have been made to 
change the currently applied stimulation parameters to improve efficacy. One of the important 
shortcomings in the field of VNS is the lack of an objective evaluation of stimulation of the vagus 
nerve. Our study shows that CAPs of the human vagus nerve can be objectively recorded in response 
to an external electrical stimulus. Recruitment curves of the vagal nerve CAP were successfully 
recorded over a time span of 1 year after implantation. 
 
 
 
Fig 3: At week 3, the vagus nerve was additionally stimulated with a pulse with longer duration, i.e. 250 µsec. Data 
were fitted to a Boltzman function, I50% and slope factor k were determined.  This curve suggests that at least two 
groups of myelinated fibers are activated, as the second group is recruited only at higher charge levels, namely 150µA 
x 250 µs en further increases in amplitude as stimulus intensity increased. 
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6.5.1 Patient outcome 
The patient implanted with the Advanced Nerve Stimulator version 300 vagus nerve stimulator was 
treated with VNS during the first year with a stimulation paradigm comparable to the one used in 
previous studies done by our group (4-7). Stimulation was initiated two weeks after surgery at the 
epilepsy clinic using the following parameters: pulse width 500µsec; frequency 30 Hz; duty cycle 30 
sec on/10 min off. The stimulation intensity was gradually increased with steps 0.25 mA until 0.75 
mA was reached. Beyond 0.75 mA the patient reported painful stimulation related sensation in the 
left neck region. Nevertheless, he became seizure free from month 7 on. This positive outcome may 
result from the adaptation of his AED regimen or combination of the latter with concomitant VNS 
treatment. 
6.5.2 CAP characteristics 
Latencies of P1 and N2 of the CAPs were short. P1 occurred between 0.8 0 msec +/-0.01 and 0.88 
msec +/-0.01 and N2 between 1.15 msec +/-0.03 and 1.21 +/-0.02 msec. This suggests that large 
diameter myelinated fibres of the vagus were activated. Ideally, the determination of the fibre type is 
based on an estimation of the nerve conduction velocity (NCV), derived from latency value 
differences between two recording contacts at a distance from each other (9). However, in order to 
be implantable, the ADNS-3.00 electrode has a restricted length, which does not allow accurate 
conduction velocity measurements. More importantly, our study shows that recruitment curves of 
the vagus nerve CAP can be recorded repeatedly over time. The main drawback of our study is the 
fact that only a restricted number of data could be recorded due to time constraints. The limited 
amount of data does not permit statistical analysis. Therefore it remains difficult to claim that 
characteristics of the dose response curves remain stable over time, although initial results do tend 
to support this hypothesis.  Future technology advancements will allow more efficient recording of 
the recruitment curves, which in turn will lead to more accurate determination of its characteristics. 
In addition to the recruitment curves, we have calculated the chronaxie and rheobase of the 
identified vagus nerve fibres based on the model described by Weiss. Stimulation of the vagus nerve 
with pulse duration equal to the chronaxie is considered to be most efficient stimulation and thus 
requiring the least amount of energy. Ideally, the chronaxie could be calculated for each patient 
individually, enhancing stimulation efficiency and consequently spearing battery life. Taking into 
account the limited number of data and the fact that the rheobase calculation is also dependent on 
the electrodes used and distance to the nerve, our results (125 µA and 121 µs respectively) compare 
reasonably with findings in the literature. Chronaxie values of canine vagal A fibres in vivo were 
reported to be 75.4 ± 24.5 µs, with a rheobase of 630 µA ± 180 µA (9,10). Nevertheless, comparisons 
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should be interpreted with caution, as they are species dependent and very sensitive to temperature. 
The chronaxie value reported in our study suggests that the optimal stimulation pulse duration for 
VNS would be around 120µs, which is strikingly less than the pulse duration of 250 or 500 µs usually 
applied in clinical practice. This element emphasizes that clinicians might use much higher VNS 
electrical charges than really required. 
6.5.3 Clinical implication of recruitment curves of human vagus nerve 
In clinical practice, stimulation intensity is gradually increased over months, until a maximal tolerable 
level is reached or a reasonable seizure control is obtained. The procedure is a time consuming 
process and has no objective rational basis. Moreover, the common procedure of increasing the VNS 
intensity up to the maximum tolerable level, contrasts with the experimental evidence that only 
myelinated fibres need to be recruited in order to provide an anti seizure effect (11,12).  
Individual recruitment curves could guide the clinician up to what level of current myelinated fibres 
can incrementally be recruited. The electrical charge required to fully activate these fibres, may then 
serve as an individual maximum stimulation intensity level. Consequently, the time needed to reach 
a maximal stimulation level can be reduced. In addition, unnecessary high output currents leading to 
painful sensations or discomfort may be prevented. Finally, reducing the stimulation strength will 
ultimately also reduce battery power consumption by the generator. In the context of individual 
adjustments of VNS parameters, until today only one author reported age dependent latency and 
threshold changes of the vagus nerve CAP derived from intra-operative recordings (13). 
6.6 Conclusion 
This study is the first to date to report chronic recruitment curves of human vagus nerve, most likely 
representing activation of large myelinated vagus nerve fibres. Implementation of CAPs in clinical 
VNS practice may help in the future to adapt the stimulation parameters on individual basis. 
Finally, implantation of a large number of patients could clarify whether CAP recordings can be 
correlated with long-term seizure response and consequently function as possible predictive 
parameter. 
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Chapter 7 
The aim of this study was to identify a marker reflecting effective stimulation of the vagus nerve. In 
the first part of the study an electrophysiological response to VNS was measured using thin-point 
recording electrodes placed near the stimulation cuff electrode. By inducing lesions at various levels 
along the vagus and recurrent laryngeal nerves, performing simultaneous EMG recording and 
applying a muscle paralyzing agent, the electrophysiological response was identified to be a far field 
potential of a VNS-induced larynx compound muscle action potential (LCAMP).  
During the second part of this study, a new self-sizing cuff electrode for combined stimulation and 
recording was designed and used to record VNS-induced LCAMP on a daily basis during two months. 
This study is the first to date to report chronic VNS induced LCAMP recordings. Importantly, nearly 
half the rats showed a delayed response and CAP’s could only be recorded 2 to 7 weeks after surgery. 
This implicates that a local recovery period might be needed before the vagus nerve can be 
adequately stimulated. This is of particular clinical interest, as it points out that recording of CAP’s 
may be important in decision when to start up-titration of VNS therapy. Moreover, it may be a partial 
explanation why some patients do not respond or respond only after a certain delay to their 
treatment. 
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Abstract 
Rationale: Vagus nerve stimulation (VNS) is an adjunctive treatment for patients with refractory 
epilepsy. In more than 30% of the patients VNS has no therapeutic effect. The goal of this study was 
to find an objective parameter that can be used as an indicator of effective stimulation of the vagus 
nerve.  
Methods: The electrophysiological response to VNS was recorded from the vagus nerve, recurrent 
laryngeal nerve and larynx muscles. Nerve lesions and muscle relaxing agent were used to find the 
source of the electrophysiological response. A cuff-electrode for chronic stimulation and recording 
was implanted for chronic recording of the VNS-induced electrophysiological response after 
implantation. Dose-response curves were determined daily during a follow-up period of 2 months.  
Results: VNS induced an electrophysiological response around 3 msec after start of the stimulation. 
This response was identified as a larynx compound action potential (LCMAP) LCMAP could be 
recorded immediately after surgery in 11/21 rats, while in the other 10/21 rats, a recovery period 
with an average of 25 days was required. Once the LCAMP could be recorded, the latency and overall 
characteristics of the doses response curves of the LCMAP remained stable during the entire follow-
up period. 
Conclusions: In this study, we provide an objective electrophysiological parameter for vagus nerve 
activation. LCAMP may indicate recovery of the vagus nerve after implantation, which may help to 
determine when uptitration of VNS therapy can be initiated. LCAMP could be of value in future 
experiments for objectification of VNS in animal models for epilepsy 
Keywords: Vagus nerve stimulation, larynx muscle potential, neural electrode, epilepsy 
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7.1 Introduction 
Epilepsy is a neurological disorder characterized by recurrent aberrant electrical activity in the central 
nervous system that typically manifests itself as seizures. It is estimated that 1-2% of the population 
is affected worldwide. About 30% of the patients with epilepsy do not respond to anti-epileptic drugs 
and are considered medically refractory (1,2). For these patients, alternative treatment modalities 
such as epilepsy surgery or neurostimulation, such as deep brain stimulation or vagus nerve 
stimulation, may be useful.  
The vagus nerve is a mixed cranial nerve that consists of 80% afferent fibres innervating the heart, 
aorta, lungs and gastro intestinal tract and 20% efferent fibres that provide parasympathetic 
innervations of these structures and innervate the voluntary striated muscles of the larynx and 
pharynx through the recurrent laryngeal nerve, which is similar in rats (3,4) and humans (5,6). 
Moreover, the proportion of myelinated axons in the cervical left vagus nerve of rats is comparable 
to humans (7,8). At last, the left superior laryngeal nerve splits from the vagus nerve identically in 
rats and humans, as it runs back superiorly behind the aortic arch in a groove between oesophagus 
and trachea to finally enter into the larynx. (4,6) 
Electrical stimulation of the left vagus nerve is used as an adjunctive treatment for patients with 
refractory seizures (9-14). The mechanism of action of vagus nerve stimulation (VNS) remains 
incompletely understood. There is little or no information available about the electrophysiology of 
the vagus nerve, although activation of the nerve is essential to its anti-epileptic effect (9-12). Many 
questions in VNS therapy remain unresolved, for example why some patients experience beneficial 
effects and others do not respond to the treatment. In current clinical epilepsy practice, no 
investigation is available to assess whether the vagus nerve is successfully activated by VNS or not. 
Defining a parameter reflecting stimulation-induced activation of the vagus nerve activation might 
provide a better understanding of the electrophysiological properties of the nerve. This in turn, could 
lead to further optimization of VNS treatment.  
The aim of this study was to identify a marker reflecting effective stimulation of the vagus nerve. In 
the first part of the study an electrophysiological response to VNS was measured using thin-point 
recording electrodes placed near the stimulation cuff electrode. By inducing lesions at various levels 
along the vagus and recurrent laryngeal nerves, performing simultaneous EMG recording and 
applying a muscle paralyzing agent the electrophysiological response was identified to be a far field 
potential of a VNS-induced larynx compound muscle action potential (LCAMP). During the second 
part of this study a new self-sizing cuff electrode for combined stimulation and recording was 
designed and used to record VNS-induced LCAMP on a daily basis and for several weeks after 
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implantation of the stimulation electrode. In humans, intra-operative VNS-induced LCAMP were 
described (15), but no studies, animal nor human, report chronic LCAMP recordings  
7.2 Materials and Methods 
7.2.1 Design of the cuff-electrode  
The self-sizing spiral cuff electrode is composed of two 80 µm thick silicone rubber sheets (Statice 
Santé, France) glued together with an adhesive which polymerizes at room temperature (Part A and 
B MED 4-4210, Nusil). The internal sheet is stretched during curling (stretch factor of 0.5) in order to 
obtain a self-curling spiral cuff. The cuff has an internal diameter of 1 mm and a total length of 9 mm.  
For the acute experiments two pieces of platinum (Alfa Aesar, 99.9% metal basis, 0.25 mm thick) are 
inserted between the silicone sheets to form the stimulation contacts (Fig1b). The inter-electrode 
distance between stimulation the anode and cathode (each 3x1 mm) was 1 mm. Windows of 500µm 
diameter are cut out in the internal silicone sheet in order to give the platinum contacts access to the 
nerve. 
For the chronic experiments a cuff electrode was manufactured with an extra contact for recording 
(Fig1a,c). Therefore a third piece of platinum (1x1 mm) was inserted between the silicone sheet at 2 
mm from the cathode, near the cuff edge directed towards the head.  
Teflon coated stainless steel wires (FWM 1x7x0.02/316LVM/EFTE, Fort Wayne metals) of 20 cm were 
welded to each platinum contact before their insertion between the electrode silicone sheets. 
Connector pins were soldered at the other extremity of the leads, allowing connection to an external 
stimulator or a recording device. 
  
 
Fig 1 (A,B): Schematic representation of a combined 
stimulation and recording self sizing cuff electrode (A) 
and a simple stimulation electrode for acute use (B) 
 
Fig 1 (C): photograph of a combined stimulation 
and recording self sizing cuff electrode 
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7.2.2 Animals 
Adult male Wistar rats (Harlan, The Netherlands), were treated according to the guidelines approved 
by the European Ethics Committee (decree 86/609/EEC). The study protocol was approved by the 
Animal Experimental Ethical Committee of Ghent University hospital (ECP 08/37). All animals were 
kept under environmentally controlled conditions (12h light/dark cycles, 20-23°C and 50% relative 
humidity) with food and water ad libitum. 
7.2.3 Surgery 
7.2.3.1 Acute experiments  
Wistar rats (250- 350 g) (n=4) were implanted with a spiral cuff stimulation electrode around the left 
vagus nerve. Rats were anesthetized with gas isoflurane anesthesia (5% isoflurane for induction, 2% 
isoflurane for maintenance). An incision was made over the left anterior cervical region. The left 
vagus nerve was carefully dissected from the aortic sheet and the cuff electrode was wound around 
the nerve with the anode placed caudally. To record the electrophysiological response to VNS thin-
point, stainless steel electrodes (125 µm diameter) were placed on different anatomical structures, 
including the vagus nerve, as well as the recurrent laryngeal nerve and the muscles surrounding the 
larynx. An epidural electrode, placed over posterior occipital cortex, was used as reference/ground 
electrode. In order to induce lesions along the nerves a nylon wire was strapped around the nerves.  
Vecuronium (Norcuron, 1 ml of 2mg/ml solution), a muscle relaxing agent, was applied to paralyze 
the larynx muscles. At the end of each acute experiment, animals were sacrificed with an overdose of 
pentobarbital (180mg/kg i.p). 
7.2.3.2 Chronic experiments 
Wistar rats (250 - 350 g) (n=21) were implanted with a spiral cuff electrode for stimulation and 
recording of the left vagus nerve. The rats were anesthetized with a ketamine/xylazine (respectively 
80 mg/kg and 7.5 mg/kg, i.p.) mixture. For chronic use, the electrode leads were tunnelled to an 
incision made in the skin above the skull. The connector pins were fixed to a skull head stage of 
acrylic cement. Four epidural stainless steel anchor screws were screwed bilaterally into the skull 
above parietal and occipital cortex. The posterior right screw, placed over occipital cortex, served as 
ground/reference for chronic electrophysiological recording. 
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7.2.4 Recording of the larynx compound action muscle potential   
The vagus nerve was stimulated with biphasic square wave pulses of 100 µs duration in the acute 
experiments in order to keep stimulation artifact as low as possible and allow recording of possible 
early physiological signals in response to stimulation. For chronic experiments 500 µs block-pulses 
were used because this pulse width is mostly used in chronic studies on efficacy of VNS in humans 
and animals. Stimuli were delivered by a constant current stimulator. Dose-response curves were 
determined  using a stimulus intensity ranging between 40 µA and 800 µA. Signals were recorded 
from stainless steel wire point electrodes placed on the vagus nerve, recurrent laryngeal nerve and 
larynx muscle or from the monopolar contact inside the cuff electrode . Signals were amplified 500 
times before high pass filtering at 0.15 Hz in order to remove DC components. Thereafter, the data 
were digitized using a National Instruments acquisition board (NI DAQ PAD 6259) and finally stored 
on a personal computer. Recording and analysis of signals were done using Matlab (2007a, the 
MathWorks, Natick, Massachusetts). 
7.2.5 Data analysis 
Both in the acute and chronic experiments, the latency of the LCAMP was determined. The latency is 
defined as the delay between the onset of the stimulus artifact and the occurrence of the major 
negative peak. In addition, acute and chronic dose response curves of the LCAMP were determined. 
In the chronic experiments LCAMP dose response curves were determined on a daily basis for five 
days per week during a follow-up period of 8 weeks after surgery. At each session, the rats were 
anesthetized using isoflurane (induction 5%, maintenance 2%) in order to reduce movement artifacts. 
The time span, during which vagus nerve was stimulated but no response could be recorded, was 
considered to represent a recovery period after surgery.  
A Boltzmann function: (M= Mmax/ 1+ e (I 50%-x)/k) was fitted to the measured dose-response 
curves. Mmax is defined as the maximal muscle potential amplitude. I50%  is the intensity needed to 
obtain a response with half the maximal amplitude and slope factor k describes the recruitment 
homogeneity of the vagus nerve fibres (Fig 2). For each stimulus intensity, 20 sweeps were averaged 
to improve the signal to noise ratio. Besides the latency, I50% and k, the impedance of the 
stimulation contacts was recorded over time. The contact impedance of the stimulation electrodes 
was expressed in kOhms and defined as the voltage to current ratio measured at the end of a 
stimulation pulse of 100 µA amplitude and 500 µs duration. At the end of the 8 week follow-up 
period animals were sacrificed with an overdose of pentobarbital (180mg/kg i.p). 
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7.2.6 Statistical analysis 
From the chronic LCAMP recordings, parameters of the dose-response curves (latency, I50% and k) 
and electrode impedances were averaged for each rat and for each of the eight follow-up weeks. 
Sensitivity analysis showed that there was no bias effect of pooling the results of the animals with a 
recovery period to the results of the rats in which the LCAMP could be recorded from the start of the 
chronic recordings. Therefore, the means and standard errors of the mean (SEM), presented in the 
figures, were calculated from all rats in which an LCAMP could be recorded during a specific week.  
Statistical analysis was performed using mixed model linear regression analysis, including random 
intercepts in order to account for dependent observations. A Bonferonni correction was used to 
correct for type I error in multiple comparisons. Calculated residuals were normally distributed, 
which supports the validity of the used statistical model. 
7.3 Results 
7.3.1 Acute experiments: identification of the Larynx Compound Muscle Action Potential  
VNS reproducibly induced a large negative peak at 2.6 msec +/- 0.2 msec after onset of the 
stimulation artifact (N1) (Fig. 3a). Based on its long latency and large amplitude we hypothesized that 
this response is a far field potential corresponding to larynx muscle activation induced by co-
activating of the recurrent laryngeal nerve with VNS. The following observations support this 
hypothesis: 
1)A lesion of the vagus nerve distal to the stimulation electrode but proximal to the aortic arch, 
abolished the recorded signals (Fig 3b), 2) a proximal lesion of the vagus nerve did not abolish the 
signal (Fig 3a). 3) an electromyography (EMG) recording of the laryngeal muscles shows a very large 
response at latency of 2.6 msec  (Fig 3c). 4) Finally, all the signals recorded at the level of the vagus 
 
Fig 2: Example of a doses response curve of the larynx 
compound action muscle potential (LCAMP) in 
response to vagus nerve stimulation. A Boltzmann 
function (M= Mmax/ 1+ e 
(I 
50%
-x)/k
) was fitted to the 
doses response curve. Imax is defined as the intensity 
needed to achieve a response with maximal 
amplitude. I50%  is the intensity needed to obtain a 
response with a half the maximal amplitude and k is 
the slope factor. 
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nerve, recurrent laryngeal nerve and larynx muscle disappeared immediately when applying the 
muscle blocking agent Vecuronium (1 ml of Norcuron 4mg/2ml ampoule) to the larynx muscles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2 Acute and chronic recordings of the Larynx Compound Muscle Action Potential  
In the acute experiments, latency of N1 of the LCAMP recorded at the level of the vagus nerve, was 
2,6 msec +/- 0,2 msec after onset of the stimulation artifact. The I50 and slope factor of acute doses 
response curves were respectively 125,8 +/- 35,7 µA and 28 +/- 30µA. 
In the chronic experiments, 21 rats were implanted with a cuff electrode for combined stimulation 
and recording of the vagus nerve.  
 
Fig 3 (A,B,C): 
(A) Recorded Larynx 
Compound Muscle 
Action Potential (LCAMP) 
at different locations on 
the vagus nerve 
(Ch1,2,3), characterized 
by a major negative peak 
(N1). LCAMP remains 
preserved after proximal 
lesion of the vagus nerve 
cranial to stimulation 
electrode. This can be 
explained by the fact 
that the recorded signals 
on all channels result 
from a far field potential 
of the larynx contraction 
(see Fig3 C) 
(B) Lesion of the vagus 
nerve distal to the 
stimulation electrode but 
proximal to the aortic 
arch, abolished all signals 
recorded at the level the 
vagus nerve (Ch1, 2, 3) 
(C) Signals recorded from 
larynx muscles (Ch 1), 
the vagus nerve (Ch 2), 
the recurrent laryngeal 
nerve (Ch 3) showed no 
difference in latency. 
Moreover, the larynx 
EMG channel (Ch 1) 
exhibited much larger 
amplitude than signals 
recorded from other 
channels. All signals were 
abolished when applying 
Vecuronium into the 
larynx muscles 
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LCMAP could be recorded immediately after surgery in 11/21 rats, while in the other 10/21 rats a 
recovery period ranging between 2 and 7 weeks (mean 25 days) was needed (Table 1). 
 
 
 
 
 
 
 
 
The latency of N1 was 3.2 msec +/- 0.1 msec and did not change significantly over time during the 8 
weeks of follow up (p=0.88) (Fig 4a). The I50% calculated from the doses response curves did not 
significantly change over time and varied between 56µA +/- 7µA and 74 µA +/- 18 µA (p=0.77) (p= 
0.77) (Fig 4b). The slope factor of the doses response curves varied between 4.2µA +/- 0.7 µA and 6.7 
µA +/-2.0 µA, indicating that implanted electrodes were able to activate vagus nerve fibres in a stable 
manner over the entire follow-up period (p=0.82) (Fig 4c).  
 
 
 
 
 
 
 
 
 
 
 
Fig 4 (A,B,C):  
Means and standard errors of the 
mean (SEM) presented in the 
figures, were calculated from all 
rats in which an LCAMP could be 
recorded during a specific week. 
(A) The latency of N1 was 3.2 ms 
+/- 0.1 ms and did not change 
significantly over time during the 8 
weeks of follow up 
(B) I50 and (C) slope factor (k) 
deduced from the dose response 
curves remained stable during 8 
weeks of follow-up. 
 
Table 1 shows amount of rats per week after 
surgery in which LCAMP was recordable. In 11/21 
rats, LCAMP could be measured immediately after 
implantation. In the remaining rats (10/21), a post-
surgical recovery period was required before 
LCAMP could be recorded adequately.  
 
Time after surgery 
(weeks) 
Amount of rats with 
recordable LCAMP 
0 11 
1 11 
2 13 
3 13 
4 13 
5 16 
6 20 
7 21 
 
 129 
 
The impedance of the stimulation contacts significantly increased over time (p<0.001), values of 
week 4 to week 8 being significantly higher in comparison to the first week (post-hoc analysis with 
bonferonni correction) (Fig 5). 
 
7.4  Discussion 
The primary objective of this study was to identify an objective electrophysiological parameter to 
assess effective vagus nerve stimulation. In the first part of the study, the LCAMP was identified as a 
candidate marker for effective vagus nerve stimulation. In the second part of this study an 
implantable electrode system for chronic stimulation and recording of VNS-induced LCMAP in 
rodents was developed. In half of the rats implanted with this electrode system for chronic 
stimulation and recording a response to VNS could only be measured after delay of several weeks. 
From the moment the LCAMP could be measured up to eight weeks after electrode implantation 
input-output relationship between stimulus intensity and amplitude of the LCAMP remained stable 
over time although the impedance of the stimulation electrodes increased slightly during the eight 
weeks after implantation.   
7.4.1 Characteristics of the LCAMP 
By introducing lesions distal to the stimulation electrode and application of a muscle relaxing agent 
we showed that the measured electrophysiological response to VNS corresponded to muscle 
potentials of the larynx and not to any neural potential originating from the vagus nerve.  Most likely 
the LCAMP is evoked by VNS-induced activation of the Aα efferent motor fibres of the vagus nerve. 
In rats but also in other mammals these vagal Aα fibres innervate the laryngeal muscles.  The LCAMP 
was recordable in a reproducible manner during a follow-up period of two months, although a 
variable recovery period after surgery was found. The latency of the LCAMP, I50% and slope factor of 
dose response curves remained relatively stable during the follow-up period after electrode 
Fig. 5: The impedance of the stimulation 
contacts increased over time, but only 
values of week 4 to week 8 were statistically 
significantly higher in comparison to the first 
week 
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implantation. However, as our experiments count a small group of animals (N=21), subtle changes 
over time cannot fully be excluded. Nevertheless, our results indicate that once the LCAMP could be 
recorded, the vagus nerve remained excitable, despite the development of a fibrous capsule around 
the electrode-nerve interface (16,17).  
The increased impedance values of the stimulation electrodes between 4 and 8 weeks after 
implantation support the idea that a fibrous encapsulated electrode-nerve interface is formed. 
Importantly, values for the I50% and the slope factor of acutely dose response curves were larger 
than the same results obtained in chronic experiments, but a smaller pulse width was used. In 
addition, a shunting effect of physiological water that was added to the dissection pouch in order to 
moisturize the vagus nerve while performing surgery may also explain the obtained results.  
7.4.2  LCMAP as a marker for vagus nerve stimulation  
Laryngeal activation is the result of efferent stimulation, while VNS in epilepsy is focused on 
stimulating afferents in order to obtain beneficial effects in the brain (18-20). The use of LMCAP as a 
marker for adequate vagus nerve stimulation thus remains an indirect surrogate parameter, as it 
does not necessarily reflect activation of the specific fibre population with anti-seizure effect (20,21). 
Nevertheless, Aα fibres, provide motor activation of striated muscles of the larynx and represent a 
relatively low threshold fiber population. Importantly, these fibres are the most sensitive to anoxia 
and injury due to surgical manipulation (19,22). Consequently, alteration in Aα function may imply 
damage to other afferent vagus nerve fibres which are thought to provide anti-seizure effect of VNS.  
On the other hand, a histological study by Evans et al, in the rabbit vagus nerve showed that 
myelinated motor fibres of the vagus nerve seem to gather in the deep lateral part of the vagus 
nerve bundle, which implicates that damage to these fibres would not necessarily imply injury to the 
medial afferent myelinated fibres (23). Data about precise configuration of different fibres bundles in 
the cervical vagus nerve in humans is lacking, therefore possible hypothesises in this field remain 
purely speculative. 
7.4.3 VNS induced vocal cord EMG in humans 
A study performed in humans by Ardesh et al, in which intra-operative vocal cord EMG was recorded 
after VNS implantation showed a very similar VNS induced LCMAP. The shape was identical, but 
longer latencies and higher amplitudes were reported (15). Activation of the larynx in humans was 
obtained by applying a VNS pulse of 0.5 mA and 130 µsec, while in our experiments maximal muscle 
activation was already reached at approximately 65 µA and 100 µsec. 
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In humans, a temporary paresis of vocal cords after VNS surgery has been described (24-26), 
indicating that the surgical procedure and implantation of the electrode often causes a transient 
vagus nerve failure, hence requiring a recovery period before to become functional again.  
7.4.4 Clinical relevance of the VNS induced LCAMP  
In clinical practice, the idea that in some patients there is a delayed effect of VNS might in some 
cases be explained by a temporary failure of VNS-induced activation of the nerve due to nerve 
damage after electrode implantation. In our study, nearly half of the implanted rats required an 
average recovery period of 5 weeks (range 2-7) before VNS could efficiently induce a LCAMP. In 
clinical practice, ramping up of VNS output generally starts two weeks after surgery (27,28). Our 
results and the larynx studies cited above, suggest that an individualized approach might be more 
beneficial, although comparisons between humans and rats must be made with caution. Currently, 
there is no specific investigation indicating whether the vagus nerve recovered sufficiently to start 
uptitration of VNS therapy. In this context, recording a VNS- induced LCAMP by EMG of the larynx 
before and at different time points after surgery, could possibly serve as a new investigative tool in 
VNS therapy. More research on this topic is needed to confirm this idea.   
Future experiments which investigate the relationship between LCAMP occurrence and therapeutic 
response to VNS treatment could be interesting. The lack of therapeutic effect of VNS may not only 
be the result of a lack of VNS effects on the brain, but also simply be the consequence of inadequate 
local recovery of the vagus nerve. 
7.5 Conclusion 
Twenty-one rats were successfully implanted with a custom-made self-sizing stimulation/recording 
electrode around the left vagus nerve, allowing repeated recording of the LCMAP over time. Our 
method provides an objective indication of effective vagus nerve activation, which could be of great 
value in all VNS experiments in animal models for epilepsy. 
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Chapter 8 
Chapter 8 bundles two different experimental vignettes. The first part describes an initial set up of 
experiments in which the goal was to identify vagal evoked potentials in the rat brain. The second 
vignette is an additional study we have performed in collaboration with the veterinary department.  
A pilot trial in one horse was carried out to test feasibility of VNS for functional laryngeal stimulation. 
Chapter 8.1 
The initial goal of this thesis was to identify an objective parameter reflecting stimulation of the 
vagus nerve. In an early phase of this work, efforts have been made to characterize vagal evoked 
potentials in anatomical sites of the rat brain to which the vagus nerve is known to project to.  
Characterization of a vagal evoked potential would have allowed to visualize stimulation of the vagus 
nerve and its effects in the brain. Moreover, recording of vagal evoked potentials could potentially 
have improved understanding of the mechanism of action of VNS. For example, questions such as 
whether fiber specific stimulation (i.e A, B or C) activates different anatomical sites could have been 
addressed.  
The results of these initial experiments showed that the recorded signals, with use of our 
extracellular deep brain electrodes, were the result of far field potentials of another local generator. 
Further experiments have finally led to the conclusion that our results were reflection of activation of 
the recurrent laryngeal nerve and contraction of the larynx muscles (see chapter 7). 
Chapter 8.2 
Recurrent laryngeal neuropathy is a common disease in horses and may be treated by functional 
stimulation. In this feasibility study, one healthy horse was successfully implanted with a VNS model 
102. Rheobase and chronaxie were calculated and values were presented as possible stimulation 
parameters for laryngeal stimulation in horses. 
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CHAPTER 8: EXPERIMENTAL VIGNETTES 
8.1 Can a VNS evoked potential be recorded in the rat brain? 
8.1.1 Introduction/Rationale 
Complementary to recording of compound action potentials of the vagus nerve, we investigated 
whether VNS induces evoked potentials (vagal EPs) in different key projection sites of the vagus 
nerve. The effect of different stimulation paradigms on the activation of different anatomical 
structures which receive vagal nerve information may be examined using those vagal EPs.  
Anatomically, the vagus nerve projects mainly to the insular cortex, but there is some evidence in 
literature that vagus nerve also projects to lateral portion of sensorimotor cortex (1,2). Moreover, it 
was shown that low intensities of VNS induce slow hyperpolarisation of parietal neurons of rat cortex 
(3). For this reason, we hypothesized that vagus nerve stimulation induces an evoked potential not 
only in the insular cortex, but also over the sensorimotor cortex. In a second stage we evaluated 
whether vagal evoked responses could be recorded in three main vagal afferent subcortical sites: 
(i)Nucleus Tractus solitaries (NTS) (ii)Locus coeruleus (LC) and (iii)Thalamus. 
 
 
 
8.1.2 Methods 
Male Wistar rats (250-350gr) were implanted with stimulating self zing silicone cuff electrode around 
left cervical vagus nerve. In addition, a multi electrode (16 contacts) was manufactured (Fig. 2) to 
VNS 
Fig. 1 Overview of vagal nerve projections into the brain. Red boxes are the anatomical sites 
which were explored for recordings of vagal EP’s 
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record VNS induced extracellular fields of the sensori-motor cortex. A craniotomy exposing cortex 
from anterior secondary visual cortex to posterior motor cortex (M2) was performed. In other 
experimental setup, additional target sites (thalamus, LC, NTS) were implanted with deep brain 
electrodes that consisted of 2 to 4 stainless steel wires of 125 µm diameters, which were polyimide-
coated and glued together. Vagus nerve was stimulated at 2 mA, 1Hz with a balanced charged 
rectangular pulse of 0.2 msec duration. Before the start of each experiment, a lead test was 
performed with the Cyberonics interrogation device to check impedance of stimulation electrodes. 
 
   
Fig 2: Multi-electrode for screening of VNS induced extracellular field potentials in sensori-motor cortex of rats 
8.1.3 Results 
 
Signals recorded over the cortex appeared 2.7 msec after the end of stimulation artifact. Mean 
amplitude varied between 20 to 30 µV. Threshold to activate these responses was 100µA-200µsec, 
500µsec. There were no latency differences between signals recorded in the neck and those 
recorded at surface of the cortex. Moreover, similar results were observed in all examined 
subcortical nuclei (thalamus, LC and NTS). In addition, no reversal of field recordings was observed, 
indicating a lack of local generators. Furthermore, in lesion experiments in which vagus nerve was 
sectioned, recorded signals in the brain disappeared, thus indicating a relationship to activation of 
the vagus nerve. 
 
Fig 3: VNS induced extracellular field 
recordings of sensori-motor cortex  
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8.1.4 Discussion  
As we could not detect any of latency differences between different recorded anatomical sites and 
peak latency was every time similar to the peak latency of signal recorded in the neck, we 
hypothesized that the recorded signals were derived from volume conduction of the activation of the 
cervical vagus nerve and/or recurrent laryngeal nerve and consequently did not correspond to VNS - 
induced evoked potentials. 
This may partially be explained by the fact that the distance between stimulation in the neck and 
registration in the brain was very small. Amplitude of local field of activation of the vagus nerve may 
be much larger in comparison to very small local field potentials in the brain, rendering recording of 
evoked potentials more difficult.  
Concerning LC and NTS recordings, an additional problem might have been the fact that these nuclei 
lack layered cell structures, which is known to facilitate extracellular field recording (4).  
8.1.5 Conclusion 
VNS-induced evoked potentials are not recordable with the techniques  described in methods section. 
Recording on a smaller level such as multi- or single unit may be useful in characterizing upstream 
vagus nerve stimulation induced activity in the brain. 
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8.2 Implantation of a VNS model 102 in a horse for recurrent laryngeal nerve 
stimulation 
8.2.1. Introduction/Rationale: 
Recurrent laryngeal neuropathy is a common disease in horses causing paralysis or paresis of the 
intrinsic laryngeal muscles innervated by the recurrent laryngeal nerve. Loss of abductor function of 
the dorsal cricoarytenoid muscle (CAD) leads to inadequate abduction of the ipsilateral arytenoid 
mostly during performances and consequently limiting capacities of racing horses (1,2). The use of 
functional electrical stimulation (FES) of the recurrent laryngeal nerve (RLN) is a possible novel 
treatment under research (3).  
A feasibility study was performed in which a VNS model 102 was implanted around the left recurrent 
laryngeal nerve of one healthy horse.  
8.2.2. Methods 
Part 1 
Measurements of recurrent laryngeal nerve diameters in cadavers lead to the assumption that the 
3m inner diameter bipolar VNS electrodes should be appropriate in the normal adult horse. 
 
Fig 1: Dissection in a horse cadaver; determination of nervus laryngeus recurrens diameter 
Part 2 
A vagus nerve stimulation electrode was wound around the left RLN at the cervical level and was 
connected to a pulse generator. Three weeks after surgery, stimulus response characteristics were 
obtained by measuring stimulated arytenoid displacement endoscopically on the standing, non-
sedated horse. A strength-duration curve of arytenoid abduction was determined based on the 
minimal intensity to evoke laryngeal muscle contraction using different parameters for pulse width 
← Head 
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(1000, 750, 500, 250, 130 µs). Rheobase and chronaxie were calculated. In addition, stimulation 
parameters that evoke maximal sustained abduction were investigated. 
8.2.3. Results 
Implantation on VNS device was successful and no major problems occurred during surgery or in the 
follow-up period. Sustained abduction of the arytenoid was achieved when RLN was stimulated at a 
frequency of at least 25 Hz. Rheobase and chronaxie were calculated to be respectively 0.5 mA and 
250 µs (Fig 2). 
 
8.2.4. Conclusion 
Functional stimulation of the laryngeal nerve in the horse with a human VNS device (model 102) is 
feasible. To obtain a full and sustained abduction of the arytenoid in the normal horse a minimal 
stimulation frequency of 25 Hz is necessary.  
Based on rheobase and chronaxie, respectively, an intensity of 1mA and pulse width of 250 µsec is 
postulated as parameters that can be used as guideline for RLN stimulation in horses. 
Fig 2 In-output curve of myelinated motor 
fibres of recurrent laryngeal nerve 
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CHAPTER 9: CONCLUSION, DISCUSSION AND FUTURE PERSPECTIVES 
9.1. Conclusion 
From the performed studies the following conclusions can be made: 
 
Animal experimental work 
 
1. Implantation of a combined stimulation and recording spiral cuff electrode around the left 
cervical vagus nerve of rat is feasible. 
2. Stimulation of the vagus nerve with parameters derived from clinical practice leads to 
activation of efferent A motor fibres of the laryngeal nerve which is a branch of the vagus 
nerve. Consequently a far field potential of contraction of the striated muscle (LCAMP) can 
be recorded with a single electrode around the vagus nerve. 
3. When the vagus nerve is stimulated with commonly used clinical stimulation parameters 
with the newly developed electrode, no vagal nerve CAPs could be recorded. The recorded 
signals were merely the result of larynx muscle contraction. 
4. LCAMP was successfully recorded chronically during follow-up of at least two months.  
5. Latency and overall characteristics of the doses response curves of the LCMAP remained 
stable during the entire follow-up period. 
6. The impedance of stimulation electrodes gradually increases over time. 
7. LCMAP could be recorded immediately after surgery in 11/21 rats, while in the other 10/21 
rats, a recovery period with an average of 25 days was required. 
8. When the vagus nerve is stimulated with a balanced charged rectangular pulse of 0.2 msec 
duration and 2 mA intensity and depth electrodes of 125 µm stainless steel wires are 
implanted in different important anatomical brain projection sites of the vagus nerve (NTS, 
LC, thalamus and sensorimotor cortex), only a far field potential of the LCAMP could be 
recorded. In contrast, no vagal evoked potentials were measured. 
9. Recording on a smaller level such as multi- or single unit may be useful in characterizing 
upstream VNS induced activity in the brain. 
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Human clinical work 
 
1. Demipulse generators appeared to have similar tolerability compared to older generators, 
and no new side effects could be described. The main technical advances were the decrease 
in size and improved options for battery life follow-up. 
2. The ADNS-300 is a new vagus nerve stimulator (Neurotech) which provides stimulation and 
recording of CAPs of the left vagus nerve and is transcutaneously rechargeable. Mean 
recharging time varied between 2 to 3 hours every week. 
3. Three patients were implanted with this new device. Two of the three patients reported 
seizure reduction of 40% after 6 months of treatment, while the third patient became seizure 
free after seventh month of treatment in combination with AEDs adjustments. In this pilot 
study no new side effects were reported.  
4. CAPs of the vagus nerve were recorded two to three weeks postoperatively in two of the 
three patients and consisted of an N1P1N2 potential with the N1 appearing 0.4 msec after the 
end of the stimulation artifact. Response threshold was low (100-150-µA and 250µsec), 
corresponding to activation of myelinated fibres.  
5. CAPs could be recorded during ten months in patient 1, while in patient 2 serial doses 
response curves were performed during a follow-up period of 12 months.  
6. The doses response curves revealed two groups of fibres, most likely corresponding to large 
and intermediate myelinated fibres. Full activation was obtained in the first group around 
30mC (50 µA x 600 µsec), while for the second group the charge required increased to 200 
mC ( 250 µsec X 800 µA).This kind of electrophysiological information may in the future guide 
clinicians in the choice of individual stimulation parameters. 
7. Medical Implant Communication Service (MICS) communication between the implant and 
the main computer system could be improved, which would allow to record more CAPs per 
session. Online filtering of the recorded CAPs will permit clinicians to interpret the recorded 
signals directly at each visit. Optimisation of mechanical manufacture of the electrode will 
improve the quality of contact between lead and recording contacts. 
 
 
 
 
 
 
 147 
 
9.2 Discussion  
9.2.1 Introduction 
Vagus nerve stimulation is a widespread adjunctive treatment for patients with refractory epilepsy. 
Although VNS was introduced many years ago, until now epileptologists do not fully understand its 
mechanism of action. The choice of parameters of stimulation is still based upon a number of 
experimental animal VNS studies in which VNS proved to induce a seizure reduction (1-3). The same 
parameters were applied in early clinical randomized controlled trials, such as the EO3 and EO5 
studies in the nineties (4, 5), which ultimately lead to the introduction of VNS in the therapeutic 
arsenal for the treatment of refractory epilepsy. Surprisingly, throughout the early development and 
even after its widespread acceptance as an additional treatment for epilepsy, the stimulation 
parameters of VNS never have been derived from individual electrophysiological data obtained from 
the vagus nerve itself. 
Optimizing and personalizing stimulation parameters according to the patient, is still a subject of 
research. In clinical practice, VNS is considered by some to be a last resort treatment, which is 
applied arbitrarily with little idea of how the vagus nerve reacts upon stimulation. Several questions 
in the domain of VNS remain unanswered. One of the main issues relates to why the responder rate 
varies between < 30% seizure reduction and > 50% seizure reduction, or even seizure freedom. There 
is little or no information about neither eventual predictive factors, nor any practical guidelines on 
how stimulation should be carried out most efficiently. This thesis focuses on objectifying stimulation 
of the vagus nerve by identifying an electrophysiological parameter that could guide VNS therapy for 
refractory epilepsy. Animal experimental work was carried out to characterize a parameter that 
reflects adequate VNS, which could be integrated in future VNS animal trials. Complementary to 
animal experimental work, human studies were performed to characterize an electrophysiological 
parameter of adequate vagus nerve activation. 
9.2.2 Experiments 
9.2.2.1. Animal experimental work 
Determination of the activation of the vagus nerve after VNS can be arbitrarily divided into two parts. 
Firstly, how can the vagus nerve be activated adequately and secondly, how does stimulation and 
activation of the vagus nerve influence different projection sites in the brain. Activation of the nerve 
itself is necessary to produce any other beneficial brain effects.  
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In this context, our experiments had as a main goal to clarify activation of the vagus nerve by means 
of recording compound action potentials (CAPs) (2,6). CAPs are the result of many superimposed 
action potentials arising simultaneously in a large number of individual axons in the nerve and can be 
elicited by stimulating the vagus nerve with extracellular stimulating electrodes. It reflects the 
activation of different axons with different diameters and nerve conduction velocities (NCV’s), which 
leads to a graded response whose magnitude increases with intensity of stimulation (7). Therefore, 
recordings of CAPs of the vagus nerve can help improve the understanding of which fiber types are 
activated at which amount of charge and subsequently more appropriately guide stimulation 
parameters in experimental settings. Ideally, the NCV of different CAP components can be measured 
by means of calculation of latency differences of different volleys at two different recording contacts 
at a distance from each other, which requires an electrode of sufficient length. In practice, such a 
stimulation and recording electrode is difficult to implant, as a small part of the vagus nerve can be 
dissected from the aortic sheet due to the risk of surgical damage to the nerve. This is the case not 
only in experimental rats, but also in humans. Researchers have often based NVC calculations on the 
basis of latency difference between cathode and only a single recording contact (2,6,8-10). In reality 
this represents an underestimation, as all fibre types need a certain time to be activated underneath 
the cathode and the first deflection of CAP that passes the recording contact is inevitably delayed. 
Attempts were made to implant electrodes with multiple recording contacts in rats, but 
postoperative success rate was low and consequently experiments were further continued with a 
single recording contact. 
In previously published preclinical data, only one group has reported the use of hook and cuff 
electrodes for combined stimulation and recording of the vagus nerve in an epilepsy model (6).  
Woodburry and Woodburry performed several experiments in the PTZ and MES model in 1990 and 
1991, in which they reported recording recorded several intra-and postoperative CAPs of the 
different vagus nerve fibre types (A,B,C)(2,6). CAPs of A- and B- fibres appeared 0.5 to 1 msec after 
stimulation artifact and were activated at threshold intensity between 30 and 70µA with a pulse 
width of 200µsec, while C-fibre activation occurred between 5 and 8 msec and required higher 
stimulation intensities, namely 500µA with pulse width of 250µsec. Calculation of NCV was based on 
the latency of the maximal CAP peak and the distance between cathode and first recording electrode, 
even though a second recording contact was available.  
 
Presumably no difference in latency of the signal between both contacts was present, although 
authors did not elaborate on that question. NCV of A- and B-fibres was estimated to lie between 1.5 
and 4 m/s, which is a large underestimation for described conduction velocities of mylelinated nerve 
 149 
 
fibres in the literature (11). In addition, C-fibres were estimated to have a nerve conduction velocity 
of 0.5 m/sec, but the amplitude of the response was large namely 2 mV, in contrast to A and B 
components which were maximally 0.5 mV. No lesion experiments of the vagus nerve or its recurrent 
laryngeal branch were carried out. Moreover, the authors did not use any muscle paralysing agents 
to exclude that the large amplitude recorded signal appearing at 5 msec was not the consequence of 
a muscle artifact. Comparison with our results still remains difficult, as the authors used rather 
different stimulation and recording techniques. Woodburry and Woodburry performed their acute 
experiments with five stainless steel wire-hook electrodes (two cathodes and one middle anode 
combined with two recording electrodes) placed immediately above the nerve. The dissection pouch 
was filled with mineral oil until the nerve was covered to prevent drying out of the nerve and 
improve recording of small voltage differences. In contrast, our electrode was a silicone spiral cuff 
with a single anode and cathode and only one recording contact. The dissection pouch was 
moistened with a limited quantity of physiological water, which induces shunting of applied current 
and consequently renders recording more difficult. Later on, Woodburry’s implanted a cuff electrode, 
allowing post operative recordings in unanesthetized animals (6). CAPs were measurable in four rats 
with a maximal recording time of 21 days for C fibres in one rat, while. A- and B-fibres tended to lose 
excitability after just a few days. They believed that this was caused by a lack of adequate blood 
supply as survival time of recorded signals increased when surgical procedure was performed more 
carefully. Autopsy findings of the nerve varied from a very swollen aspect to a more normal 
histological structure with identification of more (remaining) blood vessels supplying the nerve. 
However, the authors did not report any impedance measurements of stimulation contacts neither 
did they describe any histological details about the presence of gliosis. Hence it is not fully excluded 
that vagus nerve was not adequately stimulated due to growth of fibrous tissue between the 
stimulation contacts and the vagus nerve. In humans, revision of the stimulation electrode is 
sometimes indicated as the impedance may exceed a certain limit due to gliotic scaring (12,13). In 
those cases, the generator- although considered to be a constant current source may not deliver 
appropriate current as determined earlier by the neurologist.  
Interestingly, in the studies of the Woodburrys higher charge values were needed to activate 
different fibres with the implanted cuff electrodes in anaesthetized animals compared to hook 
electrodes used in anesthetized rats, which pleads for the development of a different post-operative 
electrode-nerve interface. Besides the problem of increasing distance between stimulation contacts 
and vagus nerve due to formation of gliotic cells, an inflammatory reaction with release of toxic 
cytokines, may have further damaged the nerve and be at the basis of loss of its excitability. Indeed, 
it was shown that implantation of cuff electrodes around sciatic nerves of rats was followed by 
resumption of postoperative oedema which was replaced by a local inflammatory reaction with 
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release of toxic cytokines, such as TNFα (14, 15). TNFα is known to have inflammatory, demyelinating 
and degenerating properties (16-18) and moreover, was demonstrated to be up regulated during 1 
month after cuff electrode implantation (15).This matches approximately the time span in which 
Woodburry and Woodburry were able to record VNS induced electrophysiological activity. In 
contrast, Woodburry and Woodburry postulated that recordings were restricted in time because of a 
low resistance shunt of fluid between nerve and cuff, which is contradictory to the idea that post-
operative oedema is largely resolved after few weeks of implantation (14). In addition, strength-
duration curves in freely moving rats were variable, as in the study performed in 1990 a pulse with a 
charge of 1500 nC was required to activate C fibres compared to a charge of 250 nC reported in 1991 
(2,6), while no differences in technique were described. Whether or not the smallest diameter C 
fibres of the vagus nerve are activated and how this contributes to therapeutic effect, remains 
unclear. 
First of all, the required current intensity to activate C fibre types with a diameter of about 1 µm is at 
least 100 times higher than the current intensity needed to activate fibre type with greater diameter 
such as for example 10 µm A-fibres, as intensity is inversely proportional to the squared diameter of 
nerve diameter (19). In practice, in the study of Woodburry and Woodburry values of at least 3 mA 
with long pulse widths of 500 µsec were necessary to recruit the smallest fibres, which was only the 
case in one of both studies (2). This amount of delivered charge is huge compared to size of the 
electrode-nerve interface in rats and is prone to activate other surrounding tissues, such as muscles 
of the neck region. In our hands, we were not able to record any C-fibre components with our 
designed electrode and choice of parameters. 
 
Subsequently the Woodburry’s implanted a cuff electrode and applied parameters that activated C-
fibres in two kinds of epilepsy models, namely PTZ and maximum electroshock model (MES). VNS 
abolished the extensor component of the tonic phase in the MES model and shortened or prevented 
tonic seizures induced by PTZ. The anticonvulsant effectiveness of VNS was directly related to the 
fraction of vagal C fibres stimulated. The question whether activation of C fibres is necessary to 
obtain anti- seizure effects remains debatable, as Krahl has shown a few years later that selective 
destruction of C fibres with capsaicin did not alter the beneficial effects of VNS in the PTZ model (20). 
Moreover, reports in which patients treated with VNS and acutely stimulated with additional high 
charged pulses (750 µsec, 0.2-2.75 mA), which according to the authors should have activated C 
fibres, did not have any cardio respiratory effects and authors interpreted this as C fibres not being 
stimulated (21, 22). 
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In domains other than epilepsy, mainly in cardiovascular and to a lesser extent in gastro-intestinal 
applications, results of vagus nerve CAP are divergent. Results depend on the stimulation electrodes, 
distance between stimulation and recording sites, the species studied, or even how the vagus nerve 
was approached. Some studies provide information about a transected vagus nerve at the level of 
the nodose ganglion (23), in other studies an isolated heart with vagus nerve preparation was used 
(24). The situation is even more different when the nerve was isolated in situ and recordings were 
performed ex vivo (25, 26). Parameters such as the medium in which the nerve lies or temperature of 
experimental set-up, influence results in a meaningful way. Therefore, not all studies provide a clear 
explanation about how the nerve was stimulated, whether a constant voltage or current source was 
used, or what the exact stimulus charge was. 
Our experiments had as a main goal to design a combined stimulation and recording electrode for 
VNS in experimental rats, to test its feasibility of implantation and to record VNS induced CAPs with 
parameters that are classically used in human epilepsy practice. Although we must keep in mind that 
extrapolating stimulation parameters from a human clinical situation to the experimental rat vagus 
nerve, most likely means stimulating the nerve with far greater charges than are really needed. In 
acute experiments, the vagus nerve was stimulated with a bipolar balanced shaped pulse. Threshold 
intensity was 65 µA for a pulse of 100 µsec duration, which yielded a very clear and easy-to-record 
signal at 3 msec away from the start of the stimulation artifact. This recorded signal had a very low 
NCV (as recording contact is located 2 mm away from the cathode), which is in accordance to the 
results of Woodburry and Woodbury and was far too slow to represent an activation of myelinated 
vagus nerve fibres.  
At this point, we believed that recorded signals were not CAPs of the vagus nerve. Nevertheless, 
lesion experiments of the vagus nerve abolished the recorded signals indicating that results were 
VNS-dependent, which excluded the possibility of different kinds of artifacts such as contracting 
muscles in the neck, heart beating-or breath oscillations. Ruling out these artifacts was important, as 
Hammond et al performed experiments in humans in which they searched for a VNS-induced scalp 
EP and found out that their results were merely far field potentials of neck muscle activation (27). 
As recorded VNS-dependent signals most likely did not represent CAPs of the vagus nerve, several 
hypotheses were suggested: (i) responses were far field potentials from VNS induced parasympatic 
contraction of smooth muscle of internal organs ;(ii) responses were a reflection of different possible 
upstream reflexes to the brainstem, such as blood pressure information from aortic baro-receptors 
which bring information to the NTS via the vagus nerve, and consequently stimulate vagal nuclei and 
activation of the parasympathetic nervous system. Another possible reflex is mediated by pulmonary 
stretch receptors present in the smooth muscle of the airways which respond to excessive stretching 
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of the lung during large inspirations and sent out information via the myelinated fibres of the vagus 
nerve to the medulla and pons to allow expiration; (iii) responses were CAPs of the recurrent 
laryngeal nerve; (iiii) responses were compound muscle potentials of the larynx striated muscle 
group innervated by the recurrent laryngeal nerve. 
Lesioning of the vagus distal to the stimulation electrode but proximal to the aortic arch, abolished 
the recorded signal, while an afferent section of the vagus nerve cranially to the stimulation 
electrode, did not have such an effect. This suggested that VNS resulted in co-activation of the 
recurrent laryngeal nerve and consequently only two possibilities remained. Recorded signals were 
either CAPs of the nervus larengeus recurrens or muscle compound action potentials of the larynx 
musle (LCMAP). EMG recording of the larynx during VNS and abolishment of signals after injecting of 
vecuronium in the larynx, allowed us to show that the nature or our recordings was in fact LCMAP.  
There are several possible reasons why LCAMPs were recorded in the absence of CAPs of the vagus 
nerve.  
First of all, we initially used stimulation parameters that are classically used in clinical epilepsy 
practice, as the first idea was to objectify stimulation and characterize an electrophysiological 
parameter that could be applicable in experimental in VNS experiments.  
Up till today, animal VNS experiments were performed with extrapolated stimulation paradigms, 
without taking into consideration of the fact that the electrode-nerve interface of rat is much smaller 
than that of a human. For example in our laboratory, the anti-seizure effect of VNS was 
demonstrated in the motor cortex model using high stimulation parameters (0.75 mA, 250µsec, 30 hz, 
30 sec on/1.8 min)(28). From our point of view, no literature is reliable about which parameters are 
sufficient to allow real CAP recording of the vagus nerve and consequently no objective basis is 
available to adapt stimulation parameters to the needs of the vagus nerve in rats. Currently, new 
experiments being performed at our laboratory indicate that stimulation pulses must be reduced to 5 
µsec to be able to appreciate CAP of the rat vagus nerve. Only when the specific parameters that 
activate the different fibres of the rat vagus nerve will be fully characterized, derivation of specific 
fibre stimulation in VNS experiments will be possible.  
A second issue is the lack of space in the cervical region of rats, which prevents implantation of 
longer cuff electrodes in which recording contacts are sufficiently distant and adequately separated 
from stimulation contacts. Better configuration of electrodes and implantation in larger animals such 
as for example in rabbits, would limit the pick-up of huge stimulation artifacts by recording contacts 
and would permit observation of latency differences between recording contacts, thus allowing a 
more precise calculation of the NCV. 
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Our experiments which had as a goal objectifying VNS, yielded recordings of far field potentials of 
LCAMP. The designed electrode permitted to stimulate and record muscle activity without 
implanting an additional electrode on the larynx, which directly facilitates surgical manipulation and 
limits the amount of foreign material implanted. This is of particular interest, as several studies in 
humans in which the effect of VNS surgery on the larynx was investigated with video-laryngoscopy 
and laryngeal electromyography have demonstrated that 50 to 60% of implanted patients suffered 
from vocal fold paresis postoperatively due to manipulation of the vagus nerve. The paresis 
spontaneously recovers between 2 to 6 months after implantation (28, 29, 30). Implantation of a 
single electrode which combines both stimulation and recording of activation of Aα-fibres of the 
vagus nerve, therefore offers the opportunity to check stimulation of the recurrent laryngeal nerve in 
experimental VNS studies. It must be emphasized that the LCMAP merely represents efferent 
activation of the vagus nerve and does not provide any information of electrophysiological properties 
of vagal afferent fibres that provide anti seizure effects.  
Consequently, the LCMAP can only be considered as a surrogate parameter for vagal nerve activation. 
On the other hand, largest myelinated Aα fibres are a type of fibres which are normally activated 
with the least amount of current compared to B- or C-fibres and consequently, if LCAMP is not 
recordable despite correct impedance values, the functionality of the vagus nerve must be 
questioned. 
Interestingly, intra-operative VNS-induced vocal cord EMG performed in humans by Ardesh et al 
showed a very similar induced LCMAP (34). Human LCAMP had an identical shape, but characteristics 
such as latency and amplitude were longer and higher respectively, corresponding to the larger size 
of the vagus nerve in comparison with rats. Activation of the larynx in humans was obtained by 
applying a VNS pulse of 500 µA and 130 µsec, which is more than 10 times higher than the 
parameters used in our experiments. 
Next, characterization of electrophysiological properties of Aα fibres and LCAMP in a chronically 
implanted vagus nerve, were analyzed over a follow-period of two months. Latency, intensity needed 
to activate a half maximal LCAMP amplitude (I50%) and slope factor of doses response curves 
remained stable over time, indicating that myelinated efferent fibres were adequately activated even 
though impedances of stimulation and of recording contacts gradually increased over time. An 
increase in impedance can be explained by natural the forming of gliosis between electrode contacts 
and nerve, which can have different consequences: on the one hand, in-growth of gliotic cells 
increases the distance between contacts and nerve, which in turn leads to higher required current 
values to activate the nerve. On the other hand, gliotic cells act as conductive tissue enhancing 
transmission of current. These two mechanisms probably compensate for each other to a certain 
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extent, “cancelling each other out”, and consequently I50% remains rather stable over time. Post-
mortem histological quantification of gliotic formation of the electrode nerve interface was not 
performed as we observed that dissection of the electrode and vagus nerve after death was a rather 
difficult procedure. The electrode was completely encapsulated with a fibrous cap and the nerve was 
barely identifiable. 
An important observation was that half of implanted rats showed an average recovery period of 25 
days before LCMAP could be recorded. If we consider that Aα fibres are the fibres that are recruited 
most easily, it is probable that other afferent fibres might have been damaged too.  
Noteworthy is the fact that in clinical practice, beneficial effects of VNS are mostly assessed after 6 
months to 1 year of therapy and no rational explanation for this fact has been given until today. In 
addition, laryngeal dysfunction has been reported after the implantation of vagus nerve stimulator 
and endoscopic evaluation documented return of vocal fold mobility 4 months after implantation (29, 
31), supporting the hypothesis of a recovery period with functional loss after surgery. Our results 
further support the idea that the vagus nerve may require a recovery period in order to regain full 
functionality. Nevertheless, epilepsy patients start their VNS up-titration two to three weeks after 
surgery, but to date no investigation is available to check whether the nerve has recuperated 
sufficiently to initiate stimulation.  
A next point of discussion, considers the efferent activation of the vagus nerve, despite the fact that 
the stimulation electrode around the left vagus nerve was oriented with the anode distally and the 
cathode cranially. Generally, this set-up is considered to preferentially activate afferent fibres, 
although in our experiments the principle of anodal block did not prevent activation of efferent 
motor fibres of the recurrent laryngeal nerve. In clinical practice, there exists a preconceived notion 
that stimulation must be directed towards the brain to avoid any side effects on heart rhythm. 
Several case-reports have described intra-operative bradycardia  and  ventricular asystole during 
testing of VNS device, but none of those patients experienced any cardiac side effects during their 
follow up with VNS (32, 33, 34). One of the possible hypotheses discussed in the literature regarding 
the underlying cause of cardiac side effects, is a reversal of electrodes counterbalancing the effect of 
anodal blocking and consequently activating more the vagal cardiac efferents. According to our 
animal experiments with implantation and stimulation of the vagus nerve with a cuff electrode, 
anodal blocking did not occur prominently, as VNS could systematically activate efferent Aα fibres 
and lead to recordable LCMAP in all our rats.  Nevertheless, no conclusions can be made concerning 
activation of vagal cardiac efferents, as no continuous cardiac monitoring was effectuated. 
Interestingly, a recent study describing excitation properties of the right cervical nerve in dogs 
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demonstrated that electrode configuration did not affect the threshold or recruitment of the vagal 
nerve fibres (35). 
Other more plausible explanations for the cause of cardiac side effects are possible variances among 
patients in anatomy of cardiac branches, which could consequently be more prone to be co-activated 
in certain patients. Different central vagal processing in the NTS of higher autonomic functions with 
an exaggerated effect on the AV node was also postulated as possible cause. Remarkably, negative 
effects on heart and lungs after VNS were mostly described in anesthetized patients and not in 
waking patients that already benefited from their treatment (32, 33, 34).  In addition, it is also known 
that frequency of SUDEP in patients treated with VNS is not increased (36).  In contrast, VNS is 
actually a new subject of research in the field of treatment for heart failure, as VNS has proved to 
improve left ventricular function in experiments with dogs, due to reduced heart rate, attenuation of 
sympathic overdrive and down regulation of the renin-angiotensin-aldosteron system (37). 
9.2.2.2 Human clinical VNS studies 
Our first study was a retrospective study in which we evaluated the efficacy, safety and practical 
improvements of the latest commercially available VNS device, the VNS Therapy Demipulse 103 
Model (Cyberonics®, Houston, USA), for the treatment of patients with refractory epilepsy (38). 
Twenty patients were included with a mean follow-up of one year and an overall mean seizure 
reduction of 39% was reported. Besides equivalent efficacy compared to previous reported clinical 
VNS studies, Demipulse generators appeared to have similar tolerability as older generators, as no 
new side effects were described. The main technical advances were the decrease in size and 
improved options for battery life follow-up. 
In next part of this thesis work, the ADNS-300, a new VNS device from Neurotech, was evaluated in a 
pilot trial (39). This new system provides stimulation and recording of compound action potentials of 
the human vagus nerve. In addition, the generator is transcutaneously rechargeable, extending 
battery life to an estimated 12 years.  
The first three patients went through a pre-surgical evaluation for refractory epilepsy, and a 
discussion at a multidisciplinary epilepsy surgery meeting lead to the conclusion that patients were 
not good surgery candidates. Instead, patients were offered a treatment with VNS, more specifically 
with the ADNS-300 system. After 1 year of treatment, all patients experienced a more than 40 % 
reduction their seizure frequency and were able to reload their battery autonomously.  
However, there has been a certain learning curve for patients as well as for the neurologist, in order 
to fully acquire all the technical skills relating to interrogation and programming of the generator, to 
recharge the battery adequately and finally to record CAPs of the vagus nerve. Moreover, the level of 
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recharging indicating that generator was fully reloaded had to be fine-tuned for of each patient to 
obtain efficient operation.  The Medical Implant Communication Service (MICS) device acting as a link 
between the implant and the main computer system functioned well, although in the first implanted 
patient, the MICS device needed to be placed less than 1 meter from the patient to allow correct 
communication. This distance increased to 2-3 meters in the two following two patients, after 
improving the hardware. All three patients were satisfied with their VNS treatment. Reported side 
effects were stimulation-related hoarseness, especially during the ramping-up period and discomfort 
and light pain sensation in the left neck region. These side effects were already described in 
previously performed studies with Cyberonics devices (40-45). 
Comparing both VNS systems, the most important differences are the following: first, the ADNS 
possesses a transcutaneous recharging system. For patients this opportunity may be an advantage, 
as replacements of generators still remain a (minor) surgical procedure. On the other hand life 
expectancy of the ADNS is extended to 12 years, so eventually younger patients will still need 
generator replacement(s) at some of time in their lives. Moreover, not all patients are able to charge 
their battery once or twice a week for about two hours. The antenna with the active coupling coil of 
the recharging system has to remain steady over the generator to permit maximum efficiency 
recharging some patients with intellectual or cognitive impairment may not be able to perform this 
procedure themselves. 
Secondly, the electrode is not a helical, but a self-sizing spiral cuff structure in which a longitudinally 
arranged tripolar set of contacts provides the derivation of the compound nerve action potential. The 
longitudinal tripolar configuration can reduce EMG signal and improves the quality of nerve 
recordings, as recordings from peripheral nerves with extraneural electrodes are much smaller in 
magnitude than signals from surrounding muscle activation (46). In addition, cuff electrodes have a 
shielding effect and minimize current leakage to the surrounding tissues, which could provide more 
efficient stimulation of the vagus nerve and reduce muscle artifacts. 
Thirdly, initial parameters of stimulation were programmed identically as per the Cyberonics models, 
with the exception of the possibility of an up-titration in steps of 0.2 or 0.25 mA, although added 
value of this possibility still needs to be examined in large patient groups.  
Concerning other parameter settings, the possibility existed to program newer ones than those 
already used in the clinic, but considering the fact that this study was a first pilot trial, no further 
adjustments were carried out. 
Other minor differences are the volume and shape of the ADNS-300, that has a more rectangular 
shape and a volume of 7 cc, while the latest Demipulse model 103 and 104 have a volume of 8/10 cc 
and a more rounded contour (47). In the surgical procedure of our first three implants, generator and 
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lead of the ADNS-300 were already connected, thus imposing a tunneling of the electrode in the 
direction of the head. In future implantations, both components will come separated and the 
technique of implantation will be very similar to the Cyberonics device implantation. 
Within the framework of this thesis, the recording of human postoperative compound action 
potentials was a major advance in VNS research. CAPs were recorded in patient 1 and 2 at 2 to 3 
weeks after implantation of the ADNS-300.  
In two patients, the vagus nerve was stimulated with a pulse of 500 µA intensity and 250 µsec pulse 
duration, which resulted in recordings of vagal nerve CAPs (N1P1N2), with a first peak appearing at 0.4 
msec after the end of the stimulus. As mentioned earlier in this discussion, NVC is ideally based on 
latency differences between two distant recording contacts, which was not fulfilled by the ADNS-300 
electrode configuration, due the evident problem of restricted length. Instead, it has a tripolar 
organisation in which the middle contact is considered to be the active recording contact referred to 
the outer two that are connected to each other (39). The first recording contact is situated 5 mm 
rostrally from the stimulation cathode, so NCV would be at least 12.5 m/sec, which falls in the range 
of velocities of myelinated (A and/or B) fibres (11). The threshold to obtain responses was quite low 
(100-150-µA and 250µsec), which is an additional support for the hypothesis of activation of 
myelinated fibres. The vagus nerve contains a number of functionally different fibres that contribute 
with different latencies and amplitudes to the CAP, but on the basis of our results, we only were able 
to conclude that CAP resulted from activation of myelinated fibers in general.  
In the literature, only two authors have described recordings of intra-operative CAPs of the vagus 
nerve (48, 49), while our results date from a late acute stage of 2 to 3 weeks and a chronic situation 
at month 11 and 12 after implantation. After implantation, electrode-nerve environment evolves 
from a situation of postoperative oedema to a steady state with an encapsulated fibrous cap 
covering the electrode and nerve. The whole process most likely takes at least 2 to 3 weeks, although 
objective information on this topic is not available. Adaptation of the body to a foreign body 
influences nerve activation and consequently our results are probably not fully comparable to the 
intra operative CAPs reported by Evans et al and Koo et al.  
Evans described three different fibre populations (A, Aδ and C), on the basis of the latency of each 
waveform from the stimulus artifact onset (48). Mean conduction velocities of 18.8, 9.5 and 2.1 
m/sec corresponding respectively to the different fibre types of the vagus nerve were described. The 
initial component, consistent with the activation of myelinated fibres, occurred after 1 msec, while 
the recording contact was 2 cm away from the cathode, which is earlier then our first peak (N1). 
Possible explanations were already mentioned above, i.e. our experiment settings might have been 
influenced by induction of an inflammatory reaction and beginning gliosis, which could have slowed 
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down NCV of myelinated fibres. Nevertheless, amplitudes of recordings by Evans were similar to our 
maximal amplitudes. Moreover, the threshold for A fibres in their study was 250 µA with a pulse of 
130 µsec duration, which is in the same range of charge needed to activate the vagus nerve in our 
patients. Koo et al described very similar vagus nerve CAP with biphasic shape and NCV of 10.2 m/sec. 
One major difference between our study and results reported by Koo et al is the fact that a higher 
stimulus charge was required, namely 1mA and 100µsec, but this can easily be explained by the 
different type of electrode they used. Interestingly, important latency and threshold changes with 
age from childhood to adulthood were described. This indicates that an individual adjustment of the 
stimulus strength based on the observed nerve activation is absolutely necessary. 
In addition, we performed a 12-month follow-up of one of the three patients and performed serial 
dose response curves of vagal nerve CAP. In the two other patients, due to technical problems 
(possibly caused by lead breakage), CAP recording was not possible in patient 3 right from the start 
of the study and in patient 2 at month 10. In these two last patients we have checked that 
therapeutic stimulation was administered correctly, by visualizing the stimulation pulse with use of 
specific hardware and software.  
The patient received classical up titration scheme and stimulation paradigms namely 0.75 mA, 30 Hz, 
500µsec, 30 sec on, 10 min off (43, 45). After 6 months, the patient did not experience any beneficial 
VNS effect and anti-epileptic drug (AED) treatment was adapted to his needs. The patient became 
seizure free starting from month 7. Therefore, it remains uncertain whether his seizure freedom 
resulted entirely from AED adjustments or was the consequence of a delayed effect of the VNS or 
even the combination of AED and VNS combined. Complementary, doses response curves of the 
vagal nerve CAP were successfully recorded over a time span of 1 year after implantation, indicating 
that CAPs of the human vagus nerve can be objectively recorded in response to an external electrical 
stimulus in a chronic way.  
The recorded curves showed recruitment of two groups of fibres, most likely corresponding to large 
and intermediate myelinated fibres. Threshold activation was obtained in the first group at 50 µsec x 
500 µA, while the second group necessary charge increased to 250 µsec X 150µA.  
One of the drawbacks of our follow-up study was the fact that limited amount of date could be 
recorded at each visit, as communication between the implant and the main computer system for 
CAP recording required a substantial amount of battery charge, which limited the number of possible 
recordings. Subsequently, we have chosen to stimulate the vagus nerve with the shortest 
programmable pulse duration, i.e. 50 µsec, in addition to larger pulse duration compatible with a 
satisfactory CAP recording. Stimulation of the vagus nerve with longer pulse durations than 250 µsec 
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led to larger stimulation artifacts, obscuring early CAP components and saturating the recording 
system.  
A second issue which needs further elaboration is the automatic filtering of data that are transmitted 
by MICS mode to the Neurotech computer. Indeed, in this pilot trial filtering was done off-line; whilst, 
in practice, the neurologist should at least be able to upload the chart showing the doses response 
curve of that day. 
9.3. Future perspectives 
9.3.1 In practice… 
First of all, the important message of this work is the fact that individualized CAP recordings of the 
implanted vagus nerve may help to guide choice of stimulation parameters. The performed studies 
only provide information on choice of stimulation intensity or pulse width. The role of other 
parameters such as stimulation frequency or duty cycle was not examined. 
In this context, we propose the following procedure: 
Dose-response curves could be performed at each visit after surgery using maximal pulse width of 
250µsec; higher pulse widths may interfere with recording of the early components of the CAP. 
Applying gradually increasing intensities from 0 to 1mA allows plotting of the CAP amplitude in 
function of the applied charge. The total amount of charge for which maximal amplitude is reached, 
may serve as an individual maximal output value. Hypothetically, the intensity or duration of pulse 
width would not be of further importance, as long as the applied parameters correspond to the 
postulated charge. This value may evolve along consecutive visits, correlating with a gradual nerve 
recovery and encapsulation of the electrode-nerve interface. If no CAP is recorded in the early stage 
of follow-up, starting stimulation would be preferably postponed, as stimulation in recovery phase of 
the nerve may not be suitable. On the other hand, functional stimulation is being applied in different 
medical areas, as for example FES of laryngeal nerve in horses with recurrent laryngeal nerve 
neuropathy (RLN), so this assumption may be incorrect.  
With respect to the idea that the vagus nerve may need recovery time - especially myelinated fibres 
seem to be sensitive to surgical manipulation-careful up-ramping is still advised. The smallest 
intensity steps in our study were programmed at 0.2 or 0.25mA. These values may be used as a 
guideline. If a pulse duration of 250 µsec is selected, up-titration can proceed in steps of 0.25 mA 
every month until the optimal result is reached. 
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One may argue that applying this method to a large number of patients may yield enough biological 
information to deliver mean values applicable to all patients, but doing so, the value of checking real 
activation per patient would be lost, which might be a key element in explaining why some patients 
have better/earlier response than others. In this context, local inflammatory reactions after 
implantation may differ between individuals, emphasizing the importance of individual parameter 
choice in function of physiological vagus nerve recordings. This approach will reduce time for up-
titration; avoid unnecessarily high outputs en save battery life. 
9.3.2. Hypotheses concerning delay of effectiveness of VNS in responders and no effect in 
non responders: role of the vagal nerve CAP. 
Implantation of larger groups of patients with the AND-300 will offer the opportunity to record vagus 
nerve CAPs on a larger scale than has so far been done in this domain. By measuring 
electrophysiological properties of the vagus nerve postoperatively and at regular intervals in the 
follow-up of VNS treatment, it may be possible to analyze whether local recuperation of the vagus 
nerve is an explanation for the delayed positive response to stimulation, i.e. 6 to 12 months are 
typically required to judge whether patient responds or not;  i.e. whether or not the start of any 
beneficial VNS effect is linked with the successful recording of a CAP after a silent period and 
consequently be a partial explanation why non-responders to do not experience any benefit of VNS, 
if no CAP is recordable at all.  
 
Several studies in vitro studies have implicated immunoregulatory cytokines such as IL-4, IL-13, IL-10, 
and transforming growth factor (TGF-β)], inflammatory cytokines IL-6 and tumor necrosis factor 
(TNFα) and chemokines (MCP-1) in the formation of the foreign body response (50-52). Moreover, as 
mentioned earlier, TNFα, which has inflammatory, demyelinating and degenerating properties, was 
shown to be upregulated during 1 month after cuff electrode implantation around the sciatic nerves 
of rats (15). In addition, certain cytokines that play a role in neural microvascular changes, such as 
Nitric oxide isoform I and II (NOSI and II) and vascular endothelial growth factor (VEGF) were 
analogously upregulated, especially in animals presenting functional deficit following electrode 
surgery (14, 15, 53). 
Considering these data, we hypothesize that after implantation of a cuff electrode around the human 
vagus nerve, a local inflammatory response with several mediators takes place, before the formation 
of the dense fibrous cap around the electrode and nerve occurs. In this phase, the vagus nerve may 
not function adequately and components of the CAP could show increased latencies, reduced 
maximum amplitudes or could even not be recordable at all.  
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Therefore the research on the action mechanisms of VNS, should not only concentrate on the 
different effects of VNS in its different projection sites in the brain, but also be conducted in the field 
of local biological mechanisms altering electrode nerve interface after surgery and in the long term. 
The degree of postoperative oedema and the time needed for complete recovery in combination 
with the extent of the inflammatory reaction is most likely different for each individual, which might 
be one of the explanations why the response to VNS is so individually different. 
In animal experimental work, no studies have been performed to sort out what the local 
inflammatory response exactly implies after vagal nerve implantation. Research on which cytokines 
play a prominent role in local demyelinisation after cuff implantation around the vagus nerve may 
not only lead to a better understanding of vagal nerve functioning, but could, in the future, also lead 
to enhanced stimulation electrodes and treatments. For example, in the cardiac domain, polymer-
coated stents that are loaded with methylprednisolone have been described and reported to inhibit 
the severe foreign-body reaction induced by the combination of overstretch injury and the coating of 
metallic stents (54). In a similar way, localized and controlled delivery of an anti-inflammatory drug to 
the electrode-vagus nerve interface could counteract the inflammatory reaction and limit the tissue 
reaction around the nerve, aiming to improve electrode performance.  
9.3.3. LCAMP  
9.3.3.1 General 
LCAMP reflects activation of efferent Aα and could function as a surrogate parameter of adequate 
vagus nerve stimulation, as we believe that applied stimulus travels in both directions in the nerve, 
namely efferent but also in afferent way. The main question is whether the dysfunctioning of the 
thickest myelinated efferent fibres may also imply some damage to the other types of fibres, 
especially to the afferent myelinated fibres that may provide beneficial anti-seizure effects. To 
evaluate the usefulness of LCAMP, new experiments in which rats are implanted with the combined 
stimulation and recording electrode and receiving VNS treatment in a specific epilepsy model must 
be performed.  Experiments investigating whether rats in which LCAMP could be recorded 
immediately after surgery have a better outcome compared to rats with a delayed LCAMP could 
provide useful information. The most important requirement for the choice of the epilepsy model is 
that VNS has already proven to have anti-seizure effects in the particular model independently of 
LCAMP. Two possible models at our laboratory fulfil this criterion.  
Firstly, VNS has proven to have seizure-suppressing effects in the intrahippocampal pilocarpine 
model for limbic seizures as a result of an increase in hippocampal noradrenalin concentration (55, 
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56). Secondly, VNS significantly increased motor seizure threshold in a cortical model for motor 
seizures (57). Stimulation paradigms were slightly different in the two models. Basically De Herdt V. 
applied 1 hour of VNS  (0.75 mA, 30 Hz, 250 µsec; duty cycle = 7 sec on – 18 sec off), while Raedt R. et 
al continued VNS during thirteen 20 minute collections of CSF which corresponds to a total duration 
of more than 4 hours of VNS at 1 mA ( other parameters settings were identical). In addition to VNS 
experiments in which outcome of two postoperative groups- namely a LCAMP group and a non 
LCAMP group are analyzed, it would be also interesting to repeat at several different time points the 
same experiment over a two-month period to investigate whether the time of delay and recovery 
inversely correlates with improved VNS response.  
In line with our previous hypothesis regarding the importance of a local inflammatory reaction and 
dymelinisation of the vagus nerve, experiments in which LCAMP are monitored over time and 
different groups of rats are sacrified at different time stages for histological investigation of electrode 
and its embedded nerve could be interesting. Cytokines or vascular factors such as TNFα, TNFβ, NO 
or VEGF could be investigated with immunohistochemical methods.  Hypothetically, rats which have 
altered Aα function do show a larger inflammatory response compared to rats in which LCAMP is 
effectively recorded.  
9.3.3.2. Possible clinical implication of the LCAMP 
In humans, larynx EMG is usually used to guide injections into the thyroarytenoid muscle in patients 
with adductor spasmodic dysphonia (58). Other medical applications are rather scarce and 
neurologists do not often use this investigation in their clinical practice. Only one author described 
intra-operative VNS induced larynx EMG in the context of epilepsy (59), but there are no reports of 
larynx EMG in patients with refractory epilepsy chronically treated with VNS, in whom a VNS pulse 
was the trigger for larynx activation. In practice, one possibility could be to activate the generator 
with the magnet to deliver an extra train of stimuli, while continuously recording EMG of the larynx. 
At the same time EEG scalp recording could provide an extra check when the VNS pulse was 
delivered as this causes a recognizable artifact on EEG. Characterization of VNS-induced larynx 
contraction in large of group of epilepsy patients could provide more information about co-activation 
of the recurrent laryngeal nerve and its induced muscle contraction during VNS. 
 
Prospective analysis of VNS-induced larynx EMG after implantation and at regular intervals after 
initiation of therapy, might lead to more insight in the mechanism of recovery of the vagus nerve 
after surgery. This idea is extrapolated from animal experimental work and a comparison between 
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rats and human situation remains delicate. Nevertheless, VNS-induced larynx EMG may become an 
additional tool besides CAP recording to evaluate vagus nerve functionality 
9.3.4. VNS induced evoked potentials 
In the search of objectifying stimulation of the vagus nerve and complementary to VNS CAPs or VNS 
induced LCAMP, VNS-evoked potentials could be further explored. In this work, only far field 
potentials from local larynx contraction were measured in several brain targets. This was partially 
explained by the fact that VNS induces local fields that are likely to be very small and only 
measurable with single or multi-unit recordings. As the vagus nerve consists of different types of 
fibres, VNS-evoked potentials could help us understand whether some fibre types preferentially 
project to specific sites, such locus coerelus, thalamus or hypothalamus, which would clarify further 
the mechanism of action of VNS. 
9.3.5. Functional stimulation of laryngeal nerve in horses with laryngeal nerve neuropathy 
Our collaboration with the veterinary department lead to a successful implantation of the Cyberonics 
model 102 device for functional stimulation of the laryngeal nerve in one healthy horse. Further 
research in functional stimulation of laryngeal nerve in horses with pathological laryngeal nerve 
neuropathy and problems with the vocal cords will clarify whether the explored technique can offer a 
total or partial recovery of laryngeal function. 
9.3.6. General possible future practical perspectives in identifying VNS responders on the 
basis of data in literature. 
Progress was made in the domain of vagal evoked potentials after t-VNS at the inner side of the 
tragus, which may offer clinicians a non-invasive technique to evaluate the effect of VNS at the level 
of the brain (61, 62). Until now t-VNS has not yet been recognized as a good alternative for cervical 
stimulation. 
Previous studies in a limited number of patients have shown that VNS influences the N13-N20 
component of the somatosensory evoked potential (62) or the P3 amplitude of visual evoked 
potentials (63). 
In the same line of interest and complementary to t-VNS EP’s, better evaluation of VNS on these 
already commonly used EP’s in a larger number of patients might be useful.  
In addition to electrophysiological investigations, further research with neuro-imaging techniques 
such as PET and SPECT may clarify whether the role of thalamic activation consistently correlates 
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with positive seizure outcome, as this anatomical projection site appears to play a key role in 
different studies (65-67). Hypothetically, transcutaneous stimulation of the vagus nerve would permit 
to evaluate CBF changes in the thalamus prior to implantation, which might lead to more adequate 
selection of patients and consequently lead to higher responder rates.  
Overall, VNS most likely induces its effect by recruiting various pathways in the brain and the 
resulting activation patterns probably interact in distinct ways, leading to an individually specific 
response. Researchers have gradually booked advances in unravelling small parts of this puzzle and a 
variety of investigations allow us to objectivise certain elements of it. Further research may lead to 
more adequate VNS, in which prediction of outcome and choice of stimulation paradigms will be 
derived from objective information in individual patients. 
9.4 Further discussion related to VNS in general 
9.4.1. Mechanisms of action of VNS in the brain 
In addition to the study of electrophysiological characteristics of the vagus nerve, understanding 
the mechanism of action of VNS lies also in unraveling different effects of VNS in the brain. 
Different anatomical sites and neurotransmitters systems have been postulated to play a key 
role in the beneficial effect of VNS in patients with epilepsy.  
9.4.1.1. Thalamus-cortex pathway 
VNS induces increased synaptic activities in the thalamus and thalamo-cortical projection 
pathways bilaterally, leading to increased arousal and possibly to decreased synchrony of 
synaptic activities between end within cortical regions (64,67,68). 
 
On cortical neurotransmitter level, the role of GABA has been pointed out in different studies. 
The development of post-traumatic seizures that occurs following brain injury may involve a loss 
of GABAergic cells and inhibitory tone in the brain. The role for the inhibitory neurotransmitter 
GABA in VNS mediated seizure suppression in humans undergoing VNS therapy is also suggested. 
At both high and low amplitude VNS, total GABA levels in the cerebrospinal fluid of VNS patients 
are significantly increased (40). Additionally, single photon emission computed tomography 
(SPECT) of GABA-A receptor density in the hippocampus following 1-year of VNS therapy showed 
a significant normalization of GABA-receptor density that correlated with seizure reduction (69). 
In the fluid percussion injury model VNS prevents the loss of GABA neurons within the cerebral 
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cortex, and possibly the hippocampal formation, which might facilitate the recovery of 
behavioral function (70). 
9.4.1.2. LC-Hippocampus pathway  
The vagus nerve projects directly to the raphe nucleus and indirectly to the LC. These nuclei are the 
major sources of serotonergic and noradrenergic neurons in the brain respectively (64). Both send 
direct projections to the hippocampus, a brain structure that is frequently involved in the generation 
of epileptic seizures in temporal lobe epilepsy (TLE) (71). Bilateral destruction of the LC has been 
found to reverse the seizure-suppressing effect of VNS in the maximal electroshock model (72). 
Single-unit recording experiments have shown that the activity of noradrenergic neurons in the LC is 
increased upon stimulation of the vagus nerve (73, 74). Enhancement of the activity of LC neurons, 
increases in extracellular noradrenaline concentration in projection areas of the LC such as the 
hippocampus and cortex in VNS-treated rats (75). In our laboratory, recent experiments have shown 
that VNS prevents the development of pilocarpine induced limbic seizures only in those rats in which 
hippocampal noradrenaline increased by at least 70%; and that selective a2-adrenoreceptor 
antagonism plays a key role in preventing seizures (56). The inter-subject variability of there response 
to VNS could be based on genetic variability and differences in external and/or internal 
environment could lead to differences in the number of noradrenergic neurons, their afferent 
and/or efferent projections and synaptic strengths within these noradrenergic neuronal 
networks. This intrinsic variation in the noradrenergic neural network could underlie the variable 
release of noradrenaline in response to VNS. 
9.4.2 Cranial nerve stimulation for epilepsy: V, IX 
In a first pilot trial in which Trigeminal nerve stimulation (TNS) was applied transcutaneously for 
patients with refractory epilepsy (76,77), TNS seemed to be well tolerated an 4 of 7 subjects who 
completed a 3 month follow-up period experienced a ≥50% reduction in seizure frequency. In a 
longer follow-up study of 1 year, the beneficial effect of TNS sustained over time (78). 
Importantly, trigeminal nucleus and vagal nuclei have extensive projections to the nucleus of the 
tractus solitarius and the locus coeruleus (LC), which may be an explanation for positive effects 
of TNS.  Beside the common anatomical projections to NTS and LC, cranial nerve stimulation 
causes desynchronization of thalamic and cortical activity and in turn reduces seizure activity. 
This effect may be explained by the fact that stimulation activates midbrain reticular formation 
resulting in generalized arousal. In this context, seizure reduction effect of VNS can also be 
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achieved by stimulation of multiple cranial nerves that convey information to the reticular 
formation (76,77,78). In addition to trigeminal stimulation, stimulator of the Hering nerve (HN; a 
branch of cranial nerve nine) was shown to control epileptiform activity in a canine model study 
(79). Interestingly, Tubbs et al have demonstrated that the ability of HNS to reduce seizure 
activity in the rats is dependent on an intact dopamine system in the basolateral amygdala (80). 
9.4.3 Profiling Vagus Nerve Stimulation Responders 
9.4.3.1 Epileptogenic zone 
A few studies have evaluated whether the lateralization of the epileptogenic zone influences the 
efficacy of VNS  and showed only a non-significant trend towards a slightly higher rate of responders 
among patients with a right-sided epiletogenic zone(81, 82). Other small series have reported non-
significant trends towards greater efficacy in patients suffering from temporal unilateral (83, 84), 
bitemporal (85,86) or frontal lobe epilepsy (81,87). Thus, at present there is no strong indication that 
the antiepileptic effect of VNS depends on the side or localization of the underlying epileptogenic 
zone. 
9.4.3.2 Underlying Lesion 
Some studies suggest that VNS is more effective in patients whose epilepsy is symptomatic of an 
underlying brain lesion, most notably malformation of cortical development (82, 88), including 
tuberous sclerosis (89).However, this issue remains controversial, with other series showing greater 
efficacy of VNS in patients with non-lesional epilepsies (90) or comparable findings in patients with 
and without abnormal findings on magnetic resonance imaging (91,92). 
9.4.3.3 Function of Age 
In three large pediatric trials, the 50% responder rate was found to be equal to or greater than that 
reported in adults, ranging from 46 to 83% after two years of follow-up (93-95). 
9.4.3.4 Seizure types in generalized epilepsies 
Several studies suggest that VNS is effective in drug-resistant idiopathic or symptomatic generalized 
epilepsy (81,82,96-100).The average reduction in seizure frequency appears comparable in these 
types of epilepsies (around 45% for follow-up ranging from three to 21 months) to that observed in 
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partial epilepsies (99,100) although a few studies suggest that higher responder rates could be 
observed in patients with symptomatic generalized epilepsy, specifically (81,82,97). VNS appears to 
be efficacious against all types of generalized seizures, including myoclonic jerks (96,100),tonic 
seizures (99), absences and generalized tonic-clonic seizures(81, 96). In Lennox-Gastaut syndrome, 
the average reduction in seizure frequency was found to be greater for atypical absences and tonic 
seizures (73 and 55%, respectively) than for partial seizures (23%) (101). Conversely, in infantile 
spasms VNS does not seem efficacious, with only two responders out of a series of 10 patients (102). 
9.4.3.5 Concomitant AEDs 
AED and VNS appear to have distinct mechanisms of actions. Sedative effects and impaired cognition 
are commonly observed with the use of AED’s, which increase GABAergic inhibition or reduce 
repeated rapid interneural action potentials by limiting sodium conductance. These adverse events 
are not seen with VNS. In contrast, stridor of vocalization often occurs during activation of vagal 
efferents, but do not appear with AED. One study reported a beneficial effect on behavior 
(specifically alertness), when topiramate and VNS therapy were associated. This positive effect 
seemed not to be a consequence of solely seizure reduction, and possible synergistic effects were 
proposed. Consequently, the AED regimen per patient may induce a different ‘brain status’, which 
might influence response to VNS. Up till now, no studies really investigated this subject, although it is 
possible that according to the AEDs taken, a different VNS response is achieved. 
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Summary 
Epilepsy is a neurological disorder characterized by recurrent aberrant electrical activity in the central 
nervous system which typically manifests itself as seizures. It is estimated that 1% of the population 
is affected worldwide. About 30% of these patients are considered refractory, meaning that they do 
not respond to anti-epileptic drugs. For these patients, alternative treatment modalities such as 
epilepsy surgery or neurostimulation (deep brain stimulation (DBS) or vagus nerve stimulation VNS) 
may be useful.  
VNS is a less invasive treatment compared to DBS and is characterized by stimulation of the left 
vagus cervical nerve through electrical pulses delivered by a generator implanted under left clavicula. 
Pulses are determined by their intensity, pulse duration, frequency and duty cycle. Until today, more 
than 50.000 patients worldwide are treated with VNS. In general outcome of VNS can be divided into 
three groups. First group experiences a seizure reduction of more than 50%. A second group of 
patients has a seizure reduction between 30 and 50%. The last group, are those patients that only 
have a minor reduction in seizure frequency of less than 30% or do not respond to VNS. 
Unfortunately, there are no predictive factors to identify responders at earlier stage. In addition, 
there are no rational individual guidelines about how to up titrate VNS most efficiently or when to 
start stimulation after surgery. In epilepsy practice, patients are invited at the consultation two 
weeks after surgery to start VNS, which will be up-ramped in steps of 0.25 mA every 2 to 4 weeks, 
until seizure reduction is achieved or side effects appear. 
The vagus nerve carries somatic and visceral afferents and efferents. Afferents compose about 80% 
of the cervical portion of the vagus and are mainly narrow-calibre unmyelinated C fibres, which 
predominate over faster conducting myelinated A and B fibres. Myelinitaed fibres need much lower 
charge densities to be activated comparing to unmyelinated fibres and are presumably the only 
fibres required to be activated to induce beneficial effects of VNS in epilepsy. Nevertheless, the 
mechanism of action of VNS remains poorly understood. 
VNS research can be divided in two main domains. The first part concerns research about activation 
of the vagus nerve itself by applying electrical pulses with the use of extracellular electrodes.  
Once the nerve is adequately activated, vagus nerve induces different effects at several projection 
sites in the brain. Characterization of those effects in the brain is a second branch of research and 
remains largely unsolved. 
Choice of stimulation parameters in clinical practice is based on previously performed VNS animal 
experiments, but in none of these studies individual electrophysiological characteristics of the vagus 
nerve were considered. Therefore this thesis had as the main goal to objectify electrical stimulation 
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of the vagus nerve. For this purpose, a newly designed combined stimulation and recording electrode 
for the vagus nerve was developed for animal use. 
Implantation of a large group of rats has resulted in recordings of VNS-induced signals that were too 
long in latency to be real compound action potentials (CAPs) of myelinated fibres of the vagus nerve. 
Experiments in which EMG recording of the larynx was performed and application of muscle 
paralyzing agents was applied, have confirmed that VNS co-activates the recurrent laryngeal nerve, a 
branch of the vagus nerve. As a consequence, contraction of the larynx could be consistently 
recorded as a far field muscle potential with a single electrode around the vagus nerve. In chronic 
experiments, we have performed daily dose-response curves and regular measurements of 
impedances of stimulation electrodes. Latency of larynx muscle compound action potential (LCAMP), 
intensity needed to activate a 50 % response and slope factor of dose-response curves remained 
stable over time. Impedances of stimulation electrodes gradually increased, consistent with the idea 
that a gliotic process encapsulates the electrode nerve interface. 
In the follow-up of implanted rats, we observed that nearly half of the rats needed an average 
recuperation time of 25 days, indicating that the vagus nerve required a certain period to recover 
from surgery and implantation of an electrode. Interestingly, in epilepsy practice, evaluation of VNS 
responders is performed after at least 6 months to 1 year of therapy. Hypothetically, implantation 
leads to a local inflammatory reaction which could be at the origin of a temporary local 
demyelinisation of the nerve explaining a possible recovery time and delay in evaluation of 
responders. Performing more animal experiments, in which the LCAMP is applied in an epilepsy 
model in which VNS is tested, could offer new insights. Hypothesis would be strengthened if the 
outcome after VNS shows to be dependent on the actual recording of the LCAMP.  
In addition, post-mortem immune histological analysis of electrode and vagal nerve could answer the 
question whether the inflammatory reaction is greater in those rats in which no LCAMP could be 
measured. LCAMP remains of course a surrogate parameter as it only reflects activation of efferent 
Aα fibres of the vagus nerve and does not give any information about myelinated afferent fibres 
which provide the anti-seizure effect of VNS. 
Complementary to animal experimental work, we have tested in collaboration with Neurotech, a 
new VNS device (ADNS-300), which is capable of delivering therapeutic vagal nerve stimulation and 
offers the opportunity of recording CAPs of the human vagus nerve. In addition, the ADNS-300 
possesses a transcutaneous recharging system, extending generator life up to 12 years. 
Three patients were implanted for the first time with the ADNS-300. Two of the three patients 
reported a reduction of seizure frequency of 40%, while the third patient did not respond. For this 
patient, anti-epileptic drug treatment was adapted as he complained from medication-induced 
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somnolence, but parameters of his VNS remained unchanged. Thereafter the patient became 
seizure- free. Thus, positive evolution of the patient’s seizure frequency could have been a direct 
consequence of the changed anti-epileptic drug treatment, but beneficial effect of VNS is cannot be 
excluded. 
In same context of the animal experiments, we succeeded in recording CAPs of the vagus nerve in 
two of the three patients 2 to 3 weeks after surgery. The vagus nerve was stimulated with a pulse of 
250 µsec duration and 500 µA intensity, which resulted in the recording of N1P1N2 CAP, with N1 
appearing 0.4 msec after the end of the stimulation artifact. Minimum threshold was 250 µsec and 
100-150µA. When pulse duration was shortened to 100 µsec, the threshold stimulus intensity 
increased to a value between 250 and 500 µA in patient 1 and 200 and 250 µA in patient 2. 
Subsequently, we have carried out dose-response curves in patient 2 during a follow-up of 1 year. 
Our results show that two groups of myelinated fibres are recruited at different levels of charge 
density. The first group was fully activated at 25 mC (500 µA x 50 µsec), while the second group 
needed higher values, ie 37.5 mC (150 µA x 250 µsec). Stimulation parameters were kept stable the 
first year and were based on previous experience with Cyberonics devices. In the future, dose-
response curves could allow clinicians to evaluate the maximum output charge to fully activated 
myelinated fibres and handle this value as a maximal stimulation level. This approach will reduce 
time for up-titration, avoid unnecessarily high outputs en save battery life 
Further research on whether the beneficial effect of VNS is linked with the successful recording of a 
CAP after a silent period,  could offer a partial explanation why non-responders to do not experience 
any benefit of VNS. Longitudinal follow-up studies in which seizure reduction is correlated with CAP 
recordings, might partially answer an important issue in clinical practice, namely why some patients 
respond to VNS and other do not. 
Finally, implantation and recording of vagal nerve CAPs in a larger group of patients, will hopefully 
lead to better electrophysiological understanding of VNS.  
 181 
 
Résumé 
L'épilepsie fait partie des affections chroniques neurologiques les plus courantes et affecte 1 % de la 
population mondiale. Les crises épileptiques sont insuffisamment contrôlées dans le cas d'environ un 
tiers des patients, malgré un traitement antiépileptique adapté. Pour ces patients, une évaluation 
pré-chirurgicale s’impose, dans un centre d’épilepsie de référence. Seulement un petit pourcentage 
des patients réfractaires peut bénéficier d’une intervention, car les lésions épileptiques sont souvent 
situées au niveau du cortex éloquent.  Pour ces patients, la neurostimulation constituerait alors un 
traitement alternatif valable. 
La stimulation du nerf vague (SNV) se distingue de la neurostimulation profonde, car elle est moins 
invasive et stimule le nerf vague uniquement dans la région cervicale gauche. Le nerf est stimulé par 
des pulsations électriques, en provenance d'un générateur implanté en dessous de la clavicule. Les 
paramètres de la stimulation sont l'intensité, la durée des pulses, leur fréquence, ainsi que le cycle de 
charge.  Actuellement, plus de 50.000 patients sont traités par SNV.  
Généralement, une réduction de la fréquence des crises de plus de 50 % est observée dans un tiers 
des cas, tandis qu'elle n'atteint que 30 à 50 % pour une même proportion des patients traités. En ce 
qui concerne le tiers restant, la fréquence est réduite de moins de 30 %  ou aucune amélioration 
n'est relevée. Il n'existe actuellement pas encore de facteurs prédictifs, ni de recommandations 
claires quant à l'utilisation de la SNV.  
En pratique, le patient consulte deux semaines après l'implantation du générateur. Une stimulation 
progressive, intensifiée par paliers de 0,25 mA, est appliquée jusqu'à la réduction de la fréquence des 
crises ou une éventuelle apparition d'effets secondaires, comme une sensation douloureuse au 
niveau de la région cervicale gauche. 
Le nerf vague est composé de trois types de fibres différentes. La majorité sont des fibres non 
myélinisées (C), une minorité est représentée par les fibres myélinisées (A, B). Il est à noter que les 
fibres myélinisées nécessitent des stimulations d'intensité bien moins importante par rapport aux 
fibres C, qui sont  moins facilement activées. Selon les données issues de la littérature, seule 
l'activation des fibres A et B semble important pour la réduction de la fréquence des crises.  
Les recherches visant à comprendre le mode d'action de la SNV portent sur deux aspects distincts de 
la problématique.  
Premièrement, l'activation du nerf s'effectue via des pulsations électriques qui génèrent un potentiel 
d'action composé. Ce dernier dépend de la fonctionnalité du nerf, d'autant plus lorsqu'une électrode 
de stimulation a été préalablement implantée. Ensuite, un second intérêt de recherche réside dans 
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les effets de la stimulation du nerf vague sur les différents sites de projection au niveau du système 
nerveux central. 
Cette thèse de doctorat vise à présenter une méthode innovante de stimulation du nerf vague, 
permettant un enregistrement de l'activité électro-physiologique résultant de sa stimulation.  
Dans un premier temps, une électrode, combinant les fonctions de stimulation et d'enregistrement, a 
été conçue et implantée chez un groupe  de rats dans l'objectif d'évaluer la faisabilité et la 
fonctionnalité de l'implant.  
Cependant, l’enregistrement de l’activité électro-physiologique du nerf vague ne  s'avérait pas être 
des actions potentielles évoquées (CAPs), mais bien la contraction du muscle laryngé (LCAMP) suite a 
l’activation d’une branche du nerf vague, notamment le nerf laryngé récurrent. En conséquence, des 
courbes de recrutement du LCAMP ont été effectuées durant une période de deux mois. Les 
caractéristiques du LCAMP comme la latence, l'intensité requise pour activer 50 % des fibres, 
l'amplitude maximale et le facteur de pente sont restés stables pendant toute la durée du suivi. 
L'impédance des contacts de stimulations mesurée s'accroît graduellement, ce qui peut s'expliquer 
par l'apparition de gliose. Néanmoins, la moitié des rats ont eu besoin d'une période de récupération 
de 25 jours en moyenne, indiquant clairement que l'implantation de l'électrode induit un dommage 
fonctionnel au niveau du nerf vague. Cette dernière observation est importante, car une attente d'au 
moins 6 mois avant l'évaluation des résultats de la SNV est conseillée chez l'homme. Cet intervalle 
pourrait donc correspondre à une période de récupération, subséquente à l'implantation, lors de 
laquelle les œdèmes résultant d'une réaction inflammatoire locale se résorbent.  
Afin de confirmer cette hypothèse, le LCAMP doit être utilisé dans un modèle d'épilepsie chronique 
qui implique l'usage de la SNV comme traitement antiépileptique. Ces résultats seraient alors 
probants dans le cas où l'enregistrement de LCAMP ou les délais de cet enregistrement  seraient 
corrélés avec les données fournies par la SNV.  
Par ailleurs, l'examen immunohistochimique  post-mortem effectué sur les rats pourvus d'une 
électrode de stimulation et d'enregistrement pourrait mettre en évidence une éventuelle réaction 
inflammatoire plus importante pour le groupe présentant un délai d'enregistrement LCAMP.  
Cependant, le LCAMP étant une mesure de la stimulation des fibres efférentes du nerf vague, les 
résultats obtenus ne correspondent en aucun cas à l'activation des fibres myélinisées afférentes, qui 
traduirait un effet antiépileptique de la SNV.  
Afin de compléter le travail de recherche expérimentale effectué, un nouveau stimulateur (ADNS-
300) du nerf vague, combinant la stimulation thérapeutique avec la possibilité d’enregistrer des 
CAPs, a été implanté pour la première fois chez trois patients.  
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Ce générateur étant rechargeable par voie transcutanée, son temps de vie est prolongé d'une durée 
qui peut atteindre 12 ans. Dans le cas de deux des patients traités, une diminution des crises de 40 % 
a été observée après 6 mois de traitement par SNV. En ce qui concerne le troisième patient, aucune 
réponse au traitement antiépileptique (AED) n'a pu être relevée au terme de cette étape du suivi 
médical. En conséquence, son traitement a été adapté en tenant compte des effets secondaires de 
somnolence observés. Depuis lors, le patient n'a plus manifesté de crises épileptiques. L'effet 
bénéfique obtenu pourrait résulter des modifications apportées à ces AED, de la SNV, ou encore 
d'une action synergique de ces deux thérapies.  
Pour deux patients sur les trois traités, des CAPs du nerf vague ont été enregistrés pour la première 
fois dans les 2-3 semaines qui ont suivi l'opération. Pour se faire, le nerf vague a été stimulé via des 
pulsations d'une durée de 250 µsec et de 500 µA d'intensité. De cette façon, un N1P1N2 CAP, avec un 
N1  apparaissant 0,4 msec après la fin de l'artifact de stimulation, a pu être enregistré.  
L'intensité minimale des pulsations requise afin d'activer le nerf se situe dans une gamme de 100 à 
150 µA et leur durée est de 250 µsec. Lorsque la durée des pulsations est fixée expérimentalement à 
100 µsec, l'intensité nécessaire à l'activation du nerf atteint des valeurs comprises entre 200 et 250 
µA en ce qui concerne le premier patient et entre 250 et 500 µA pour le deuxième. 
Les enregistrements de CAPs ont été poursuivis chez un des patients sur une durée de 12 mois.   Au 
terme de chacune des sessions, des courbes doses-réponses ont été obtenues. Les résultats ont 
démontré que deux groupes distincts de fibres myélinisées peuvent être recrutées. Dans le cas de 
l'un, les fibres sont activées à 25 mC (500 µA x 50 µsec), tandis que pour l'autre, des paramètres fixés 
à 37.5 mC (150 µA x 250 µsec) sont requis. 
Dans un futur proche, une courbe dose-réponse pourrait être mise à la disposition du neurologue au 
cours de chaque visite. L'amplitude de la charge maximale ou l’amplitude du CAP n'augmente plus, 
pourrait correspondre à une valeur maximale de stimulation qui indiquerait alors qu'un 
accroissement de l'intensité au-delà de ce seuil n'apporterait pas plus de gains. Au contraire, elle 
causerait davantage d'effets secondaires et le générateur serait alors utilisé de manière inadéquate.  
En conséquence, cette nouvelle approche pourrait signifier un important gain pour les couts et 
avantages de la SNV.  De plus, des études additionnelles pourraient investiguer si l’enregistrement du 
CAP est corrélé  avec la response therapeutique, ce qui pourrait partiellement expliquer l’existence 
de « non-responders ». Ce dernier aspect du traitement étant un élément très discuté et 
insufisssamment  examiné jusqu’a présent. En effet, une réponse à la SNV défavorable peut résulter, 
non seulement du manque d'effets de ce traitement sur le cerveau, mais également d'un problème 
local lié à la stimulation du nerf vague, comme, par exemple, une inflammation subséquente à 
l'implantation.  
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En conclusion, l'implantation du dispositif ADNS-300 chez un plus grand nombre de patients 
épileptiques  permettrait une meilleure compréhension du fonctionnement electrophysiologic de la 
SNV.  
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Samenvatting 
Epilepsie is één der meest frequent voorkomende chronische neurologische aandoening met een 
prevalentie van 1%. Bij ongeveer 30% van de patiënten reageren de aanvallen niet op de klassieke 
anti-epileptische behandeling en wordt de diagnose van refractaire epilepsie gesteld. Een 
doorverwijzing naar een epilepsie referentiecentrum is op dat ogenblik aangewezen. Slechts een 
klein deel van deze patiënten komt in aanmerking voor een chirurgische behandeling, daar de 
epileptogene zone zich vaak in de eloquente cortex bevindt. Voor deze patiënten zijn andere 
behandelingsmogelijkheden een optie, met name diepe hersenstimulatie (DBS) of nervus vagus 
stimulatie (VNS). VNS onderscheidt zich van DBS, daar het een minder invasieve behandeling betreft. 
De nervus vagus wordt buiten de hersenschedel, nl. ter hoogte van de linker hals, gestimuleerd. Deze 
stimulatie bestaat uit elektrische pulsen die gegenereerd worden door een generator die onder het 
sleutelbeen wordt geïmplanteerd. Parameters van stimulatie worden bepaald door de intensiteit, de 
pulsbreedte, de frequentie en duty cycle.  
Tot op heden worden er ruim 50.000 patiënten behandeld met VNS. Algemeen stelt men dat één 
derde van deze patiënten goed respondeert en een aanvalsreductie kent van meer dan 50%. Een 
tweede groep reageert minder goed en ervaart een aanvalsreductie tussen 30 en 50%. Ten slotte 
ondervindt een laatste groep patiënten een  aanvalsreductie van minder dan 30%  of helemaal geen 
reactie op VNS. Tot op heden bestaan er geen goede predictieve factoren om de respons op VNS op 
voorhand in te schatten. Daarenboven bestaan er geen duidelijke, wetenschappelijk gebaseerde 
richtlijnen voor titratie en keuze van stimulatie parameters. In de praktijk wordt bij de patiënt een 
VNS systeem geïmplanteerd, waarna hij twee weken later terugkomt op consultatie en de stimulatie 
gestart wordt. Vervolgens wordt de stimulatie met 0.25 mA per keer verhoogd, tot er een 
aanvalsreductie optreedt. Indien er vroeger nevenwerkingen ontstaan, kan een verdere opdrijving 
van de output worden gestaakt. 
De nervus vagus bestaat er drie verschillende soorten vezeltypes: de niet-gemyeliniseerde dunne C-
vezels en de dikkere gemyeliniseerde en intermediaire A- en B-vezels. De gemyeliniseerde vezels 
vereisen kleinere hoeveelheid lading om geactiveerd te worden, dit in tegenstelling tot de niet-
gemyeliniseerde vezels. Uit de literatuur blijkt dat stimulatie van gemyeliniseerde vezels volstaat om 
bij VNS een aanvalsreductie te bekomen.  
Onderzoek naar het werkingsmechanisme van VNS kan ingedeeld worden in twee grote luiken. Het 
eerste luik bestaat uit onderzoek naar adequate activatie van de zenuw en een onderdeel hiervan 
wordt bepaald door het registreren van “Compound Action Potentials“(CAPs). Deze meting is 
uiteraard sterk afhankelijk van de functionaliteit van de zenuw, die na een operatie en implantatie 
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van een cuff elektrode, mogelijks kan veranderen. Een tweede luik bestaat erin de effecten van VNS 
op de verschillende en talrijke projectieplaatsen in de hersenen te onderzoeken. 
Dit doctoraatswerk heeft als doel de stimulatie van de nervus vagus te objectiveren, door een VNS 
geïnduceerde elektrofysiologische parameter te identificeren die adequate activatie van de nervus 
vagus weergeeft. Hiervoor werd getracht vagale CAPs te karakteriseren. Met dit doel voor ogen, 
werd in de eerste plaats een nieuwe cuff elektrode voor dierexperimentele doeleinden ontworpen 
om de zenuw te stimuleren en tegelijk ook de CAPs te registreren. 
Implantatie bij een grote groep ratten heeft aangetoond dat de implantatie en registratie van VNS 
geïnduceerde activiteit met een dergelijke elektrode haalbaar is. Met de gebruikte methode werd 
echter ook aangetoond dat opgemeten signalen geen CAPs van de nervus vagus waren, maar wel het 
gevolg zijn van co-activatie van de nervus laryngeus recurrens, die aanleiding geeft tot contractie van 
gestreepte larynx spieren (Larynx compound muscle action potential of LCAMP) 
Vervolgens werden de LCAMP metingen chronisch opgevolgd gedurende een periode van twee 
maanden. Hierbij werden er dagelijks dosis respons curven en wekelijks impedantie van de 
stimulatie-elektroden opgemeten. De kenmerken van de LCAMP, zoals latentie, de intensiteit nodig 
om een 50% maximale respons te bekomen en de hellingsgraad van de dosis respons curven, bleven 
stabiel doorheen de tijd. Impedantie van de stimulatie elektroden steeg geleidelijk over 8 weken, in 
overeenstemming met het concept dat na de implantatie, er een gliotisch proces ontstaat waardoor 
de geïmplanteerde elektrode en zenuw volledig worden ingekapseld. 
Bij opvolging van de ratten bleek de helft van de groep een recuperatietijd nodig te hebben van 
gemiddeld 25 dagen, wat een indicatie geeft dat de heelkunde en implantatie van de elektrode een 
zekere zenuwschade oplevert. In de klinische praktijk wordt er tevens aangeraden minstens 6 
maanden te behandelen alvorens de uiteindelijke respons op VNS te beoordelen. Hypothetisch 
ontstaat er lokaal een inflammatoire reactie met demyelinisatie tot gevolg, waardoor de nervus 
vagus enige hersteltijd nodig heeft. Om de hypothese van lokale inflammatie en herstel verder te 
ondersteunen zijn bijkomende experimenten noodzakelijk. Eerst en vooral zou de LCAMP moeten 
worden toegepast in een chronisch epilepsiemodel waar bij VNS wordt getest. Dit experiment zou 
nagaan of de positieve outcome van VNS gerelateerd is met het al dan niet onmiddellijk of later 
registreren van de LCAMP. Daarnaast zou men met post-mortem immunohistologische coupes 
kunnen nagaan of de inflammatoire reactie groter is bij de non-LCAMP.  
LCAMP blijft echter wel een surrogaat parameter, aangezien deze enkel de weerspiegeling is van de 
activatie van efferente Aα-vezels van de nervus vagus en geen informatie geeft over het al dan niet 
functioneel zijn van de gemyeliniseerde afferente vezels die het anti-epileptisch effect van VNS 
verzorgen. 
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Aanvullend bij dit dierexperimenteel werk, werd er in samenwerking met Neurotech, een nieuwe 
nervus vagus stimulator ontwikkeld (ADNS-300) en getest. Deze stimulator levert zowel 
therapeutische stimulatie als de mogelijkheid om CAPs van de nervus vagus te meten bij de mens. 
Daarnaast is hij ook transcutaan oplaadbaar, waardoor de levensduur van de generator wordt 
verlengd tot 12 jaar. 
Na 6 maanden behandeling rapporteerden twee van de drie geïmplanteerde patiënten een 
aanvalsreductie van ongeveer 40%. De derde patiënt toonde op dat ogenblik nog geen respons op 
zijn VNS. Zijn anti-epileptische medicatie werd aangepast daar hij belangrijke medicamenteus 
geïnduceerde somnolentie vertoonde. Parameters van VNS bleven ongewijzigd. De patiënt werd kort 
nadien echter wel aanvalsvrij. Deze gunstige evolutie kan dus zowel het gevolg zijn van de 
veranderingen van zijn medicatieschema als van zijn VNS behandeling, of combinatie van beiden. 
Samenlopend met het uitgevoerde dierexperimenteel werk, hebben we bij twee van de drie 
patiënten 2 à 3 weken postoperatief, CAPs van de nervus vagus geregistreerd. Hiervoor werd de 
zenuw gestimuleerd met een puls van 250 µsec lang en 500 µA sterk, waardoor een N1P1N2 CAP kon 
worden opgemeten. N1 verscheen 0.4 msec na het einde van het stimulatie artefact. De minimum 
vereiste lading om een CAP te kunnen registreren bedroeg een puls van 250 µsec lang en tussen 100 
en 150 µA sterk. Wanneer de pulsduur werd verkort tot 100 µsec, lag de drempelwaarde intensiteit 
tussen 250 en 500µA bij patiënt 1 en tussen 200 en 250 µA bij patiënt 2. 
Vervolgens is er bij één patiënt (patiënt 2) een follow-up studie uitgevoerd, waarbij op regelmatige 
tijdstippen dosis respons curven van de CAP werden geregistreerd. Uit deze metingen bleek dat er 
twee groepen gemyeliniseerde vezels gerekruteerd kunnen worden. Een eerste groep werd 
geactiveerd bij een stimulatiepuls van 25 mC (500µA x 50µsec), terwijl de tweede groep een hogere 
lading nodig had, nl 37.5 mC (150µAx250 µsec). Parameters van stimulatie werden het eerste jaar 
ingesteld op gelijkaardige wijze als bij eerder uitgevoerde studies met Cyberonics stimulatoren.  
Het gebruik van dosis respons curven in klinische praktijk zou de behandelende neuroloog toelaten 
een maximale stimulatie output te hanteren, waarbij hogere stimulatie intensiteiten enkel zou leiden 
tot inefficiënt batterij verbruik en toename van het risico op optreden van bijwerkingen. In deze 
context kunnen de CAP metingen een belangrijke bijdrage vormen voor het kosten-baten aspect van 
deze behandeling. Daarenboven kunnen toekomstige longitudinale studies, waarbij zowel 
aanvalsreductie als CAP registraties worden uitgevoerd, mogelijks een antwoord bieden waarom 
bepaalde patiënten al dan niet gunstig reageren op de behandeling. 
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Implantatie en registratie van CAPs van de nervus vagus bij een grotere groep patiënten, zal hopelijk 
leiden tot een beter begrip van het werkingsmechanisme en elektrofysiologische aspect van VNS.  
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Oral presentations 
 
Ghent University Hospital- Neurology Department May 29, 2008: “Vagus nerve induced evoked potentials” 
 
VUB October 24, 2009: Belgian Society of fundamental and clinical physiology and pharmacology 
“In vivo measurements of vagus nerve compound action potentials in experimental rats” 
 
Ghent 21 -22 -May 2010: International Epilepsy workshop: new approaches for epilepsy treatment in Europe: 
back to the future. “Compound action potentials of the vagus nerve in humans and experimental rats”  
 
ULB October 16, 2010: Belgian Society of fundamental and clinical physiology and pharmacology 
“A novel implantable vagus nerve stimulation system (ADNS-300) for combined stimulation and recording of 
the vagus nerve: pilot trial at Ghent University Hospital” 
 
Congrescentrum "Lamot" te Mechelen”, Herfstvergadering Vlaamse Vereniging voor Neurologie (VVN), 
"Nieuwe onderzoekstechnieken in de Neurologie:cost-benefit", November 20,2010: “A novel implantable vagus 
nerve stimulation system (ADNS-300) for combined stimulation and recording of the vagus nerve: pilot trial at 
Ghent University Hospital” 
 
Kempenhaeghe- Landelijke Werkgroep Nervus Vagus Stimulatie (NL), wetenschappelijke VNS vergadering 
September 15, 2011: “VNS & Evoked potentials”  
 
Teaching and students 
 
Practica Neurofysiologie 2006-2007: ‘Reflexen, electromyografie en zenuwgeleiding' (Prof. Dr. L.  
Leybaert)- 1ste jaar geneeskunde 
 
Karakterisatie van het corticale stimulatie model. Voorbereiding onderzoekstage-1
ste
 Master Biomedische 
wetenschappen -Ine Buffel 
 
Thesis: Karakterisatie van het corticale stimulatiemodel, 2
de
 master Biomedische wetenschappen- Ine Buffel 
 
 
